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Abstract
Acute myeloid leukaemia (AML) is a heterogeneous disease, both in terms of biology 
and clinical outcome. Approximately 45% of all AML patients are cytogenetically normal at 
diagnosis and as such are placed in the intermediate risk group where their clinical outcome is 
unpredictable hence there remains a need for more prognostic markers. This study concerns a 
specific molecular genetic mutation, the mixed lineage leukaemia partial tandem duplication 
(MLL PTD). MLL is a transcriptional regulator that is known to be instrumental in both 
normal haematopoiesis and in leukaemogenesis. This study aimed to evaluate the prognostic 
importance of this abnormality through investigation of its influence on clinical outcome, its 
utility as a marker of minimal residual disease (MRD) and the downstream effects of its 
expression. A qualitative PCR assay was established and determined the frequency of MLL 
PTD to be 5.2% in de novo AML. MLL PTD was found to be a useful independent prognostic 
marker being associated with a greater risk of relapse and a reduction of relapse free survival 
and overall survival. A quantitative PCR (QPCR) assay was developed that reliably 
distinguished AML-related MLL PTDs from the low level of background MLL PTDs 
occurring normally. Despite a high rate of cytogenetic clonal evolution MLL PTD expression 
remained stable between diagnosis and relapse, making it a suitable marker for MRD. Results 
also suggested the QPCR assay could determine onset of remission and prediction of relapse. 
Gene expression profiling was used to identify a gene signature unique to the MLL PTD and 
was found to be distinct from that associated with MLL translocations. Analysis of the gene 
signature also identified three candidate chemotherapy compounds predicted to antagonise the 
effects of the MLL PTD. The results of this study could prove instrumental in improving the 
treatment of MLL PTD patients.
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1 Introduction
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1.1 Haematopoiesis
Blood is the fluid that sustains vertebrate life, performing a number of functions 
beyond nourishment and waste removal including protection of the body from infection by 
innate and adaptive immune responses, prevention of haemorrhage by coagulation and 
production of growth factors. The diverse functions performed by the blood are possible 
because of haematopoietic cell lineages that result in the production of specialised types of 
mature blood cells. The evolution of the lineages from a small population of haematopoietic 
stem cells (HSC) is called haematopoiesis.
1.1.1 Normal Haematopoiesis
Haematopoiesis is the ongoing process of differentiation, maturation and proliferation 
of mature blood cells from a renewable population of HSCs that occurs throughout the 
lifetime of an individual and gives rise to cell types that are specially adapted for a specific 
purpose within the body (Figure 1.1). Monocytes and granulocytes, (including neutrophils, 
eosinophils and basophils) represent the principal components of the innate immune system 
and co-operate to mount a non-specific defence against pathogens by phagocytosis, 
inflammation and B-cell signalling. The adaptive immune system, composed of B and T 
lymphocytes, is dependent on antigenic stimulation. The B lymphocytes undergo a process of 
education and maturation before they are capable of providing a defence through antibody- 
dependent cell-mediated cytotoxicity. The CD4+ T helper lymphocytes are instrumental in 
this process, while the CD8+ T suppressor-cytotoxic cells kill infected host cells. 
Additionally, T cells participate in the regulation of the immune system via cytokine 
production. The erythrocytes are responsible for the transport of oxygen and carbon dioxide
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between tissues and the lungs. Platelets are instrumental in the initiation of the coagulation 
cascade to prevent haemorrhage, in addition to the release of cytokines, such as platelet 
derived growth factor, that promote wound repair through the regeneration of connective 
tissues.
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Figure 1.1 Haematopoietic Development
The curved arrows represent self-renewal, while the straight arrows represent developmental 
transitions in haematopoiesis. Red hoops represent points where developmental progress is 
blocked if the indicated transcription factor is absent. LT-HSC: long term haemtopoietic stem 
cell; ST-HSC: short term haematopoietic stem cell; CMP: common myeloid progenitor; CLP: 
common lymphoid progenitor; MEP: megakaryocyte/erythroid progenitor; GMP:
granulocyte/macrophage progenitor; RBCs: red blood cells (Orkin & Zon 2008).
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1.1.La The Hematopoietic Stem Cell
Haematopoiesis is typically described as a hierarchical process with a pluripotent stem 
cell at the apex, able either to differentiate into any cell lineage or maintain its population 
indefinitely through self-renewal. The existence of a population of cells able to initiate and 
sustain haematopoiesis was demonstrated by the survival of lethally irradiated mice following 
bone marrow transplantation (Ford et a l 1956). The HSC was first described in 1961 by Till 
and McCulloch when the hierarchical nature of the haematopoietic process was demonstrated 
by the production of colonies in the spleen of recipient mice after allotransplant of bone 
marrow cells. These colonies displayed evidence of myeloid differentiation with the presence 
of erythroblasts, megakaryocytes and myelocytes (Till & McCulloch 1961). The authors 
surmised that only a small population of primitive cells possibly as few as one, were 
responsible for the colonies produced, due to the small number of colonies that arose in 
proportion to the number of nucleated marrow cells injected, i.e. 1 colony to lxlO4 cells 
transplanted. In a more recent study, the size of the HSC subpopulation is estimated to be less 
than 0.01% of the total cells in the bone marrow (Rizo et al. 2006).
With differentiation, the lineage potential of the cell grows increasingly restricted. 
HSCs are thought to become restricted in their lineage potential to form either a common 
myeloid progenitor (CMP) or common lymphoid progenitor (CLP). This represents a major 
divide in lineage commitment of the haematopoietic stem cell as the CLP gives rise to B and 
T lymphocytes as well as natural killer (NK) cells while the CMP can potentially develop into 
a megakaryocyte, erythrocyte, macrophage or granulocyte cells (Akashi et al. 2000; Kondo, 
Weissman, & Akashi 1997). To summarise, the HSC is defined by the features of indefinite 
self-renewal coupled with the ability to produce multiple lineages of differentiated progeny. 
Understanding the process of haematological regulation is of great importance as the
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governing factors of regulation may suggest points within the haematopoietic network for 
therapeutic targeting when disrupted regulation results in leukaemic disease.
1. L 1. b Regulation o f Haematopoiesis
l .l .l .b .i  Overview
A regulated mechanism for the production of mature blood cells must maintain a 
steady state system by replacing old and damaged cells, and producing increased numbers of 
specific cell types in response to injury or infection. The process of haematopoietic 
differentiation is capable of producing 1012 mature cells every day from a relatively small 
population of HSC residing in the bone marrow (Ogawa 1993). The “traditional” hierarchy 
model where HSC become irreversibly lineage committed and progress to terminally 
differentiated progeny is likely an oversimplification; however, it has proved useful as a 
template for deciphering the stages of differentiation and the mechanisms by which 
haematopoiesis is regulated. A more accurate description of an HSC might be that of a cell 
with variable differentiation potential that is primarily controlled by the intrinsic influence of 
transcription factors and the extrinsic influence of haematopoietic growth factors (cytokines). 
Intrinsically, the transcription factors are required for HSC formation and lineage 
determination. The extrinsic influence of cytokines is critical in maintaining homeostasis by 
regulating the numbers of cells produced and can influence a variety of processes including 
quiescence, self-renewal, proliferation, differentiation, and apoptosis. Though the relative 
contribution of intrinsic and extrinsic regulation is unclear, it is understood as haematopoiesis 
proceeds there is a decrease in the capacity for self-renewal while the mechanisms promoting 
proliferation and differentiation increase (Figure 1.2). Additionally, negative regulation in the 
form of apoptosis contributes to overall homeostasis (De et al. 1999). Ultimately, the balance
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of self-renewal, proliferation, differentiation and apoptosis regulates haematopoiesis so the 
function of supplying the necessary mature blood cells to the host is maintained.
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Figure 1.2 Self-Renewal and Differentiation in Haematopoiesis
A simplified schema demonstrating the balance between self-renewal and differentiation in 
normal haematopoiesis. As cells progress through the stages of lineage commitment, the 
capacity for self-renewal is lost while differentiation potential is increased. Early lineage 
decisions are prescribed by transcription factors (TF) while terminal differentiation is 
promoted by growth factors (GF) or cytokines. LT-HSC: long term heamtopoietic stem cell; 
ST-HSC: short term haematopoietic stem cell; CLP: common lymphoid progenitor; MEP: 
megakaryocyte/erythyroid progenitor; GMP: granulocyte/macrophage progenitor; RBCs:red 
blood cells adapted from (Rosenbauer & Tenen 2007).
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1.1. l.b.ii Bone Marrow Microenvironment
A limited environment in the bone marrow where the HSC resided in a steady state was 
proposed before the actual site was identified. The theory was proposed to address the 
question of how the HSC maintained the capacity for self-renewal as well as the capacity for 
differentiation into mature blood cell types. Upon HSC cell division one daughter cell would 
remain in the niche with the potential for self-renewal preserved while the other would begin 
proliferation and differentiation (Schofield 1978). In 2003, two independent groups 
investigating the interactions between the HSC and bone cells identified the endosteal niche 
(Figure 1.3). Analysis of mice with conditional deletion of the bone morphogenetic protein 
(BMP) receptor showed a correlation between the increase of osteoblasts and HSC numbers. 
The attachment of HSCs to osteoblasts was thought to be mediated by N-cadherin (Zhang et 
al. 2003). The authors suggested that the osteoblasts lining the niche supported the HSCs 
while BMP regulated HSC numbers through control of the niche size. In another murine 
model, stimulation of osteoblasts with parathyroid hormone receptors generated raised levels 
of the Notch ligand jagged 1, which in turn promoted an expansion in the number of HSCs 
exhibiting Notch activation (Calvi et al. 2003). Furthermore, injection of parathyroid 
hormone in wild type mice caused an increase in stem cell production and enhanced post­
transplant survival. This indicated osteoblasts within the endosteal niche promote an increase 
in HSC numbers. The receptor tyrosine kinase Tie2 and its ligand angiopoietin-1 promoted 
quiescence and anti-apoptosis in HSCs in addition to enhanced bone adhesion (Arai et al. 
2004). However, the adherence function of osteoblasts, as well as the necessity of osteoblasts 
for the maintenance of HSC populations has been called into question (Kiel, Radice, & 
Morrison 2007). Recently, a vascular niche composed of sinusoidal endothelial cells has been 
proposed (Kiel et al. 2005). Whether there are two independent niches performing separate 
functions or one common niche that is a composite of the two has yet to be determined. The
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functions of the niche are clinically relevant to bone marrow transplantation and resistance to 
chemotherapy as quiescent cells are resistant to the actions of cell cycle specific drugs.
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Figure 1.3 Haematopoietic Stem Cell Niche
Haematopoietic stem cells are next to osteoblasts in the endosteal niche and adjacent to blood 
vessels in the vascular niche. These niches may be intertwined within the bone marrow. 
Stromal cells support haematopoiesis through adhesion sites for HSCs and the secretion of 
cytokines that influence stem cell and progenitor function and survival. HSC: haematopoietic 
stem cell; BMP: bone morphogenetic protein (Orkin & Zon 2008).
l.l.l.b .iii Role o f Transcription Factors
Haemopoietic transcription factors control the maintenance of HSCs, including self­
renewal, and co-ordination of lineage specific development (Orkin & Zon 2008). 
Interestingly, many transcription factors have functions within the HSC in addition to the 
lineage restriction roles, which are important later in differentiation. Furthermore, there is 
often interplay of transcription factors in the regulation of cell fate. For example, over 
expression of PU.l promotes the commitment of HSC to a myeloid stem cell (or CMP).
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Subsequently, the relative expression of purine rich box-1 (PU .l) and GATA binding protein- 
1 (GATA-J) determine the potential of the CMP to give rise to myeloid (GMP) or 
erythroid/megakaryocytic (MEP) differentiation. In experimental studies, GATA-1 over 
expression reprogrammed myeloid cells to become erythroid and megakaryocyte cells while 
PU.l over expression repressed erythropoiesis and promoted myeloid differentiation in 
erythroid cell lines (Cantor et al. 2008; Iwasaki et al. 2003; Yamada et al. 2001). The 
proposed model was that the protein in excess prevented gene activation by blocking the 
binding sites of the competing factor’s target genes while instigating a positive autoregulatory 
loop (Chen et al. 1995; Nerlov et al. 2000; Zhang et al. 2000) In another example, down 
regulation of the transcription factor friend of GATA-1 (FOG), which is required to be co­
expressed with GATA-1 for erythroid and megakaryocytic development, was necessary for 
GATA-1 to promote mast cell development (Orkin & Zon 2008). Thus the level of the 
transcription factor is important in lineage determination where over expression is shown to 
be antagonistic to the influence of competing factors (Orkin & Zon 2008).
The homeobox (HOX) gene family encodes transcription factors that have specific 
functions, including regulation of embryonal development and cell differentiation in 
haematopoiesis, and recent findings suggest a role in HSC self-renewal (Argiropoulos & 
Humphries 2007). HOX genes were originally identified as regulators of the anterior- 
posterior segmentation in Drosophila development and later discovered to have human 
homologues (Krumlauf 1994). The gene is organised into four genomic clusters labelled A- 
D, which are further divided into numbered members of the clusters termed paralogues. Many 
of the HOX gene subtypes in clusters A-C are expressed during haematopoiesis. The genes 
are primarily expressed in HSC and early progenitor cells and expression subsequently 
decreases as the lineage commitment of the cell progresses (Pineault et al. 2002; Sauvageau et 
al. 1994). Individual paralogues can increase the population of progenitors. Over expression
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of Hoxb4 and Hoxa9 cause expansion of the murine HSC population and in the case of 
Hoxa9, leads to leukaemogenesis (Antonchuk, Sauvageau, & Humphries 2001; 
Thorsteinsdottir et al. 2002). The number of different gene paralogues suggests the 
importance of the gene may be protected through redundancy of gene function. Redundancy 
has been demonstrated between some paralogues but appears to be stage specific. For 
example, the recovery of HSC progenitor growth in cells lacking Hox expression was 
mediated by individual expression of Hoxa9 or Hoxb4 genes, however the subsequent 
differentiation was unique to the gene expressed (Ernst et a l 2004b). The mixed lineage 
leukaemia gene (MLL) maintains the expression of the HOX  genes possibly through 
interaction with the HOX  promoter region and is a key regulator of haematopoietic 
development.
Evidence that MLL is necessary for definitive haematopoiesis was shown in mouse 
studies using Mil deficient cells. Mir1' cells were unable to generate HSC or progenitor cell 
populations in foetal liver chimeras and transplantation of Mir1' embryonic cells into 
sublethally irradiated recipients failed to demonstrate HSC activity. Furthermore, a reduced 
number of recipients engrafted with M lt1' were repopulated with donor cells indicating a 
critical level of Mil expression is needed for haematopoiesis to occur (Ernst et al. 2004a). 
Conditional deletion of Mil resulted in a loss of self-renewal capacity in the HSC population 
(Jude et al. 2007; McMahon et al. 2007). Quiescent HSC populations were maintained in Mil 
deficient cells, while there were contrasting effects on downstream cells, with proliferation of 
myeloid-erythroid progenitors reduced and no expansion of committed lineage cells observed 
(Jude et al. 2007). The role of MLL as a regulator of HOX  expression is the probable reason 
for the decrease in proliferation, with re-expression of a single Hox gene capable of 
reinstating the haematopoietic process. There is less evidence for the role of Hox involvement 
in the quiescent status of the HSC population, as this result has not been reported in other Hox
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knock-out studies (Brun et al. 2004; Scott et a l 1994). These studies demonstrate that MLL 
plays an instrumental role in haematopoietic development, with multiple functions dependent 
on the timepoint and cellular context of the expression. The MLL gene is discussed further in 
Section 1.2.3.a. The importance of transcription factors to haematopoiesis is perhaps best 
exemplified by the high number linked with leukaemia, which is discussed in Section 1.1.2.b.
1.1. l.b.iv Role o f  Cytokines
Cytokines are glycoproteins that influence haematopoiesis by binding to cytokine 
receptors on target cells to activate cell signalling pathways. The majority of cytokines are 
synthesised in T lymphocytes, monocytes and bone marrow stromal cells, apart from 
erythropoietin and thrombopoietin, which are produced in the kidney and liver respectively. 
Cytokines can remain membrane bound or be secreted allowing them to function in the local 
environment or circulate to act systemically. The function of individual cytokines is often 
difficult to ascertain due to cytokine pleiotrophy, redundancy and synergy in addition to cell 
type (context-specific) responses. The colony stimulating factors (CSF) for macrophage (M- 
CSF), granulocyte (G-CSF), granulocyte-macrophage (GM-CSF) and multiple colonies 
(multi-CSF, more commonly referred to as interleukin-3 (IL-3)), are so named due to the 
lineage of the colony produced by progenitors in in vitro assays; these factors play an 
important role in the development of the mature cells of the myeloid lineages. 
Straightforwardly, G-CSF and M-CSF are lineage specific cytokines that contribute to the 
proliferation and terminal differentiation of granulocytes and macrophages, whereas IL-3 
modulates many lineages including macrophage, neutrophil, basophil, eosinophil, erythrocyte 
and mast cells. Cytokines that may also contribute to lineage commitment at earlier stages of 
haematopoiesis include IL-3, GM-SCF, fms-like tyrosine kinase 3 ligand (FL) and stem cell 
factor (SCF or c-kit ligand) (Blalock et a l 1999).
1-14
FL expression is involved with proliferation, differentiation, survival and mobilisation 
in haematopoietic precursor cells. FL has two forms, soluble and membrane bound, and both 
are able to promote proliferation of HSCs. Although FL alone was a weak stimulator of 
growth, it exhibits synergistic promotion of growth in CD34+ BM cells when combined with 
cytokines SCF and IL-3 (Lyman et al. 1993; Rusten et al. 1996). Disrupting FL expression 
with murine knockout studies resulted in reduced overall leukocyte numbers in the BM, and 
significant reduction of myeloid and B-lymphoid progenitors indicating a role for FL in 
haematopoiesis (McKenna et al. 2000). FL is the cognate ligand for the fms-like tyrosine 
kinase 3 (FLT3) receptor, which is expressed on myeloid and lymphoid progenitor cells 
(though the level of expression decreases with differentiation). Activating mutations of FLT3 
occur in over 30% of all acute myeloid leukaemia (AML) patients and the FLT3 ITD in 
particular is associated with poor prognosis (Section 1.2.4.b and 1.2.6.b) (Kottaridis et al. 
2001).
SCF and FL are not only similar in size and overall protein structure, but they also 
share a number of functions. SCF expression promotes survival, mobility and proliferation of 
HSCs. SCF is involved with the prevention of apoptosis and promotes proliferation of HSCs 
through interaction with the cytokine thrombopoietin (Hassan & Zander 1996; Ku et al. 
1996). Inhibition of the SCF receptor (c-kit) causes pancytopenia and decreased cellularity in 
the marrow suggesting that SCF is needed for normal haematopoiesis (Ogawa et al. 1991). 
Specifically, SCF promotes the expansion of myeloid progenitors throughout differentiation 
and enhances erythropoiesis (Lyman et al. 1994). The membrane bound SCF is associated 
with HSC adhesion in the bone marrow niche; cleavage of this form decreases adhesion 
resulting in HSC mobilisation (Heissig et al. 2002; Kollet et al. 2006). The cognate receptor 
for SCF (SCF-R) is the product of the c-kit oncogene. Mutations in the c-kit gene are
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associated with core binding factor (CBF) AML, and appear to have a negative impact on 
these favourable risk cytogenetic groups (Paschka et al. 2006; Schnittger et al. 2006)
Cytokine signals are transmitted to the nucleus via binding to cognate receptors 
located on the membrane of the target cell. Activation of the receptor initiates a signalling 
pathway that ends in the nucleus with the activation or inactivation of a gene. This results in a 
change in the target cell programming which may include entering the cell cycle, 
commencement of differentiation, resistance to apoptosis or becoming functionally active 
(Hibbert & Johnston 2001; Olsson et al. 1996). All cytokine receptors are transmembrane 
glycoproteins with the common features of an extracellular amino terminal ligand binding 
domain, a hydrophobic transmembrane domain and a carboxy-terminal intracellular domain. 
Activation of the signalling pathways within the cell is generally regulated by 
phosphorylation of tyrosine residues which in turn can influence transcriptional processes. 
Within the cytokine receptor families this is accomplished either with a cytoplasmic domain 
that interacts with the Janus kinases (JAK) (class I) or by a tyrosine kinase domain in the 
receptor itself (tyrosine kinase superfamily). A cascade of phosphorylation events leads to the 
activation of transcription factors in the nucleus. For example, in the class I family of 
cytokine receptors, the IL-3 receptor binds to its cognate ligand and dimerises to enable 
binding and activation of JAK2. JAK2 mediates the intracellular phosphorylation of the 
tyrosine residues within the receptor creating SH2 binding sites. STAT5 signalling proteins 
are subsequently recruited to these sites and are phosphorylated thus allowing STAT5 to 
migrate into the nucleus where it initiates transcription. Creation of SH2 binding sites can 
also result in the recruitment of proteins leading to the initiation of other pathways including 
the mitogen-activated protein kinase and phosphoinositol-3 kinase pathways (Ihle & Kerr
1995). The tyrosine kinase receptors (FLT3, c-kit (SCF-R) and M-CSFR) act in a similar
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fashion, with signalling proteins binding to the autophosphoylated tyrosines to promote 
proliferation and survival traits in the target cell.
1.1.2 Myeloid Leukaemogenesis
The hallmarks of leukaemia are uncontrolled proliferation of haematopoietic cells and 
a loss of terminal differentiation. Such disruption in the normal flow of haematopoiesis can 
result in several types of leukaemia, where developmental arrest can occur in different 
lineages with various extents of differentiation (Sachs 1986). Interestingly, myelodysplasia 
(MDS) and myeloproliferative neoplasms (MPN) are haematological disorders that 
demonstrate only a subset of the characteristics of leukaemia. MDS exhibits a dysregulated 
differentiation, whereas MPN is characterised by increased cell proliferation but with terminal 
differentiation; both disorders are able to progress to acute leukaemia. Leukaemias are 
grouped into acute and chronic categories, dependent upon the patient’s symptoms (Sawyers, 
Denny, & Witte 1991). The subject of this study, the MLL partial tandem duplication (PTD), 
occurs primarily in AML therefore the remainder of the introduction will focus on this 
disease.
1.1.2. a Multiple Mutations Needed fo r  Leukaemogenesis
Despite the differences in the proposed progression of leukaemia, it is generally 
agreed that the characteristics of self-renewal and lack of differentiation are the result of an 
accumulation of multiple mutations within a cell causing an imbalance in the regulatory 
systems and resulting in a neoplastic phenotype. Mutations that confer the capacity for self- 
renewal, if not possessed by the cell originally, are essential for the development of cancer 
(Hanahan & Weinberg 2000). Deregulation of cell maintenance and DNA repair genes as
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caused by AML fusion proteins promote further accumulation of abnormalities and contribute 
to multistep leukaemogenesis (Alcalay et al. 2003; Suela et al. 2007). As with all cancers, the 
balance of proto-oncogenes and tumour suppressors plays an important part in the onset of 
disease, with multiple mutations necessary before leukaemia is established (Cline 1994; 
Rabbitts 1991). A landmark paper published by Knudson (1971) demonstrated the multistep 
nature of carcinogenesis in a study of hereditary retinoblastoma. The study compared the 
onset time of retinoblastoma in hereditary and non-hereditary cases. The tumours in the 
hereditary cases that required only one additional mutation occurred much earlier than those 
in the non-hereditary cases that needed two co-occurring mutations (Knudson, Jr. 1971). 
Assuming a constant mutation rate, the shorter onset in the hereditary patients was in 
agreement with the multiple-hit theory of cancer. The mutations involved in the molecular 
pathogenesis of AML are discussed in more detail below (Section 1.2.3-5).
1.1.2. b Leukaemia Initiating Cells
Models of leukaemogenesis are varied and provoke debate among the haematological 
community, with most models dependent upon the existence of the leukaemic stem cell 
(LSC), an HSC that developed leukaemic potential from the accumulation of oncogenetic 
insults. However, the existence of such a cell has been questioned with the proposal that 
more mature blood cells can regain stem cell characteristics thus enabling them to generate 
the disease (Passegue et al. 2003).
The hypothesis of leukaemia as a disease that requires an accumulation of mutations 
over time suggests that the most likely candidate cells would develop from a long-lived 
population like HSCs (Figure 1.4) (DePinho 2000). In support of this, long term (LT) HSCs 
in populations of older mice demonstrated increased self-renewal, decreased lymphoid 
potential and raised expression of genes associated with leukaemic transformation (Rossi et
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al. 2005). A widely accepted paradigm of leukaemia is its derivation from a single cell and 
maintenance by a subpopulation of LSCs (Hope, Jin, & Dick 2004; McCULLOCH et al. 
1979). Evidence of leukaemic abnormalities (eg. runt-related transcription factor 1 (RUNX1)- 
runt-related transcription factor 1; translocated to, 1 (RUNX1T1) breakpoint cluster region 
(BCR) c-abl oncogene 1, receptor tyrosine kinase (ABL1)) present in both lymphoid and 
myeloid cells indicate that the mutation can occur in a multilineage stem cell or HSC 
(Miyamoto, Weissman, & Akashi 2000; Secker-Walker & Craig 1993). Similarities between 
HSC and LSC include the state of quiescence. Populations of quiescent primitive progenitor 
cells have been detected in AML patients with up to 96% of the LSC in the Go phase of the 
cell cycle (Guan, Gerhard, & Hogge 2003; Guzman et al. 2001). Quiescent LSCs could 
explain the subsequent relapse of patients who had successfully achieved remission, as these 
cells are unaffected by cell cycle specific chemotherapy agents.
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Figure 1.4 Leukaemia Stem Cell (LSC) Induction
The schematic diagram demonstrates normal myeloid differentiation and the transcription 
factors involved in self-renewal and differentiation. The lightning strikes indicate possible 
sites of transformation within the stem cell and progenitor stages of normal development. 
HSC: haematopoietic stem cell; MPP: myeloid pluripotent progenitor; CMP: common 
myeloid progenitor; MEP: megakaryocyte/erythroid progenitor; GMP:
granulocyte/macrophage progenitor. (Gudgin.E. 2009)
/
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The ability to test the LSC concept further came with the development of mouse 
xenotransplant models of severe combined immunodeficiency (SCID) and non-obese diabetic 
severe combined immunodeficiency (NOD/SCID). BM from AML patients was transplanted 
into SCID and NOD/SCID mice and the resulting leukaemic grafts were found to be 
representative of the patient's original disease. A population of cells termed SCID-leukaemia 
initiating cells (SL-IC) had significant self-renewal capacity determined through serial 
dilution studies. Purification of the transplanted fractions identified the CD34+/CD38‘ as the 
fraction containing the SL-IC. No engraftment was seen when the more differentiated 
fraction CD34+/CD38+ was transplanted (Bonnet & Dick 1997; Lapidot et al. 1994). A recent 
study has identified a potential problem in the NOD/SCID mice used for xenograft 
experiments (Taussig et al. 2008). The mice were found to retain an immune response against 
the CD38 antibody, which inhibited the engraftment of CD38+ fractions. When the mice were 
treated with immunosuppressive antibodies, CD38+ fractions were successfully engrafted, 
suggesting that the number of cell types capable of initiating leukaemia in SCID mice was 
previously underestimated. The demonstration that LSCs were equivalent to colony forming 
cells (CFCs) in murine studies using MLL-AF9 also led to the conclusion that LSCs, at least 
in the MLL driven model, are much more abundant than estimated by xenograft models 
(Somervaille & Cleary 2006). This new model suggested one in four cells are LSCs, 
compared to one in 104 by xenograft modelling. Additionally, the impact of the 
microenvironment upon the engrafted cells may have been underestimated. Extrinsic factors 
needed for potentially leukaemic human cells to engraft may have been unavailable in the 
mouse marrow microenvironment, leading to over estimation of the non-leukaemic population 
(Rosen & Jordan 2009).
Data from other studies indicated that more committed cells may be able to initiate 
leukaemia (Figure 1.4). An early study of AML patients suggested a heterogeneous origin of
1-21
the disease (Fialkow et al. 1981). Some patients exhibited differentiation restricted to the 
granulocyte-monocyte pathway, with normal erythroid development still possible, while in 
other cases, the disease affected stem cells with potential to differentiate into granulocytes, 
red cells and platelets. In experimental models, a number of translocations (MLL-AF9 [ALL- 
1 gene fused to chromosome 9, also called MLLTS], MLL-ENL [eleven-nineteen leukaemia 
also called MLLT1] and MOZ-T1F2 [monocytic leukaemia zinc finger-transforming growth-p 
induced factor 2]) introduced into CMP and GMP cells promoted leukaemia in murine models 
(Cozzio et al. 2003; Huntly et al. 2004; Krivtsov et al. 2006). In more recent examples, mice 
deficient in the translation of CCAAT/enhancer binding protein alpha (Cebpa) p42 
demonstrated increased proliferation of the committed myeloid progenitors leading to AML. 
The GEP signature of the cells was shared with progenitors transformed with MLL-AF9 
suggesting a common pathway system for progenitor transformation (Kirstetter et al. 2008). 
Furthermore, Somervaille et al. used MLL fusion genes to identify a transcriptional program 
that results in the generation of myeloid leukaemia stem cells from myeloid progenitor cells. 
The MLL fusion genes exhibited significantly different LSC frequencies as determined by 
assessment of colony-forming cells in the spleen and bone marrow of leukaemic mice. The 
fraction of cells with the highest proportion of LSCs also contained the highest number of 
cycling cells indicating that they were proliferating, metabolically active cells (Somervaille et 
al. 2009). These high LSC frequency MLL cell populations were associated with the 
expression of embryonic stem cell-like program genes including the transcription/chromatin 
regulating genes high-mobility group box 3 (HmgbS'), myeloblastosis viral oncogene homolog 
Myb and chromobox homolog 5 (Cbx5). Co-expression of these three genes in BM 
progenitor cells enabled clonogenic activity in replating assays (Somervaille et al. 2009). 
Interestingly, the MLL transformation pathway of Hoxa and Meis homeobox 1 (Meisl) was
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not utilised in the development of these clonal populations, suggesting a redundancy in the 
process of LSC development within MLL leukaemia..
In summary, mutations affecting both HSCs and committed progenitor cells have been 
demonstrated to give rise to myeloid leukaemia. As for the presence of an LSC, these cells 
may be better defined by an “LSC state” instead of a more strictly defined “LSC phenotype”, 
which may not exist due to the diversity of the cell types involved in leukaemia (Ravandi & 
Estrov 2006).
1.2 Acute Myeloid Leukaemia
Leukaemias are a family of haematological disorders caused by mutations that alter 
the normal progression of haematopoiesis. In AML, accumulated mutations eventually give 
rise to a malignant clone of the myeloid lineage with altered proliferation, differentiation and 
survival characteristics; this results in a rapid increase of immature blasts in the bone marrow 
(BM) and peripheral blood (PB). AML is the most common form of acute leukaemia for 
adults, but it remains a rare disease with an incidence of approximately 2.5-3 cases per
100,000 per year worldwide (Swerdlow et al. 2008). However, the likelihood of developing 
AML increases with age, with a median age at presentation of 70 years, and an incidence of 
18 per 100,000 per year (Estey & Dohner 2006).
Patients with AML usually present with symptoms resulting from either bone marrow 
failure and/or organ infiltration caused by an excess of blast cells. Bone marrow failure with 
loss of terminal myeloid differentiation can lead to anaemia, neutropenia, and 
thrombocytopenia causing fatigue, infection, fever and excessive bleeding. Patients with high 
white blood cell count may complain of bone pain caused by the increased pressure in the 
bone marrow and in extreme cases may suffer from respiratory distress and altered mental
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state (leukostasis) requiring immediate medical attention. In rare cases, AML manifests as an 
extramedullary tumour mass consisting of myeloid blasts and is termed a myeloid sarcoma 
(Pileri etal. 2007).
1.2.1 Aetiology of AML
Although there have been a number of risk factors linked with the development of 
AML, the majority of de novo cases have no known aetiology (Sandler & Collman 1987). 
Cases of AML with known aetiology include patients with a previous history of exposure to 
occupational/environmental mutagens such as radiation or benzene; or cases of secondary 
AML arising from an existing haematological disorder (e.g. MPN or MDS), or exposure to 
chemotherapy (also termed therapy-related AML). Some therapy-related AML patients are 
believed to be predisposed to errors in the repair of mutations caused by cytotoxic therapy due 
to defects in the mismatch repair system, however, for most patients the method of 
pathogenesis remains unclear (Rund et a l 2005). Particular cytogenetic abnormalities have 
been shown to have an association with specific drugs. For example, alkylating agents are 
associated with monosomy 7 and monosomy 5; epipodophyllotoxins with balanced 
translocations at 11 q23 and topoisomerase II inhibitors with balanced translocations t(8;21), 
inv(16), and llq23 (Odero et al. 2001; Pedersen-Bjergaard et al. 2002) (Pui et al. 1989; 
Quesnel et al. 1993). The rate of cure for secondary AMLs (sAMLs) is considerably worse 
than de novo AML with a survival rate of less than 10% (Section 1.2.2 and 1.2.6.b) 
(Swerdlow et al. 2008).
Congenital conditions can also be associated with increased risk of AML. In Down’s 
syndrome (DS), children under five, AML incidence has been estimated to be up to 150 fold 
greater than in children without DS, with acute megakaryoblastic leukaemia the predominant 
classification (Swerdlow et al. 2008). Additionally, children with DS often suffer from 
transient abnormal myelopoiesis (TAM), a disorder that is virtually indistinguishable from the
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most frequent type of DS AML. TAM resolves spontaneously over a short time period but 
may recur as non transient AML 1-3 years later (Zipursky et al. 1999). Both the non transient 
form of AML and TAM are often associated with GATA-1 mutations, and this mutation 
confers a better prognosis in children without DS who have AML (Greene et a l 2003; Lange 
etal. 1998).
1.2.2 Classifications of AML (WHO)
The classification of AML disease has changed tremendously in the past 35 years, 
with the basis for distinction progressing from morphological differences to cytogenetic 
aberrations and, most recently, including molecular genetic mutations.
Historically, the classification has been achieved using the dominant and most 
common method of cell classification; cell morphology. The heterogeneity of AML 
morphology was recognised in 1976 with the introduction of the French-American-British 
(FAB) classifications (Table 1.1) (Bennett et al. 1976). This system grouped AMLs 
according to the level of differentiation identified by observing the morphology of the 
leukaemic cells. The eight categories describe different types and extents of differentiation, 
starting with the primitive cells of MO which show no differentiation, to the more 
differentiated groups such as M6 and M7 which contain blast cells derived from erythroid and 
megakaryocyte lineages respectively. The FAB system provided the clinician with a clear 
morphological picture of the patient’s disease, yet the clinical response of patients was varied 
within individual FAB classifications. The discovery of consistent cytogenetic abnormalities 
such as t(8;21), llq23 translocations, and more complex karyotypes demonstrated genetic 
diversity within the FAB groups and provided insight to the genetic pathogenesis of AML 
subtypes. The diagnostic cytogenetics of AML were recognised as independent prognostic
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factors and led to the inclusion of AML subtypes defined by cytogenetic abnormalities in the 
3rd edition of the World Health Organisation (WHO) Classification of Tumours of the 
Haematopoietic and Lymphoid Tissues published in 2001 (Section 1.2.6.b) (Vardiman et al. 
2002, Grimwade et al. 1998). This was the first time that genetic information was 
incorporated into the WHO myeloid neoplasm classification system, which previously was 
the result of information compiled from morphology, immunophenotype, cytochemistry, and 
clinical features to create distinct clinically relevant disease entities (Vardiman et al 2009). 
The importance of submicroscopic genetic mutations recently found to contribute to 
leukaemogenesis is such that the fourth edition of the WHO Classification of Tumours of the 
Haematopoietic and Lymphoid Tissues has introduced new provisional entities into the 
disease classifications based principally on genetic features.
FAB____________________ AML__________________
M0 Minimally differentiated myeloblastic leukaemia 
M l Myeloblastic leukaemia without maturation
M2 Myeloblastic leukaemia with maturation
M3 Hypergranular promyelocytic leukaemia 
M4 Myelomonocytic leukaemia 
M4Eo Myelomonocytic leukaemia with eosinophils 
M5 Monocytic leukaemia 
M6 Erythroleukaemia 
M7 Megakaryocytic leukaemia
Table 1.1 French American British (FAB) Classification of Acute Myeloid Leukaemia
(Bennett et al. 1976)
The current WHO AML classification can be seen in (Table 1.2). The four main 
subgroups are: AML with recurrent cytogenetic abnormalities, AML not otherwise specified 
(NOS), AML with myelodysplastic-related changes and therapy related myeloid neoplasms. 
Existing groupings within “AML with recurrent genetic abnormalities” were modified and
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two new “provisional entities”, AML with mutated nucleophosmin (NPM1) and AML with 
mutated CEBPA, were added for the 4th edition of the WHO classifications. The current 
definition of AML is a de novo myeloid neoplasm containing more than 20% blasts in the PB 
or BM, where “myeloid” is classified as granulocytic, erythroid, monocytic/macrophage, 
megakaryocytic or mast cell lineages. The cell characteristics used to ascertain the lineage are 
determined by a combination of methods including morphology, immunophenotyping and 
cytochemistry.
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Acute Myeloid Leukaemia and Related Myeloid Neoplasms
Acute myeloid leukemia with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
AML with inv(l6)(pi3. Iq22) or t(16;16)(pl3.1;q22); CBFB-MYH11 
APL with t(15;l 7)(q22;ql2); PML-RARA 
AML with t(9; 11)(p22;q23); MLLT3-MLL 
AML with t(6;9)(p23;q34); DEK-NUP214 
AML with inv(3)(q21q26.2) or t(3;3)(q21 ;q26.2); RPN1-EVI1 
AML (megakaryoblastic) with t(l;22)(pl3;ql3); RBM15-MKL1 
Provisional entity: AML with mutated NPM1 
Provisional entity: AML with mutated CEBPA 
Acute myeloid leukemia with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
Acute myeloid leukemia, not otherwise specified 
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukemia 
Acute monoblastic/monocytic leukemia 
Acute erythroid leukemia 
Pure erythroid leukemia 
Erythroleukaemia, erythroid/myeloid 
Acute megakaryoblastic leukemia 
Acute basophilic leukemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma
Myeloid proliferations related to Down syndrome 
Transient abnormal myelopoiesis 
Myeloid leukemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm
Table 1.2 Acute Myeloid Leukaemia and Related Myeloid Neoplasms
World Health Organisation classifications for myeloid neoplasms (Swerdlow et al. 2008).
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The number of subtypes of AML is reflected by the variability in the characteristics 
seen in Table 1.3. The strength of the association between AML and t(8;21)(q22;q22), 
inv(16)(pl3.1q22), t( 16; 16)(p 13.1 ;q22) and t ( l5; 17)(q22;ql2), dictates that patients with 
these translocations are diagnosed as having AML even when the blast count is <20%. 
Previously all MLL translocations were included in the group AML with 1 lq23 abnormalities, 
the most common MLL translocation t(9;l I)(p22;q23); MLLT3-MLL has now been recognised 
as a distinct clinical entity with intermediate prognosis. However, all other balanced 
translocations of MLL should be specified in the diagnosis (Vardiman et al. 2009).
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Characteristic Diagnostic Features of AML
BM Cellularity 
% Marrow Blasts
Maturation
Morphology
Haematopoiesis 
Blood Counts
Organomegaly
Usually increased 
Increased, >20%, except in some 
cases with specific cytogenetic 
abnormalities or in some cases of 
erythroleukaemia.
Varies, usually minimal 
May or may not be associated 
with dysplasia in one or more 
lineages
Ineffective or effective 
WBC variable, usually anaemia 
and thrombocytopenia 
Uncommon
Table 1.3 Characteristic Diagnostic Features of AML
The biological heterogeneity of AML is apparent in the variability of the diagnostic 
characteristics displayed. WBC: white blood cells (Swerdlow et al. 2008).
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Cases of AML that do not qualify for any other subgroups are placed under the 
heading AML NOS, where they are subdivided by the level of differentiation as in the 
original FAB system. As the number of mutations discovered increases and more genetic 
entities are created the proportion of patients assigned to AML NOS would be expected to 
decrease (Swerdlow et al. 2008).
Patients who do not present with de novo AML are divided into two groups: AML 
with myelodysplastic changes and therapy-related myeloid neoplasm (Section 1.2.2). 
Therapy-related myeloid neoplasms are no longer grouped by the type of drug administered 
z'.e. alkylating agents, topoisomeras II inhibitors or therapeutic radiation, because many 
patients have received combinations of these agents (Swerdlow et al. 2008). Despite the 
frequent observation of genetic mutations also observed in de novo AML, patients with 
therapy-related AML (t-AML) are reported to have a significantly worse rate of survival than 
those with the identical mutation in de novo AML with the exception of favourable prognoses 
conferred with t(8;21)(q22;q22), inv(16)(pl3.1q22), t( 16; 16)(p 13.1 ;q22) and
t( 15; 17)(q22;q 12). This may indicate biological differences between t-AML and de novo 
AML and supports the maintenance of a t-AML subgroup (Rowley & Olney 2002; Smith et 
al. 2003).
The mutations associated with the new provisional diagnostic entities have had 
considerable impact on the basic understanding of AML; they also have valuable clinical use 
as prognostic indicators especially in the context of CN AML, thus justifying the subgroup 
status (Section 1.2.6.b). As provisional entities, the two mutations are classified in the 
scheme with the understanding that further characterisation is required. The difficulty with 
the new mutations is that they are not clearly identified with consistent morphological or 
clinical characteristics, nor are they mutually exclusive of cytogenetic abnormalities or each 
other. In fact, one of the most prognostically significant gene mutations, FLT3, is not
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considered a distinct entity due to the number of associations with cytogenetic abnormalities 
in previously established groups such as t(6:9) and t(15;17), in addition to overlap with other 
molecular mutations (Thiede et al. 2006; Vardiman et a l 2009).
1.2.3 Cytogenetic Mutations in AML
1.2.3.a The MLL gene and MLL translocations
The MLL gene and translocations are covered in detail to familiarise the reader with 
the gene that is the focus of this thesis. The MLL gene is also known as HRX, ALL-1 and 
Htrxl on account of its similarity with the Drosophila trithorax gene and due to its 
independent cloning in several different laboratories in 1991 and 1992 (Cimino et al. 1991; 
Ziemin-van der et al. 1991) (Tkachuk, Kohler, & Cleary 1992). The Drosophila trithorax 
homologue gene is involved in the regulation of developmental processes in the organism. 
The MLL gene is 100 kb long with 37 exons (Nilson et al. 1996); it is widely expressed in cell 
types throughout the body, including haemopoietic cells (Butler et al. 1997). The MLL 
protein has multiple regions that confer significant functional activity including DNA binding 
domains, transcriptional activation and repression domains, plant homeodomain (PHD) finger 
domain (associated with chromatin remodelling), self-association motifs and a C-terminal 
variegation/enhancer of zeste/trithorax domain (SET) (Figure 1.5). The ability to bind DNA 
is found in the adenosine-thymine (AT) hooks and methyl transferase (MT) region of the 
protein and could be involved in transcriptional regulation via direct deoxyreibonucleic acid 
(DNA) binding. MLL may mediate transcriptional repression through recruitment of 
repressor complexes such as histone deacetylases (HDAC) or polycomb group proteins via 
the MT domain (Xia et al. 2003).
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Figure 1.5 Structure of the MLL Gene and Protein
A. The schematic representation (exon and intron sizes not to scale) of the MLL gene shows 
the location of the partial tandem duplication (PTD) and the breakpoint cluster region (BCR) 
where translocations occur. B. The protein domains affected by the PTDs and translocations 
are shown as well as the taspase 1 cleavage site. The MLL protein domains include AT-hook 
(DNA binding motif which binds adenosine-thymidine rich DNA), speckled nuclear 
localisation sites (SNL), DNA methyltransferase domain (DNMT), plant homeodomains 
(PHD), transactivation domain (TAD), and suppressor of variegation/enhancer of 
zeste/trithorax (SET) domain (Harper & Apian 2008).
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During maturation, the MLL protein can be cleaved by the protease taspase I into two 
sections, an N-terminal with transcriptional repression properties and a C-terminal with 
transcriptional activation activity (Yokoyama et al. 2002). Interaction between the N and C 
peptides via the corresponding F-y rich N and C terminus domains (FYRN and FYRC 
respectively) on each is required to create a stable protein and the correct subnuclear 
localisation of MLL (Hsieh et al. 2003). MLL has been identified as part of a multi-protein 
super complex containing at least 27 proteins, most of which are involved in transcription. 
The complex includes chromatin remodelling proteins, HDACs, promoter recognition 
proteins and surprisingly proteins associated with transcriptional silencing. The SET domain 
of MLL mediated methylation of H3-K4 histones in the promoter region of HOX genes. 
Methylation in this region is associated with transcriptional activation (Nakamura et al. 2002). 
Knockout studies of taspase 1 revealed the loss of HOX regulation, specifically the early 
expression of the 3’ HOX  genes, while the 5’ genes were unaffected (Hsieh, Cheng, & 
Korsmeyer 2003). This is in contrast to the unilateral affects on HOX gene expression caused 
by MLL knock-out. Therefore, cleavage by taspase 1 appears to be a mechanism for the 
regulation of MLL and HOX  genes which is lost in MLL fusion genes due the loss of the 
taspase cleavage site (Gilliland 2003). The amino terminal section of the MLL gene is 
retained after the translocation and can interact through a conserved binding motif with 
menin, the protein product of the tumour suppressor gene multiple edocrine neoplasia type I 
(MEN1) to promote transcription (Yokoyama et al. 2005). As with MLL, the down-regulation 
of menin disrupted the maintenance of HOX  genes, stopped the differentiation arrest and 
abrogated the leukaemogenic properties of the MLL transformed leukaemic cells.
The MLL gene is very promiscuous, with over 70 translocation partners identified at 
the 11 q23 locus; however, the mechanisms of leukaemogenesis promoted by these 
rearrangements are largely unknown (Harper & Apian 2008). The frequency of MLL
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translocations is around 10% in de novo AML and greater than 85% in sAML (Look 1997). 
All of the translocations occur in an 8.5 kb breakpoint cluster region (bcr) between the exons 
8 and 14 (new nomenclature according to Nilson et al.) (Nilson et al. 1996). The reported 
prognostic significance varies, with some groups reporting an intermediate risk and others 
adverse (Dimartino & Cleary 1999; Rubnitz, Behm, & Downing 1996). This may be the 
result of differences in prognosis arising from different partner genes. For example, the 
clinical outcome in t(9; 11) translocation in de novo AML is significantly improved compared 
to other 1 lq23 translocations in terms of complete remission duration and event-free survival 
(Mrozek et al. 1997). For this reason the category of “Acute myeloid leukaemia with 
t(9;ll)(p22;2q23)” was established in the 2008 WHO classifications (Section 1.2.2). 
Furthermore, the refined Medical Research Council (MRC) cytogenetic risk classification has 
categorised t(6;l 1) and t(10 ;ll)  in the adverse risk group while leaving the other llq23 
mutations in the intermediate classification (Grimwade & Hills 2009). The translocations 
occur in both acute lymphoblastic (ALL) and AML, however there is a bias with t(4;l 1) most 
commonly identified in ALL and t(9; 11) seen more often in AML, suggesting a potential 
influence of the partner gene on the disease phenotype (Dimartino & Cleary 1999; Mrozek et 
al 1997; Tkachuk, Kohler, & Cleary 1992).
The role of the partner gene in MLL translocations is an important one, not only when 
considering the domains lost by MLL but also the characteristics the new gene contributes. 
The regulatory domains removed from MLL include self-association motifs, SET (a histone 
methyltransferase) and transcriptional activation domains, one of which influences the 
transcriptional regulation of HOX  genes. It has been suggested that the MLL fusion proteins 
be divided into two groups based on the proposed leukaemogenic mechanism. Class I fusion 
proteins involve nuclear proteins that have intrinsic transcriptional activity and promote 
aberrant recruitment of transcriptional complexes to downstream MLL targets (Prasad et al.
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1995; Slany, Lavau, & Cleary 1998). This is illustrated by the MLL partner gene ALL-1 
fused gene from chromosome 10 (AF10) (also known as MLLT10) which interacts with the 
histone methyltransferase, DOT 1-like, histone H3 methyltransferase {hDOTIL). hDOTIL 
associates with AF10 via a conserved region of AF10 that is essential for its leukaemic 
potential. When MLL was directly bound to hDOTIL, the construct up-regulated HOXA 
genes and immortalised murine myeloid progenitor cells. Interaction of MLL with hDOTIL 
whether through association with (AF10) or MLL construct, leads to the hypermethylation of 
H3-K79 and subsequent up regulation of HOX  gene expression and promotion of 
leukaemogenesis (Okada et al. 2005). On the other hand, class II fusions involve partners 
able to dimerise yet lacking intrinsic transactivating potential (Martin et al. 2003; So et al. 
2003; So & Cleary 2004). The ability of the fusion gene to dimerise results in MLL gene 
dimerisation as well, which is thought to confer leukaemogenic potential (So et al. 2003). 
The partner genes may have a secondary role since even non-pathogenic genes may also 
promote MLL dimerisation as demonstrated by mice with an MLL-LACZ knock-in which 
showed up-regulation of HOX  genes and developed myeloid and lymphoid leukaemias 
(Dobson et al. 2000). A gain of function through dimerisation could result in aberrant 
recruitment of coactivators or prevention of corepressor binding to cause upregulation of 
target gene expression (Martin et al. 2003; So et al. 2003).
The suggestion that HOX  gene expression may not be necessary for MLL 
leukaemogenesis has been proposed. The class 2 fusion, MZZ-growth arrest-specific 7 
0GAS7), which activates MLL via a dimerisation mechanism was able to transform Hoxa9 and 
Hoxa7 deficient mice, though the resulting phenotype and penetrance was affected (So et al. 
2004). Likewise, HOX  genes were reported to influence the phenotype but not the incidence 
of MLL-AF9 fusion gene leukaemia in a mouse model (Kumar et al. 2004). Additionally, a 
cell line derived from an MLL-AF4 positive patient has functional MLL but lacks HOX  gene
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expression suggesting the transforming potential of the MLL gene can be independent of HOX  
(Bertrand et a l 2003). A likely explanation for the different results in relation to HOX  
expression and leukaemogenesis, is that the need for HOX  is dependent upon the fusion gene 
and cell type being studied. An example of an aberration within the MLL gene that is not a 
translocation is the MLL partial tandem duplication (PTD) which is discussed in Section 
1.2.4.a.
1.2.3.b CBF mutations
The CBF is the most frequently affected site for chromosomal translocations in human 
leukaemia. Common CBF translocations: t(8;21)(q22;q22), invl6(pl3;q22), and t(16;16)) are 
associated with a younger age group and favourable prognosis. The core binding factor 
mutations, t(8;21)(q22;q22), invl6(pl3;q22), and t(16;16) prevent the dimerisation of the a  
and p protein components needed to initiate transcription of genes necessary for normal 
haematopoiesis. The t(8;21)(q22;q22) translocation involves the fusion of RUNX1 gene (also 
known as core binding factor a  2 (CBFal)) with the RUNX1T1 gene. It occurs in 10-15% of 
AML patients and is generally associated with FAB type M2 (Nucifora & Rowley 1995). The 
RUNX1 protein binds to the core enhancer sequences (TGGTGT) of genes responsible for 
haematopoiesis. Whereas the CBFfi subunit has no inherent DNA binding capacity, it 
increases the DNA binding affinity of the resulting heterodimeric unit (Cleary 1999; 
Kagoshima et al. 1993). The RUNX1 transcription factor up-regulates genes necessary for 
normal haematopoiesis including GM-CSF and M-CSFR which are involved in progenitor 
differentiation and proliferation (Rhoades et a l 1996; Takahashi et a l 1995). The 
translocation partner RUNX1T1 is a transcriptional repressor protein. Although it cannot 
physically bind DNA, it forms stable complexes with the repressor complex nuclear co­
repressor (N-CoR) and the silencing mediator for retinoid or thyroid-hormone receptors
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(SMRT) via the zinc finger domain and recruitment of histone deacytylases (HDAC). 
Retention of the ability of RUNX1T1 to bind stably with the repressor complex after 
translocation is thought to convert RUNX1 from an activator to a repressor, leading to a block 
in myeloid differentiation (Gelmetti et al. 1998).
The inversion of chromosome 16 (invl6(pl3;q22)) also disrupts the CBF transcription 
complex by joining the CBFp gene with the smooth muscle myosin heavy chain (MYH11) 
gene. The mutation is associated with a favourable prognosis and the FAB subtype M4Eo. 
The absence of Cbfb caused mice to die at midgestation, however the rescue of foetal liver 
haematopoiesis using a fusion protein restored early development although lymphoid and 
myeloid development failed, with the mice dying at birth (Miller et al. 2002). The data 
suggests that Cbfb is needed for the normal development of the myeloid and lymphoid 
lineages.
1.2.3.C PML-RAR
The t( 15; 17) PML-RAR translocation results in the fusion of the promyelocytic 
leukaemia protein (PML) to the retinoic acid receptor a  (RARA) gene and is associated with 
a favourable prognosis and the FAB classification M3. A hypogranular morphological 
variant is sometimes observed, presenting with an elevated leukocyte count whereas the 
typical hypergranular cases are often leukopenic, but both exhibit a block in granulocytic 
differentiation (Puccetti & Ruthardt 2004). The retinoic acid receptor a  (RARa) forms a 
heterodimer with the retinoid X receptor (RXR) to convey retinoid signalling within the cell. 
The heterodimer binds to specific retinoic acid response elements (RARE) on the target genes 
and initiates transcription via the recruitment of co-activators and histone acetyltransferases 
(HATs). When the ligand is unavailable, the co-repressor complexes NCoR/SMRT and
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HDAC are recruited by the heterodimers at the RAREs, resulting in transcriptional repression 
and a block in granulocytic differentiation (Vitoux, Nasr, & de 2007). When translocated 
with the tumour repressor gene PML, the retinoic acid binding domain on the RARa protein 
is retained and pharmacological concentrations of retinoic acid can reinstate transcriptional 
activation and differentiation (Grignani et al. 1998). The ability to repair the haematopoietic 
pathway through application of retinoic acid is an example of a molecular-based targeted 
leukaemic therapy and is a goal for other leukaemia treatments (Section 1.2.6).
1.2.4 Molecular Genetic Mutations in Cytogenetically Normal AML
Cytogenetic analysis is a useful tool in the prognostic stratification of AML patients 
but it does have its limitations, specifically with regard to the large proportion of patients 
(-45%) that are cytogenetically normal (CN) and placed in the intermediate classification 
(Figure 1.6) (Byrd et al. 2002; Grimwade 2001). AML is typified by its diverse subgroups 
and broad range of patient prognosis. Nowhere is this more evident than in the CN cohort, 
with reported overall survival rates ranging from 24-42% suggesting underlying molecular 
heterogeneity (Farag et al. 2005; Mrozek, Heinonen, & Bloomfield 2001).
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Figure 1.6 Cytogenetic Classification Frequencies
Relative frequencies of recurrent cytogenetic entities in AML. (Gulley, Shea, & Fedoriw 
2009).
Recent findings have identified molecular genetic markers with prognostic 
significance in the CN group; these include NPM1, FLT3, CEBPA and MLL PTD. Such 
submicroscopic mutations are beginning to provide prognostic distinctions within the CN- 
AML patient group. As these mutations cannot be detected by normal cytogenetics they are 
typically detected by the sensitive method of polymerase chain reaction (PCR).
1.2.4m MLL PTD
The MLL PTD is an internal mutation of the MLL gene that often occurs in CN-AML. 
While previously discussed translocations in MLL (Section 1.2.3.a) implicated in the 
leukaemogenesis of AML all translocate with partner genes, the MLL PTD is the tandem
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duplication of an internal sequence. The MLL PTD occurs in the bcr, with either exons 9 to 3 
(e9/e3). 10 to 3 (el0/e3) or 3 to 11 (e ll/e3) creating an in-frame fusion protein. The MLL 
PTD was discovered by association with trisomy 11 and normal cytogenetics (Caligiuri et al.
1996). A proposed mechanism for the PTD is the homologous recombination of Alu 
elements. These are a family of -300 bp genes found throughout the genome which are 
flanked by Alu restriction sites. The reported reconstitution of an Alu site in the region where 
the MLL PTD inserts suggests that Alu elements are potential mediators for MLL PTDs 
(Strout et al. 1998) (Schichman et al. 1994b). By inserting 3' of the AT hooks and the methyl 
transferase and 5' to the zinc finger motifs, the distances between the DNA interacting regions 
are disrupted. This alteration in the pattern of the regulatory elements of MLL could be 
responsible for changing how the protein regulates haemopoietic genes (Figure 1.5) (Downing 
& Look 1996). The duplication of functional domains in MLL PTD may enable it to function 
in a manner similar to the class 2 MLL translocations, which dimerises to duplicate these 
regions (Section 1.2.3.a) (Ayton & Cleary 2001). The MLL PTD construct has 
transactivation activity comparable to that of a dimerised MLL translocation construct (Martin 
et al. 2003). MLL PTDs of various composition have been shown to exist in the PB and BM 
of healthy donors when a sensitive nested PCR technique is used (Schnittger et al. 1998). 
This suggests that careful optimisation of the PCR method would be required before the test 
could be made a routine diagnostic assay. This finding also suggests that the MLL PTD alone 
may not be enough to cause the onset of leukaemia.
Several links can be made between MLL PTD and FLT3 internal tandem duplications 
(ITDs). Both MLL PTD and FLT3 ITD have been reported to be associated with 
cytogenetically normal AMLs and appear to be susceptible to breakage by topoisomerase II 
inhibitors (Libura et al. 2003). There is also the evidence of the two duplications occurring 
simultaneously in AMLs (Steudel et al. 2003).
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1.2.4.b FLT3
The FLT3 gene is located on chromosome 13 and is a member of the class III tyrosine 
kinase receptor family. The gene encodes a membrane bound protein that is involved in 
haematopoiesis through the regulation of proliferation, differentiation and apoptosis of 
progenitor cells (Stirewalt & Radich 2003). FLT3 is mutated in approximately one third of all 
AML patients, making it one of the most common mutations detected. There are two types of 
mutations that occur in the FLT3 gene, the internal tandem duplication (ITD) and the tyrosine 
kinase domain (TKD) mutation. The more frequent ITD creates a variable length insertion in 
the juxtamembrane (JMD) region of the receptor and occurs in approximately 30% of CN- 
AML patients (Frohling et al. 2002; Kottaridis et al. 2001; Schnittger et al. 2002; Thiede et 
al. 2002). The TKD mutation is a missense mutation in the activation loop of the tyrosine 
kinase domain and occurs in 10% of CN-AML patients (Beran et al. 2004; Frohling et al. 
2002; Thiede et al. 2002). Both mutations promote constitutive phosphorylation of the 
receptor in the absence of ligand and activate downstream signalling pathways including 
JAK2, STAT5 and mitogen activated protein kinase (MAPK) (Grundler et al. 2005; Lee et al.
2007). Furthermore, both FLT3-YYD and FLT3-TKD show a significant association with high 
bone marrow blast percentages and high white blood cell count at diagnosis (Frohling et al. 
2002; Mead et al. 2007; Whitman et al. 2001). The FLT3-TKD generates conflicting clinical 
outcomes while studies have consistently shown that the FLT3-ITD has a negative impact on 
clinical outcome (Section 1.2.6.b) (Bacher et al. 2007b; Mead et al. 2007; Whitman et al. 
2008b; Yanada et al. 2005). Differences between these two types of FLT3 mutations are seen 
in experimental models. The TKD mutation promotes an oligoclonal lymphoid disorder in 
murine transplantation studies with a long latency period, whereas the ITD generates a 
myeloproliferative disease. Neither is capable of inducing AML (Grundler et al. 2005; Lee et
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al. 2007). Together with the observation that FLT3 mutations are often lost upon disease 
relapse, this indicates that the FLT3 mutations are a secondary genetic event incapable of 
initiating disease (Gilliland & Griffin 2002; Kottaridis et al. 2002).
1.2.4.C NPM1
The NPM1 gene has both tumour suppressor and oncogenic properties, dependent 
upon the context, and occurs in approximately 50% of CN-AML patients (Boissel et al. 2005; 
Falini et al. 2005; Schnittger et al. 2005a; Thiede et al. 2006). Over 40 mutations have been 
described in NPM1, the most common being a four basepair insertion that occurs in >75% of 
AML cases. All of the mutations result in aberrant localisation of the protein to the cytoplasm 
where its normal functions are disrupted; these include regulation of ribosomal protein 
assembly and the tumour suppressor pathways ADP-ribosylation factor 4 (ARF) and tumor 
protein p53 (p53) (Falini et al. 2005). The FLT3-ITD is detected in around 40% of all 
patients with NPMJ mutations. The clinical outcomes of patients with the NPMJ mutation 
but lacking the FLT3-ITD were significantly better than those with FLT3 ITD alone (Section
1.2.6.b) (Dohner et al. 2005; Thiede et al. 2006). The suggestion that NPM1 may be an early 
event in leukaemogenesis was supported by evidence that the NPM1 mutations preceded 
mutations of FLT3 and is a stable marker through relapse (Chou et al. 2006; Gorello et al. 
2006; Thiede et al. 2006).
1.2.4.d CEBPA
CEBPA is a transcription factor belonging to the CCAAT/enhancer binding protein 
family and is involved in terminal differentiation and cell proliferation. The gene is 
instrumental in the early stages of myeloid differentiation and is expressed in 
myelomonocytic cells. The frequency of CEBPA gene mutations in de novo AML is -9% ,
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with most of the mutations occurring in M l, M2 and M4 (Nerlov 2004). Support for the 
association with myeloid development is demonstrated by CEBPA expression beginning with 
the commitment of myeloid precursors and increasing during granulocyte differentiation. 
Additionally, mice without CEBPA expression lack mature granulocyte cells while other 
lineages are unaffected (Zhang et al. 1997). During haematopoietic development, CEBPA 
down regulates c-MYC to promote differentiation and up regulates genes involved in 
granulocytic differentiation (Johansen et al. 2001; Radomska et al. 1998). Despite evidence 
that CEBPA mutations cause dysregulation of granulopoiesis and myeloid progenitors, 
deletion of the gene fails to cause leukaemia (Heath et al. 2004; Zhang et al. 2004)(Kirstetter 
et al. 2008; Porse et al. 2001). There are two groups of mutations in CEBPA: N-terminal 
mutations which allow expression of the 30kDa protein while blocking translation of the 
larger 42kDa protein, and C-terminal mutations that disrupt the DNA binding domain (Nerlov
2004). Bereshchenko et al. investigated the influence of these two mutation groups found 
concomitantly in the majority of all AML patients with a CEBPA mutation (Bereshchenko et 
al. 2009). Homozygous mutations of either terminal are uncommon, whereas the 
combination of both mutations is detected in >90% of biallelic CEBPA mutations. This 
selection pattern indicates that each mutation contributes a particular function which 
combines to promote leukaemogenesis. The study determined that the C-terminal mutation 
promotes proliferation of the HSC population while the N-terminal, mutation promotes HSC 
differentiation to the stage of myeloid progenitor cells. The pro-leukaemic function of the C- 
terminal mutation takes place in a cell type upstream of the final leukaemic cell population, 
which has implications for the targeting of cells for therapeutic intervention (Section 1.2.6.c).
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1.2.5 Pathogenesis of AML
A model of co-operative mutations has been proposed where two complementary 
categories of mutations are needed to generate AML. The two categories are mutations that 
enhance the proliferative and survival ability (Class I mutations) and mutations that impair 
differentiation and/or create the ability for self-renewal (ClassII) (Gilliland & Griffin 2002; 
Renneville et al. 2008). Although this is a reductionist model of co-operative mutations and 
confounding examples can be found (e.g. some mutations have been observed occurring 
simultaneously with mutations of the same class (Ishikawa et al. 2009)), it is a useful tool for 
understanding the onset of AML. Some class 2 AML fusion proteins including RUNX1- 
RUNX1T1 and PML-RAR generate a ‘‘mutator” phenotype by the induction of processes that 
promote self-renewal while concomitantly down regulating genes involved in DNA repair 
(Alcalay et al. 2003). The idea of class 2 mutations preceding and promoting the class I 
mutations is supported by other mutator phenotypes associated with leukaemia including 
Down’s syndrome and familial CEBPA mutations. Furthermore, the stability of class II 
mutations seen at relapse (NPMl,CEBPa, and AML translocations) as contrasted with the 
variability of class 1 mutations (FLT3, c-KIT and rat sarcoma (RAS')) supports this theory 
(Boissel et al. 2005; Kottaridis et al. 2002; Nakano et al. 1999; Shih et al. 2006b). The 
acquisition of a new class I mutation following remission is a possible explanation for the 
variability seen. Successful initial chemotherapy targeting cycling leukaemic cells with the 
class I mutation may return the disease to a previous stage of leukaemogenesis; from this 
stage, acquisition of a new class I mutation could cause relapse of the disease (Section
1.2.6.b).
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1.2.6 Treatment of AML
1.2.6. a Current treatments
The first goal of AML treatment is to induce complete remission (induction), defined 
as <5% blasts remaining in the bone marrow, followed by further treatment to extend the 
remission for as long as possible (consolidation). Patients who have maintained complete 
remission for >3 years have less than a 10% risk of relapse (Estey et al. 1997). The method 
of achieving complete remission has changed little in the past 30 years with the standard 
intensive chemotherapy remaining relatively unchanged. Currently, the decision of whether a 
patient receives standard treatment, allogeneic transplant, investigational treatment or 
palliative care is based on prognostic factors such as age and cytogenetic risk classification, as 
well as performance status (Estey & Dohner 2006) (Section 1.2.6.b). Recent advances in 
understanding the molecular pathogenesis of AML and predicting prognosis have led to the 
investigation of prognosis stratified treatment and therapies targeted to particular pathways. 
Such tailored treatments may offer improved clinical outcome, particularly to the elderly and 
poor-risk patients. (Section 1.2.6.C).
The standard treatment for AML patients consists of induction chemotherapy followed 
by a post remission therapy of further chemotherapy or a bone marrow transplant. The so- 
called “3+7” treatment is seven days of continuous intravenous infusion of cytarabine and 
three days of intravenous duanorubicin. Various combinations of alternative anthracyclines 
and doses, as well as other cytotoxic agents during induction have not improved patient 
outcome overall, although certain subgroups do benefit (Estey & Dohner 2006). Any benefits 
owing to higher doses in induction have to be balanced against the increase in toxicity and 
mortality. Generally, prognostic considerations dictate that favourable and intermediate risk 
patients proceed with consolidation chemotherapy after remission, usually consisting of 
multiple courses of high dose cytarabine (Section 1.2.6.b) (Jabbour, Estey, & Kantarjian
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2006; Rowe 2008). The other alternative for patients with intermediate risk would be 
allogeneic bone marrow transplant. However, despite improved relapse-free survival there is 
generally no improvement in overall survival, due to treatment mortality together with a 
reduction in patient’s quality of life (Burnett et al. 1998; Cassileth et al. 1998; Stone, 
O'Donnell, & Sekeres 2004)(Gale et al. 2005). Additionally, poor-risk FLT3 ITD patients 
receiving a bone marrow transplant from a related donor show no improvement in outcome 
than over those without (Gale et al. 2005). This indicates that a less favourable prognosis 
does not necessarily benefit from more aggressive treatment. However, other studies indicate 
a positive clinical outcome for poor risk patients receiving an allogeneic transplant (Schlenk 
et al. 2008, Comelissen et al. 2007).
1.2.6. b Factors Affecting Clinical Outcome
Prognostic factors including age, performance status and genetic characteristics are 
critical to determining the appropriate treatment strategy for the patient (e.g. standard 
treatment, molecularly targeted therapies or supportive care) and identifying those who might 
benefit from allogeneic transplant (Section 1.2.6.a and 1.2.6.c). One of the current goals in 
AML prognosis is to understand the relationships between the genetic mutations, including 
the more recently discovered molecular genetic aberrations, and the established indicators 
(e.g. age and white blood cell count) so that a stratified therapy can be administered with 
optimal benefits for all patients. In addition to the pre-treatment factors, the patient response 
to treatment as assessed by molecular and immunological minimal residual disease (MRD) 
methods contributes to the overall patient prognosis (Section 1.3) (Grimwade & Hills 2009). 
Prognostic scoring systems have been proposed including the HO VON/S AKK prognostic 
score which combines pre-treatment (including molecular genetic markers) with microarray
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expression data to produce four risk categories with different outcomes for determining which 
patients would benefit from allogeneic transplant (Comelissen et al. 2007).
The decision to consider alternatives to standard therapy for adverse risk karyotypes is 
due to the poor outcome; less than 50% respond to induction therapy and fewer than 10% of 
those who achieve remission will remain relapse free with either high dose cytarabine or 
autologous transplant (Bloomfield et al. 1998; Stone, O'Donnell, & Sekeres 2004; Suciu et al. 
2003). This is in comparison to AML patients overall receiving standard therapy whose 
remission rates range from 50-85%, with 20-30% achieving the goal of long term disease free 
survival (Shipley & Butera 2009). Patients with secondary AML or who are elderly, are also 
associated with poor outcome. Refractory disease can occur in all three of these patient 
groups due to chemoresistance mediated by intracellular mechanisms (e.g. up-regulation of 
the multidrug resistance protein-1) that promote the removal of chemotherapeutic agents from 
the cell (Mahadevan & List 2004). Relapse following remission suggests that a small 
population of cells capable of expansion remain or arise via mutation despite the therapy 
administered. The high sensitivity of molecular techniques such as PCR and 
immunophenotyping enable detection of leukaemic cell populations well below the levels 
associated with the clinical definition of remission. The monitoring of MRD and its value to 
patient prognosis is discussed further below (Section 1.3). The rate of remission and disease 
free survival have a negative correlation with increasing age, with the rate of complete 
remission in the elderly ranging from 41-62% with dismal long term survival rates (Goldstone 
et al. 2001; Rowe et al. 2004). This is due to co-morbidity factors and an increased 
proportion of adverse cytogenetics. Analysis of cytogenetics is combined with assessment of 
performance status to determine if elderly patients are candidates for either intensive 
chemotherapy, investigational trial or would be better served by non-intensive or supportive
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care (Section 1.2.6a). Despite conflicting reports of clinical outcome, allogeneic bone 
marrow transplant is the usual treatment for adverse risk patients (Shipley & Butera 2009).
While the root causes of many cases of AML remain unresolved, there are a number 
of acquired genetic abnormalities that are closely associated with the disease. Balanced 
translocations, complex karyotypes and sub-microscopic mutations are all examples of 
acquired mutations and most have a distinct prognosis.
The first impact of molecular biology on classification and prognosis arose from the 
association between diagnostic cytogenetics and outcome (Section 1.2.2) (Estey & Dohner 
2006; Grimwade et al. 1998). Genetic abnormalities such as chromosomal deletions, 
additions, translocations and complex karyotypes have become the primary means for 
determining prognostic outcome of AML. Three clear groups, favourable, intermediate and 
adverse, were observed with markedly different outcomes. Compared to those patients with 
normal cytogenetics, the favourable group (including t(8;21) RUNXI-RUNX1T1, inversion 
16 CBFB-MYH11 and t ( l5; 17) PML RARA), did significantly better in overall survival and 
the adverse group (including the monosomies 5 and 7, and complex karyotypes (five or more 
abnormalities) did significantly worse (Figure 1.7). Patients with MLL llq23 translocations 
or other cytogenetic abnormalities that were not significantly different in clinical outcome 
than cytogenetically normal including the trisomies +11 and +21 were placed in the 
intermediate grouping (Grimwade et al. 1998). The largest subgroup in the breakdown of 
diagnostic cytogenetics is the cytogenetically normal group, with 40-50% of all AML patients 
in this class. These CN patients are placed in the intermediate prognostic group due to the 
lack of informative markers.
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Figure 1.7 Overall Survival of AML Patients Grouped by Karyotype
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Recognising the patients that may fall into the adverse risk group is particularly 
difficult in the cytogenetically normal group because the overall prognosis depends on the 
standard indicators as well as any molecular mutations acquired. New methods to assess CN- 
AML patient's risk category prior to initial treatment, as well as guidelines for mutational 
screening have been proposed which incorporate the prognostic impact of molecular genetic 
mutations (Mrozek et al. 2007; Renneville et al. 2008; Santamaria et al. 2009). Additionally, 
gene expression profiling (GEP) is capable of identifing subsets of CN-AML with a poor 
clinical outcome (Section 1.4.2) (Bullinger et al. 2004). There is general consensus that the 
FLT3-ITD confers lower disease free survival (DFS), overall survival (OS), and an increased 
risk of relapse (RR) (Figure 1.8) (Kottaridis et al. 2001; Sheikhha et al. 2003; Yanada et al.
2005). Studies specific to CN-AMF found the FLT3 ITD to be an independent adverse 
prognostic marker that conferred a lower OS and complete remission duration (CRD) (Baldus 
et al. 2006; Frohling et al. 2002; Whitman et al. 2001). On the other hand, the NPMJ 
mutation confers a favourable prognosis, but only in the absence of a FLT3 ITD. This 
improved outcome was demonstrated in better CR rates, relapse free survival (RFS), DFS and 
OS (Dohner et al. 2005; Gale et al. 2008; Thiede et al. 2006). In contrast, the patients with 
both an NPMJ mutation and FLT3-ITD showed no improvement on intermediate poor 
prognosis conferred by the absence of both mutations (Gale et al. 2008). A prognosis 
determined without assessment for multiple mutations could be highly inaccurate and may 
prevent the patient from getting the best possible care. In fact, a recent study reported that 
FJT3 TKD positive patients exhibit all possible prognoses dependent upon the identity of 
concomitant mutations. FLT3 TKD as the sole abnormality has no effect, FLT3 TKD with 
PML-RAR confers an unfavourable outcome and FLT3 TKD with either NPMJ or CEBPA 
confers a favourable impact greater than that seen with either mutation on its own (Bacher et 
al. 2007b). The identification of more molecular genetic mutations will surely discover more
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complexities in the interactions between these and pre-existing mutations and their affect on 
prognosis.
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Figure 1.8 Impact of FLT3 ITD on Risk of Relapse in Cytogenetic Risk Groups
The FLT3 ITD is associated with a higher risk of relapse in every cytogenetic risk group. The 
influence of the mutation is greatest in the intermediate and adverse risk groups. ITD: 
internal tandem duplication.
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1.2.6.C New Treatments
Older patients and younger patients with adverse prognosis and no donor often opt for 
investigational therapy as the best option for improved clinical outcome (Estey & Dohner
2006). New treatment strategies including targeted therapies, epigenetic therapies and 
refinements to existing compounds, offer avenues of investigation for these adverse risk 
groups for whom standard therapy offers little help.
There are many trials currently being conducted to assess the benefit of new therapies 
in AML. The ideal example of a targeted therapy based on a genetic mutation (t(9;22) BCR- 
ABL) is the drug imatinib, which is used in chronic myeloid leukaemia (CML); this drug is 
associated with a three-year survival rate of over 94% (Hughes et al. 2003). Imatinib inhibits 
the BCR-ABL tyrosine kinase by physically blocking the binding site used by the fusion 
protein, thus preventing the activation of downstream genes. The idea of similarly targeted 
agents for AML subtypes based on genetic mutations is appealing and several compounds are 
under investigation including inhibitors of FLT3 mutations such as the small molecule 
inhibitors PKC-412 and CEP-701. However, due to the genetic diversity of AML it is 
unlikely there will be a “one-size-fits-aH” drug for AML. In initial trials as a single agent, 
these inhibitors appear to have a transient clinical response, however pre-clinical evidence 
suggests synergy between FLT3 inhibitors and standard chemotherapy agents and trials in 
combination with chemotherapy are underway (Knapper et al. 2006; Knapper 2007; Shipley 
& Butera 2009). On a more global genetic scale, transcription modulators (DNA 
demethylating agents and histone deacetylase inhibitors) that affect epigenetic pathways have 
also been tested. DNA hypermethylation and histone deacetylation have been implicated in 
carcinogenesis via the suppression of tumour suppression genes; the reversal of these 
processes can reinstate tumour suppressor and pro-apoptotic gene function (Fandy, Carraway, 
& Gore 2007). Early studies have shown that AML patients have a positive response to
1-53
demethylating agents and histone deacetylating compounds, as well as to the combination of 
both and further trials are being conducted (Shipley & Butera 2009). As more genetic 
markers are discovered and the understanding of the existing markers expands there is 
increasing opportunity for discovering new genotype specific targets that could be exploited 
for therapeutic benefit. However, due to the small size of some genetic subgroups identified, 
large clinical trials are needed to assess their full contribution to prognostic stratification. 
Furthermore, to obtain a complete picture of the effectiveness of treatment modalities, all 
prognostic markers need to be taken into consideration so that independent prognostic 
variables can be identified.
1.3 Minimal Residual Disease
1.3.1 Background
The monitoring of minimal residual disease in AML is an important tool for 
determining the patient’s initial response to treatment and for detection of impending patient 
relapse post-treatment. In acute promyelocytic leukaemia (APL), MRD evaluations are 
commonly used to enable the clinician to make a well-informed decision for further treatment. 
When a patient achieves the clinical definition of complete remission (<5% blasts in the bone 
marrow by morphological identification), the number of leukaemic cells still remaining can be 
as high as 1010 (Campana & Pui 1995). Between 50-70% of patients who achieve complete 
remission will relapse within three years, which implies a residual population of leukaemic 
cells was able to regenerate the disease (Liu Yin 2002b; Robak & Wierzbowska 2009). 
Patient response to induction therapy (gauged by the morphological detection of blasts) is an 
independent prognostic factor predicting for risk of relapse and overall survival, and carries 
recommendations for treatment (Cheson et al. 2003; Robak & Wierzbowska 2009). A
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sensitive MRD assay would allow early identification of patients with either an inadequate 
response to treatment or at risk of relapse and would give clinicians an opportunity to alter the 
therapy at an earlier stage of disease progression, potentially improving the clinical outcome 
(Grimwade & Lo 2002; Liu Yin 2002b).
1.3.2 Methods of Detecting Minimal Residual Disease
The ability to detect leukaemic cells at a level below the level of morphological 
assessment has increased tremendously in the past 20 years. With the advent of new MRD 
methodologies, sensitivity has improved from approximately 1 cell in 20, detected by 
cytogenetic karyotyping/morphology to 1 cell in 500 by fluorescent in situ hybridisation 
(FISH) to 1 cell in 103-104 by flow cytometry and 1 cell in 103-106 by real time quantitative 
polymerase chain reaction (RQ-PCR) (Estey & Dohner 2006; Freeman, Jovanovic, & 
Grimwade 2008). The reported sensitivity is dependent on the methods used and the targets 
selected. Initially, conventional cytogenetic karyotyping was used to follow leukaemic 
disease, the leukaemic aberration present at the patient’s diagnosis was absent during 
remission and then reappeared at relapse (Testa et al. 1979). FISH analysis is more sensitive 
than conventional cytogenetics and can detect some rearrangements not identified by 
karyotyping, however the higher sensitivities of flow cytometry and RQ-PCR make them the 
most effective MRD techniques.
One of the major advantages of flow cytometry for MRD analysis is its broad 
applicability to >80% of patients, through detection of aberrant expression of surface markers 
on leukaemic blasts (Al-Mawali, Gillis, & Lewis 2009; Kern & Schnittger 2003). While RQ- 
PCR measures MRD by the expression level of the marker gene, flow cytometry counts cell 
numbers using a leukaemia-associated aberrant immunophenotype (LAIP) that differentiates 
blast cells from normal cells. Although the sensitivity is lower than RQ-PCR, MRD analysis
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using flow cytometry has predicted relapse free survival using cell numbers determined either 
after induction or consolidation (Kern et al. 2004; San Miguel et al. 2001). Disadvantages to 
this technique include lower sensitivity (compared to most RQ-PCRs) and possible 
inappropriate selection of markers due to poor specificity, sensitivity and stability in LAIPs 
(Al-Mawali et al. 2008).
The work presented in this study utilised RQ-PCR as a method of MRD detection so 
the associated methodology is discussed in greater detail. PCR is the most sensitive of the 
MRD methodologies, capable of detecting between 1 AML cell in 103 to 106 normal cells, 
however, MRD detection using PCR requires the identification of a leukaemic specific 
markers such as fusion genes (e.g. PML-RAR), mutations (e.g. NPM1 mutation or FITS  ITD) 
or AML associated gene overexpression (e.g. Wilm’s Tumour ( WT-1). The main advantages 
of PCR as a method o f MRD monitoring are that it is highly sensitive, quantitative and rapid, 
while disadvantages are risks of contamination and reduced sensitivity due to degraded RNA 
or inefficient reverse transcription. Additionally, a negative result must be considered not as 
the absence of disease but the absence of detectable disease by the methodology used (Liu 
Yin 2002a). This consideration is applicable to all types of MRD assays. Reasons for 
negative results include low or absent marker, low sensitivity in a particular sample or a 
change in the genotype of the patient (e.g. FLT3 ITD). The PCR consists of multiple cycles 
o f amplification of a target DNA specified by small complementary primer DNA sequences 
resulting in the exponential expansion of the target sequence. Reverse transcription PCR 
(RT-PCR) is a method where cDNA (following reverse transcription from RNA) is the 
template material for amplification. Qualitative RT-PCR is often used in diagnostic and 
follow up analysis of AML patients (Dolken 2001; Hokland & Pallisgaard 2000). A 
European consortium, “BIOMED-1 Concerted Action: Investigation of minimal residual 
disease in acute leukaemia”, established standardised qualitative RT-PCR conditions for many
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of the most common translocations in acute leukaemia (van Dongen et a l 1999). To increase 
sensitivity and reduce the risk of contamination, the Biomed-1 amplification used nested 
primers, with the second set internal to the first (van Dongen et a l 1999). However, 
differences in the kinetics of decreasing disease meant that haematological remission was 
found to be possible despite persistent positive results in core binding factor leukaemias 
making the results of qualitative tests uninformative if positive (Costello et a l 1997; Tobal & 
Yin 1996b). Therefore, despite being generally less sensitive, the method of RQ-PCR is often 
more informative than a qualitative RT-PCR due to the determination of an accurate 
quantitation of residual disease.
One of the early methods of quantitative PCR was competitive PCR. Competitive 
PCR is a technique where a known concentration of an internal control is serially diluted and 
amplified with the same primers as the unquantified target gene. The internal control is a 
different size to the target so the intensity of the amplification endpoints can be compared to 
determine the quantity of the target sample. Despite the success of this method at detecting 
relapse in RUNX1-RUNXT1 patients, it was labour intensive and was superseded with the 
advent of fluorescent based RQ-PCR technology (Tobal & Yin 1996a).
Using RQ-PCR technology, detection of fluorescence from internal probes or a 
fluorescent dye enables the calculation of the amount of target template present in an 
amplified sample. The fluorescence produced is proportional to the level of target being 
amplified allowing quantitation to be based on the accumulation of target instead of the 
endpoint amount, thus preventing misinterpretation due to “plateauing” of the PCR. The 
accumulation of fluorescence is measured on every successive cycle with the quantitation of 
the product based on the cycle at which the fluorescence is first detected. The number of 
cycles needed for detection of a sample is called the crossing point (Cp) or cycle threshold 
and this value is used to calculate the amount of target produced. Further discussion on RQ-
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PCR can be found in Section 2.6.2 of materials and methods and in Chapter 4. Advantages to 
RQ-PCR are the speed of the testing, the reduction of contamination risk due to the 
elimination of post-PCR processing and the capability for automation and standardisation. 
The main disadvantage to RQ-PCR is the general lack of sensitivity in comparison to the 
qualitative testing (Liu Yin 2002a; Takenokuchi et a l 2004).
1.3.3 Assessment of Treatment Response and Prediction of Relapse
The two main goals of RQ-PCR MRD detection are assessment of the patient’s initial 
treatment response as a prognostic guide to further therapy and prediction of post-treatment 
relapse. As examples of treatment response assessment, in RUNX\-RUNXJTJ and CBFB- 
MYH11, the level of MRD following induction and consolidation was found to have a 
positive correlation with relapse risk with one study reporting RUNX1 -R UNX1T1 MRD to be 
an independent prognostic factor after adjustment for other pre-treatment factors (Krauter et 
a l 2003; Perea et a l 2006; Weisser et a l 2007). Several of the groups reported that 
achieving a 2-log reduction of disease related transcripts was prognostically significant in 
CBF leukaemias and leukaemias with WT-1 overexpression (Krauter et a l 2003; Lapillonne 
et a l 2006; Stentoft et a l 2006). An example of where prediction of post-treatment relapse 
by RQ-PCR has been used as a prognostic guide is in the management of APL: an increasing 
level of PML-RAR transcript, detected by sequential RQ-PCR testing of the bone marrow 
successfully predicted relapse; preceding clinical relapse by 3 months (Lo-Coco & Ammatuna 
2006; Reiter, Lengfelder, & Grimwade 2004). Furthermore, pre-emptive treatment studies to 
assess the dangers of associated coagulopathy in APL demonstrated a benefit to early 
treatment intervention on the basis of MRD analysis (Esteve et a l 2007; Lo et a l 1999a).
In addition to the different kinetics of disease reduction in different leukaemias, the kinetics of 
relapsing disease also have to be considered when analysing the effectiveness of MRD. The
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length of time from first molecular detection of MRD to haematological relapse can differ 
from four months for APL to 1-2 months for CBFB-MYH11 (Ommen et al. 2008). Relapse 
kinetics coupled with different sensitivities between peripheral blood and bone marrow make 
the sample type and time points used for MRD crucial to success (Figure 1.9).
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Figure 1.9 Minimal Residual Disease Kinetics
Different MRD kinetics in the bone marrow of long term survivors of three favourable 
cytogenetic translocations are shown following standard chemotherapy, a) PML/RARA 
becomes undetectable after induction/consolidation, whereas high dose treatment of 
CBFB/MYH1 land AML 1/ETO (RUNXVRUNX1T1) take around 12 months. The effect of 
different treatment methods are shown with low dose consolidation of AMLHETO 
(RUNX1 /RUNX1 Tl) remain low but detectable with the patient in complete remission. 
ATRA: all trans retinoic acid; HiDAC: high dose cytarabine (Jaeger & Kainz 2003).
Further study is needed to confirm the effectiveness of MRD monitoring in identifying 
patients whose suboptimal response to initial treatment indicates they may benefit from an 
alternative treatment. Additionally, the effectiveness of early intervention in post-treatment 
patients on the basis of increasing MRD needs to be studied in groups other than APL. These 
studies should consider how MRD analysis could supplement the prognostic factors already in 
use to improve clinical outcome. An RQ-PCR standardisation methodology has been 
reported for MRD detection in leukaemia (Gabert et al. 2003), however, an international 
adoption of common methodology is needed to address variations in sample type, monitoring
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schedule, PCR technique, efficiency and reporting methods. Preferably, methodologies 
would be established for the different AML genotypes tested, similar to the approach being 
used for MRD in CML (Hughes et al. 2006).
Ideally, all of the techniques mentioned above are utilised and discussed in a 
multidisciplinary setting so that diagnostic results can be compared. This provides a forum 
for discussion of unusual cases and helps to resolve cases where conflicting results are found 
by different technical methods. The understanding of other techniques by members of a 
multidisciplinary team leads to an enhanced ability to find solutions to the challenges of a 
rapidly changing field. Most importantly, analysis of results with clinical and scientific staff 
present leads to a consensus regarding the best method of MRD for each individual patient.
1.3.4 Additional Minimal Residual Disease Targets
It appears likely that MRD analysis will be beneficial to improving patient outcome 
(Section 1.3.3), however the most commonly tested translocations (RUNX1-RUNX1TJ, 
CBFB-MYH11 and PML-RAR) occur in only 25% of all AML patients, therefore additional 
MRD targets are needed. Molecular genetic aberrations, mutations and gene over-expression, 
have been tested as targets for MRD. The use of FLT3-ITD appears promising due to the 
high incidence in all AMLs, but is hampered by instability at relapse and the need for patient- 
specific primers to increase the sensitivity (Schnittger et al. 2002; Schnittger et al. 2004). 
Initial studies of NPM1 and WT-1 as MRD markers are encouraging. NPM1 is the most 
frequent mutation in CN-AML, is stable upon relapse, and requires only three primer sets to 
encompass >90% of all mutations (Figure 1.10) (Falini et al. 2005; Gorello et al. 2006). The 
expression level of NPM1 has been shown to be predictive of relapse and a 3-log reduction 
was associated with a reduced risk of relapse (Chou et al. 2007; Gorello et al. 2006). WT-1 is 
over expressed in the majority of AML cases and despite misgivings regarding detection of
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over-expression in a background of normal expression, it has shown promise as an MRD 
marker (Garg et al. 2003b). Patients with the greatest reduction of WT-1 expression after 
induction had a significantly lower risk of relapse after adjustment for WBC and cytogenetics; 
conversely continuing to express WT-1 after consolidation had a significantly higher risk of 
relapse (Cilloni et al. 2009). In summary, the use of new molecular aberrations for MRD 
monitoring appears to be prognostically useful, although the assays are often less 
straightforward than translocation testing.
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Figure 1.10 Sensitivity of NPM1 by RQ-PCR
The sensitivity of NPM1 is shown by a limited dilution series of NPM1 positive sample into a 
NPM1 negative sample. The mutation is nearly detectable to 1:1,000,000. (Kern et al. 2008).
016
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1.4 Gene Expression Profiling
Gene expression profiling provides a new technique for the analysis of the 
heterogeneity of AML by measuring the expression level of thousands of gene transcripts 
simultaneously. Genetic and biological diversity is a hallmark of AML and is used to 
determine prognosis and predict the response to different therapies (Section 1.2.6.b). Given 
that a large proportion of AML are cytogenetically normal and multiple mutations appear to 
be needed to promote leukaemogenesis, the heterogeneity of AML is likely to increase with 
improved test resolution (Dash & Gilliland 2001). The ability of GEP to evaluate multiple 
gene expressions in a single analysis offers a potential solution to this dilemma. Researchers 
have used GEP investigations to gain insight into the complexity of AML with the aim of 
predicting AML subsets, predicting prognosis and identifying new leukaemia related 
pathways.
1.4.1 Prediction of AML Subgroups
GEP analysis has been proposed as a method of clinical diagnosis for AML due to its 
success as a predictor of AML subgroups. Studies such as the Microarray Innovations in 
Leukaemia (MILE), aim to standardise GEP for use in a routine diagnostic setting (Kohlmann 
et al. 2008). Class prediction is used to predict groups based on known sample information 
(e.g. cytogenetic abnormality) whereby a unique signature is identified for a particular 
cytogenetic aberration and subsequently used to predict that group from the expression data of 
unknown samples. This method was first used to study acute leukaemia in 1999, when Golub 
et al. analysed 38 samples from acute leukaemia patients using a set of 50 predictor genes to 
successfully differentiate AML and ALL samples (Golub et al. 1999). Unique gene
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signatures attributed to the favourable cytogenetic translocations t(8;21) RUNX1 -RUNX1 T l , 
t( 15; 17) PML-RAR and inv(16) CBFB-MYH11 have been used to predict the subgroups with 
up to 100% accuracy (Debemardi et al. 2003; Valk et al. 2004)(Ross et al. 2004). Results for 
the more diverse llq23 rearrangements were conflicting, with reports of 90% accuracy and 
no prediction value at all (Haferlach et a l 2005; Verhaak et a l 2009). Furthermore, the 
investigation of other cytogenetic abnormalities such as complex karyotype, trisomy 8 and 3q 
have failed to demonstrate accurate prediction (Bullinger et a l 2004; Verhaak et a l 2009; 
Virtaneva et a l 2001). Prediction of the molecular genetic mutations has met with similarly 
mixed success. Prediction accuracy of CEBPA biallelic mutations was 100%, while 
prediction of NPM1 was 66% and FLT3 ITD was either low prediction accuracy or none at all 
(Verhaak et a l 2009). Generally, the mutations with more direct roles in transcription 
modulation such as the CBF translocations were more accurately predicted while non­
transcription factor abnormalities (e.g. FLT3 ITD) fared less well (Wouters, Lowenberg, & 
Delwel 2009a). In summary, the success of GEP subgroup prediction was limited to certain 
groups of diagnostic markers; the identification of additional signatures able to classify the 
non-transcription factor abnormalities would give GEP greater potential as a diagnostic assay.
1.4.2 Prediction of Prognostic Subgroups
GEP analysis is a potential solution to the difficulties of prognostic classification of 
patients due to the rising number of genetic markers being identified and the complexity of 
combinatorial effects. The strength of GEP is not primarily in the prediction value of singular 
definitive markers, but in the overall signature of expression, which has been investigated 
with the aim of predicting prognosis. In fact, while FLT3 ITD was poorly predicted as an 
entity, the gene signature was a significant indicator of clinical outcome. The poor prediction 
may have been due in part to the identification of similar signatures that arose from other
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mutations or epigenetic changes without involvement from FLT3 ITD (Baldus & Bullinger
2008). Several studies have reported the identification of new prognostic subgroups using 
GEP analysis. A set of 133 predictor probe sets was determined to be an independent 
prognostic factor, successfully predicting the OS of AML patients including those with CN- 
AML. The CN-AML patients were divided into two groups with significantly different 
overall survival (Bullinger et al. 2004). A laboratory using a different GEP methodology 
independently validated these results. The presence of FTL3 ITD contributed to some of the 
prognostic effect (Radmacher et al. 2006). Furthermore, a gene signature composed of 86 
probe sets was an independent predictor of OS in CN-AML patients, and maintained its 
prognostic value after multivariable analysis considered other prognostic variables including 
age, FLT3 ITD and NPM1 status (Metzeler et al. 2008). Recently, GEP was used to identify a 
gene expression ratio capable of predicting the chemotherapeutic response of the patient to 
tipifamib, a fanesyl transferase inhibitor (Raponi et al. 2008). The ability to predict the 
response of the patient’s leukaemic cells to chemotherapy agents would allow clinicians to 
make a better informed decision on treatment options. Whether the ability of GEP to predict 
prognosis will ultimately identify subgroups or possibly novel markers that are independent of 
the prognostic markers already established remains to be seen.
1.4.3 Pathway Identification
Another potential application of GEP is the discovery of new biological pathways 
related to leukaemogenesis. Introduction of leukaemic mutations into animal or cell line 
models followed by GEP analysis may identify downstream pathways or targets instrumental 
to leukaemogenesis. For example, ablation of Cebpa p42 translation in a knock-in mouse 
study demonstrated a common gene signature between Cebpa and MLL-AF9, indicating the 
utilisation of a common pathway specific to the transformation of committed progenitor cells
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(Kirstetter et al. 2008). A similar methodology was used to identify the use of an embryonic 
transcriptional pathway in myeloid progenitors with MLL translocations (Section 1.1.2.b) 
(Somervaille et a l 2009). The method o f defining an AML subgroup, identifying 
differentially expressed genes and selecting genes for further study is described as the 
supervised class comparison strategy (Wouters, Lowenberg, & Delwel 2009b). The 
interpretation of gene expression data in relation to pathway analysis is made possible by a 
number of bioinformatic analyses (e.g. KEGG, DAVID and CMAP). These utilise literature 
and gene signature databases to identify connections between genes, gene pathways and drug 
treatments, further detail on these analyses can be found in Chapter 5 (Section 5.3.7) (Lamb et 
al. 2006) (Kanehisa et al. 2010b) (Dennis, Jr. et al. 2003). For example, a subgroup of 
CEBPA negative patients was identified with a GEP similar to that of patients with the 
CEBPA mutation. The silencing of the CEBPA gene in the subgroup was often due to 
promoter hypermethylation (Wouters et al. 2007). Pathway analysis was used to reveal that 
the leukaemic cells in this group of patients expressed a combination of myeloid and T- 
lymphoid genes; these findings were subsequently confirmed by the expression of T- 
lymphoid genes in mice lacking expression of CEBPA.
The next step in genome wide studies is the integration of GEP with other whole 
genome investigations including microRNAs, epigenetic changes (eg. methylation status and 
histone acetylation) and ultimately whole genome sequencing (Magic, Supic, & Brankovic- 
Magic 2009; Mardis & Wilson 2009; Mrozek et al. 2009; Nervi, Fazi, & Grignani 2008).
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1.5 Aims of Study
Despite improvements in treatment and care, many AML patients fare poorly, with 
only 20-30% of patients achieving long term disease free survival (Shipley & Butera 2009). 
The predominant reason for this is treatment failure due to refractory disease and relapse 
particularly in adverse risk patients. Identification of adverse risk patients who are unlikely to 
benefit from standard chemotherapy treatment is one method of improving clinical outcome. 
Investigation of different treatment modalities such as allogeneic transplant or targeted 
therapy (e.g. FLT3 inhibitors) through clinical trials has the potential to improve these 
patients overall survival. The principal means of determining prognosis is through the 
patient’s diagnostic cytogenetics, however, there is still variation in survival rates within these 
prognostic classifications, particularly within the CN-AML patients due to the absence of a 
cytogenetic marker. Additionally, minimal residual disease monitoring can contribute to the 
prediction of prognosis through initial treatment response and the detection of impending 
relapse post-treatment in many types of AML. The recent identification of molecular genetic 
mutations such as FLT3, NPMJ and CEBPA has enabled a refinement of prognostic 
classification, especially in the CN-AML group where many of the mutations are detected. 
Another recurrent molecular genetic mutation identified is the partial tandem duplication of 
the MLL gene. Early studies suggest the MLL PTD has an association with CN-AML and 
poor prognosis. The MLL gene plays an instrumental role in normal haematopoiesis and its 
disruption through fusion genes has been shown to be leukaemogeneic, though the 
mechanism for this is unclear. The general aim of this thesis is to investigate the prognostic 
significance of the MLL PTD in AML and provide information for determining appropriate 
treatment for this subgroup of patients.
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Specifically three aims were set:
1) Chapter 3. Evaluate the use of MLL PTD as an indicator of poor prognosis at diagnosis
2) Chapter 4. Investigate the usefulness of the MLL PTD as a marker for MRD
3) Chapter 5. Identify a gene signature unique to MLL PTD using gene expression 
profiling to discover potential targeted therapeutic options and to determine if the 
signature can be used for class prediction (and if the validated genes are candidate 
genes for MRD markers)
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2 Materials and Methods
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2.1 Aims
The purpose of this chapter is to explain in detail how the experiments employed in 
this thesis were performed and why certain techniques were used. For more uncommon 
techniques, additional explanation is given to explain the underlying processes within the 
experiment. The techniques described include: PCR, RQ-PCR, RNA isolation, sequencing 
and gene expression analysis. Any experimental modifications of the specific methods and all 
technical optimisations are cross referenced to a more detailed description in the relevant 
chapters.
2.2 Materials
2.2.1 Chemicals
Unless otherwise indicated general chemicals were purchased from Sigma-Aldrich, 
(Dorset, UK) or Fisher Scientific, (Loughborough, UK) and were of analytical grade. The 
water used was water for injections from Hameln Pharmaceuticals (Gloucester, UK).
2.2.2 Enzymes
All enzymes related to reverse transcription and PCR were purchased from Applied 
Biosystems, (Warrington, UK). RQ-PCR enzymes were obtained from Roche, (West Sussex, 
UK).
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2.2.3 Nucleic acids
DNA size markers were purchased from Abgene, (Epsom, UK) or previously lkb 
ladder from Life Technologies, (Warrington, UK). Deoxyribonucleoside triphosphates were 
purchased from Applied Biosystems, (Warrington, UK). All PCR and RQ-PCR primers were 
ordered through Thermo Electron, (Epsom, UK), where they were purified by high 
performance liquid chromatography and verified for concentration by spectrophotometry. 
Trizol, used in RNA isolation was purchased from Invitrogen Life Technologies, (Paisley, 
UK).
2.2.4 Photography
Black and white Polaroid film 667, ISO 3000, was purchased from Fahrenheit, 
(Milton Keynes, UK) and was used for all gel photography.
2.2.5 Capillary Electrophoresis
All labelled DNA markers, capillaries and associated reagents for the ABI Prism 310 
Genetic Analyzer were purchased from Applied Biosystems, (Warrington, UK).
2.2.6 Miscellaneous
Thin walled 0.5ml PCR tubes were purchased from Abgene, (Epsom, UK). Tubes 
used for RNA isolation and storage were obtained from Bioquote Ltd, (York, UK). All tubes 
used were certified Rnase/DNase, DNA and pyrogen free. PCR reagents were all purchased 
from Applied Biosystems, (Warrington, UK). Aerosol resistant tips were bought from 
Anachem, (Luton, UK). 50ml polypropylene tubes used for cell lysis were purchased from
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Sarstedt, (Leicester, UK). Further laboratory consumables were obtained from Bioquote Ltd 
(York, UK), Eppendorf UK limited (Histon, UK) Fisher Scientific UK Ltd (Loughborough, 
UK), Bioquote Ltd (York, UK), Eppendorf UK limited (Histon, UK) Fisher Scientific UK Ltd 
(Loughborough, UK).
2.2.7 Commercial Kits
Compositions of some of the solutions provided by commercial kits were not 
provided. ABI Big Dye Sequencing Kit 3.1 was purchased from Applied Biosystems, UK. 
Qiagen Dye Ex 2.0 Spin Kit, Qiagen Gel purification Kit and Qiagen PCR Purification Kit 
were bought from Qiagen, UK. LightCycler FastStart DNA Master Syber Green was 
purchased from Roche, (West Sussex, UK).
2.2.8 Service Providers
The Cardiff University Central Biotechnology Services (CBS) genomics section 
electrophoresed all sequencing products using the ABI 3130x1.
2.2.9 Cell Lines
RNA from the cell lines tested for use as positive controls in gene validation studies 
were kindly provided by Cardiff University Haematology Department and included HL-60, 
Kasumi, K562, KG-1, NB4, NB4-R2 and U937.
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2.3 Patient Samples
2.3.1 Patient Material
A total of 386 patients and 20 healthy controls were tested for the presence of MLL 
PTD in this study. The healthy control samples were obtained from donor samples collected 
for bone marrow transplant, no treatment was given prior to collection. The patient samples 
were derived from two groups; all healthy donor samples and 130 of the Medical Research 
Council AML Trial-United Kingdom (MRC-UK) patients were obtained from Cardiff 
University, University Hospital Wales and 256 patients were assayed by the Haematology 
department’s RT PCR AML screen assay.
All samples were tested originally as “query new AML” from the clinicians’ initial 
findings. As the full blood count results and observational clinical details converged on the 
possibility of AML, a bone marrow was taken to determine the state of haematopoiesis. The 
diagnosis of AML was determined using a combination of cell morphology, flow cytometry, 
cytogenetic analysis and PCR, culminating in a multidisciplinary meeting where the diagnosis 
was decided along with the optimal method of MRD detection. The FAB classification 
(Bennett et al. 1976) and/or WHO categorisation (2002) was also determined (Vardiman, 
Harris, & Brunning 2002). A complete list of all patients tested and characteristics can be 
found in Appendix A and a full list of AML patients’ clinical characteristics in Section 3.2.1. 
The majority of the samples were from bone marrow aspirates taken at diagnosis, yet in some 
cases where a bone marrow was unavailable peripheral blood was used. Bone marrow was 
the preferred sample as it is the site of haematopoiesis containing stem cells and their 
differentiated descendents. Occasionally, the origin of the sample was not able to be 
determined, in these instances it was labelled “not specified”. To optimise conditions for 
isolating RNA, BM and PB samples were collected into ethylenediaminetetraacetic acid
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(EDTA) tubes and stored at room temperature until lysing. EDTA is a common anti­
coagulant used to prevent samples from clotting in the time between sample collection and 
when the red blood cells are lysed.
2.3.2 Patient Treatment
All data used for clinical outcome analysis was obtained from intensively treated trial 
patients from MRC AML trial 11, 3.5% (8/225); from trial 12, 7.1% (16/225); from trial 14, 
18.2% (41/225) and from trial 15 71.1% (160/225). The patients were treated according to 
trial protocols with the particular therapy given dependent upon their randomisation to a 
specific therapeutic arm of the study. Details of the treatments can be found at the following 
websites or are given in brief in (Grimwade et al. 2010; Wheatley et al. 2009).
AML 11 http://www.cancer.gov/clinicaltrials/MRC-LEUK-AMLll
AML 12 http://www.cancer.gov/clinicaltrials/MRC-LEUK-AML12
AML 14 http://www.download.bham.ac.uk/bctu/amll4/
AML 15 http://www.amll5.bham.ac.uk/
2.4 RNA Isolation
RNA was the basis of all the assays undertaken. The advantage of RNA versus DNA 
was that it gave evidence of expression, expression levels and avoided the problematic 
amplification of large products caused by intervening intronic areas. The disadvantage of 
RNA was the problem of degradation due to enzymes which degrade RNA called RNases.
The major difficulty with RNA work was preventing degradation via RNases. Great 
care was taken to reduce the possibility of RNase contamination at all stages of the testing
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including the use of RNase and DNase free tubes, tips and water. All tips used contained 
filters to prevent samples being transferred from one tube to another through aerosols in the 
barrel of the pipette chamber. Gloves were always worn and every effort was taken to keep 
the work area as free from dust as possible.
The method of isolation used was dependent upon the denaturant guanidine 
isothiocyanate and phenol to both lyse the cells and denature RNases to prevent RNA 
degradation. Chloroform was added to create an organic phase containing the DNA and 
protein while the RNA remained in the upper aqueous phase. Isopropanol precipitated the 
RNA which was then washed with 75% ethanol and resuspended in molecular grade water. 
All of the experiments conducted used RNA as starting material. Total RNA (ribosomal, 
transfer, nuclear and messenger) was isolated using RNAzol Bee or Trizol, in both instances 
the manufacturer’s protocols were followed. The change from RNAzol Bee to Trizol was 
made to unify with the protocol required for the Affymetrix assay. Bone marrow samples 
were used preferentially; PB was used if BM was not available.
Red blood cell lysis was undertaken in order to derive a pellet of white blood cells 
(WBCs) for RNA isolation not contaminated with anucleated RBCs. The buffer contained 
ammonium chloride, which lysed red cells with minimal effect on lymphocytes. To minimise 
the risk of exposure to aerosols the processing of samples was done in the fume hood. The 
red cell lysis buffer (RCLB) was 0.15M NH4CI, 0.1 mM EDTA and lOmM KHCO3 which 
was autoclaved and stored at 4°C.
2.4.1 Red Cell Lysis
The PB or BM sample was poured into a 50 ml polypropylene tube. To maximise the 
amount of sample collected, especially with small marrow samples, 2ml of lx  RCLB was
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pipetted into the EDTA tube, inverted and then gently poured into the 50ml tube. For 
efficient lysing no more than 3-4ml of PB was used in a 50ml tube.
The tube was filled with 45ml of lx  RCLB and rotated until the solution changed from 
opaque to clear indicating lysis of the majority of RBCs, usually 10-15 minutes. PB often 
took longer than BM due to the greater number of RBCs present. Samples with unusually 
high WBC counts never became completely clear due to the high number of unlysed WBC 
present.
The samples were spun at 1559xg for 10 minutes to pellet the WBC. The supernatant 
was gently decanted so the pellet remained in the bottom of the tube. 40ml of lx RCLB was 
added to the WBC pellet and vortexed until resuspended. Step 3 was repeated (centrifugation 
for 10 minutes at 1559xg, decant gently.). 40ml of PBS was added to the pellet and vortexed 
until resuspended. Once again, step 3 was repeated (centrifugation for 10 minutes at 1559xg, 
decant gently.) The small amount of remaining PBS was pipetted off being careful not to 
disturb the cell pellet.
lml of Trizol stored at 4°C was added to the pellet and resuspended by a combination 
of repeated pipetting with a lml pipette and vortexing. If the WBC pellet was very small (not 
opaque) or not visible at all then 500pl was used. If the solution was not easily pipetted after 
adding lml, usually due to a large WBC pellet, an additional lml of Trizol was added to the 
sample. This was indicated when the cell pellet volume was more than 10% of the Trizol 
volume.
The sample was stored at -70°C for up to 1 week before RNA isolation. The sample 
can be stored for up to 6 weeks before degradation begins. Some methods such as RNA later 
allow for longer storage times.
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2.4.2 RNA Isolation
Samples were removed from the -70°C and left to thaw at room temperature. 
Chloroform was added to an empty 1.5 ml eppendorf tube to the concentration of 0.1 volume 
of chloroform per ml of Trizol (usually -130 pi).
The Trizol solution containing the WBCs was added to the chloroform, capped tightly, 
inverted for 45 seconds and left at room temperature for 5 minutes. Tubes were then 
centrifuged for 15 minutes at 16,000xg at 4°C. Using a lml pipette, the upper RNA 
containing aqueous layer was carefully pipetted off without disturbing the protein interface 
below and transferred to a second tube containing 0.6  volumes of isopropanol (usually 
~600pl). The samples were inverted for 20 seconds and left to sit at room temperature for 10 
minutes. Samples were then centrifuged for 15 minutes at 16,000xg at 4°C. The supernatant 
was decanted, lml of 75% ethanol was added to the pellet, and inverted several times. Tubes 
were again centrifuged for 15 minutes at 16,000xg, at 4°C. The supernatant was discarded 
and the tubes inverted to let the ethanol evaporate from the RNA pellets. Pellets were not 
allowed to over dry as the RNA can become very difficult to resuspend. Dependent upon 
size, the pellet was resuspended in 15pl-200pl of “molecular genetic” grade water.
2.4.3 RNA Quantitation and Storage
To ensure that the same amount of RNA was used as starting material in each 
experiment, the concentration and quality of RNA was determined using an ultra violet 
spectrophotometer to measure optical density (OD). A solution of RNA with an OD of 1.0 at 
260nm in a 10mm path length has a concentration of 40pg/ml. The absorbance of the purified 
RNA was measured using either a Gene Quant pro or Nanodrop spectrophotometer. The 
Gene Quant spectrophotometer was purchased from Amersham Biosciences, UK, and the
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Nanodrop from Labtech International, UK. The change between the spectrophotometers was 
made in September 2005 as equipment was upgraded. Checks were made to verify that the 
results derived from the new machine were comparable with those obtained previously.
RNA was measured on the Gene Quant by using a quartz micro cuvette. Molecular 
grade water was used as a reference and then 2pl of RNA was added into 70pl molecular 
genetic grade water. Measurements were made at 260nm and 280nm and the concentration 
was calculated using the formula:
Concentration (pg/pl) = (OD260nm) x conversion factor x dilution factor x (lm l/1000pi).
Where the conversion factor is 40pg/ml.
The purity of the sample was determined by dividing the A260 by the A280 
absorbance values. Pure RNA should give a ratio between 1.8 and 2.0. The purity was 
calculated by the formula:
RNA purity = OD260/ OD280
To measure OD with the Nanodrop, 2pl of the sample was loaded directly onto the 
instrument. The instrument produces a column of liquid between two “posts” and then reads 
the OD through the sample column. The instrument was set to zero using 2pi of water as a 
reference and then the RNAs were measured neat using 2pl of the total sample. The 
Nanodrop uses the following formula to calculate the concentration of RNA. To prevent 
degradation during storage all RNA samples were kept at -70°C.
Concentration (ng/pl) = ( O D 2 6 0 n m )  x conversion factor x (1000 ng/pg) x (lml/lOOOpl).
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Where the conversion factor is 40pg/ml.
2.5 Reverse Transcription
RNA was then reverse transcribed into complementary DNA (cDNA) using the 
reverse transcriptase enzyme isolated from Moloney murine leukaemia virus (MMuLV) using 
reagents for reverse transcription purchased from Applied Biosystems. The manufacturer’s 
guidelines were followed with minor modifications. All assays, except for the t(8;21), used 
random hexamers to prime the reverse transcription. For the t(8;21) PCR, the outer sense 
primer was used as a specific primer to prime the reverse transcription reaction. This was 
necessary to achieve the sensitivity needed to detect MRD in follow-up patient samples. All 
assays contained a negative control containing water with no RNA as a check for 
contamination.
One pg of RNA was used as template for each reaction. Water was added to make the 
total volume up to 20pl after all of the reagents were added. The following reagents were 
used at a final concentration of: 2.5pM random hexamers, IX PCR buffer pH 8.3 (lOmM 
Tris-HCl, 50mM KC1), lUnit/pl RNase inhibitor, 5mM MgCh, 2.5Units/pl MuLV reverse 
transcriptase and ImM each deoxynucleoside triphosphates (dNTP). The tube was spun 
briefly and run on the ABI 9700 (Applied Biosystems, Warrington, UK) using the PCR 
programme: 25°C for 10 minutes, 42°C for 30 minutes, 95°C for 5 minutes and 4°C 
indefinitely. cDNA was either used immediately or stored at -20°C until needed for PCR.
For the t(8;21) reaction, an additional reverse transcription (RT) was done using the 
specific ETO primer from the first round. The outer primer from the nested PCR replaces the 
random hexamers in the RT reaction at a concentration of 123nM. The reaction was then
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completed as stated above. This protocol modification was used to increase the level of 
sensitivity to that comparable with the other tests.
2.6 Polymerase Chain Reaction (PCR)
PCR is a method where millions of copies of a specific region of DNA can be 
produced from a small amount of starting material. PCR was conceived in 1986 by Kerry 
Mullis (Mullis et al. 1986). Since then PCR has revolutionised research by reducing the 
amount of time and starting material needed to produce large amounts of DNA.
PCR is a technique that utilises the ability of the DNA polymerase enzyme to 
recognise and extend double stranded DNA in a 5’ to 3’ direction. By creating two small 
stretches of DNA (primers) specific to the area of amplification, one complementary to the 
sense strand and the other to the antisense strand, a unique area of DNA can be amplified. 
The reaction is repeated through cycles of DNA separation from double to single stranded 
(denaturation), binding of complementary primer DNA (annealing) and elongation of the 
template at optimum temperature (extension) so that the amplicon becomes the most abundant 
DNA in the reaction. With near doubling of product at every cycle the amplicon is 
exponentially amplified with the reaction capable of creating up to 1 million copies of target 
sequence. The discovery of heat stable Taq DNA polymerase meant that the enzyme did not 
have to be added after every denaturation step and made the technique universally accessible. 
There are a number of areas in which a PCR can be optimised in order to improve sensitivity 
and productivity. The majority of PCRs need to be optimised to find the combination of 
factors that will make the reaction as robust and productive as possible. The annealing 
temperature of the primers needs to be tested empirically to find the temperature that reduces 
non-specific products and gives good yield. If the temperature is too low the primers may 
bind to sites that are slight mismatched causing non-specific bands, and if it is too high they
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may not even bind to the matched site and thereby reduce the overall yield. The requirement 
for magnesium ions is another important component to the reaction as it affects the stringency 
of primer binding and is a catalyst for Taq activity. The length of time for the different stages 
of the PCR may need to be adjusted to allow for complete extension depending on the length 
of the product to be amplified.
Additional advances in the efficiency of PCR machines and the Taq enzyme have 
made PCR reactions faster, more specific and the reactions more robust. Specifically, the 
ability to prevent Taq enzyme from being active until the reaction has been heated to the 
denaturation temperature of 94°C, has produced a significant improvement in the specificity 
and yield of PCRs. These so called “hotstart” enzymes prevent the Taq enzyme from 
amplifying non-specific products at sub-optimum conditions during the PCR set up thereby 
inhibiting the production of incorrect duplicates at a very early stage. All of the PCRs 
described in this study used the hotstart enzyme Taq Gold.
The speed, sensitivity and efficiency of recognising target sequences make PCR well 
suited for doing mutational testing. Turnaround times are shortened using PCR, and for 
haematology testing the increased sensitivity meant it could be used to detect minimal 
residual disease (MRD) at a much lower level than previous methods allowed (cytogenetics, 
FISH, immunophenotyping) (Section 1.3). The disadvantage of PCR is the risk of 
contamination. The increased sensitivity is coupled with the danger of a false positive 
resulting from even the smallest amount of contamination or non-specific amplification 
during the reaction. For this reason negative controls are always used from the RT reaction 
all the way through to the PCR reaction itself and very strict procedures are observed to 
prevent contamination from post amplification samples.
An area dedicated for the preparation of PCR reactions was used for all assays. 
Dedicated pre PCR pipettes were used and all tubes and filter tips were quality assured to be
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RNase and DNase free. To prevent contamination after amplification, all post PCR 
manipulations were carried out in a separate room.
2.6.1 Qualitative PCR
Qualitative PCR was used as a sensitive method for finding mutations in diagnostic 
samples and the subsequent detection of the marker in follow-up samples for MRD. All 
qualitative PCRs were done on the ABI 9700. cDNA was used as template for all o f the 
AML screening PCRs including t(8;21), Inv 16, t( 15; 17), FLT3 ITD (semi quantitative) and 
MLL PTD. All of the original qualitative AML screening assays used between 1.5 and 5pl 
cDNA starting material and were amplified in two successive (nested) PCRs to increase the 
sensitivity. The exceptions were the FLT3 ITD, the MLL PTD and the ABL PCR which were 
amplified for only one round. The PCRs were run using standard laboratory protocols with a 
positive control consisting of a known positive from either a cell line or confirmed patient 
sample and a negative control consisting of water included from the reverse transcription step. 
Every sample had an ABL PCR run as a control for both RNA quality and the presence of 
PCR inhibitors. Any sample lacking an adequate ABL result was not included in the study.
The Biomed-1 PCR protocol was established in order to create standardisation between 
laboratories for molecular testing by PCR (van Dongen et al. 1999). As most laboratories 
have set up their own PCR tests from publications or in-house methods there is a considerable 
amount of variation form one lab to another, preventing accurate comparisons of test results 
between centres. In 1999, the Biomed-1 primers were designed to detect the most common 
mutations occurring in AML. The primers were selected specifically so that all tests could be 
amplified under the same cycling conditions and reagent concentrations, enabling all of the 
tests to be run simultaneously on the same PCR machine. As the tests needed little or no 
optimisation, laboratories using Biomed-1 primers would be able to compare results. The
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t( 15; 17), t(8;21) and inversion 16 PCRs are all Biomed-1 based and use the same cycling 
conditions and reagent concentrations as given:
The first round cDNA was added to make a total volume of 25 pi per sample 
containing: 2mM MgCl2, 200pM dNTPs, IX PCR Buffer II ([ImM] Tris-HCl, pH8.3,
[5mM] KC1), 0.4pM of each primer, and 0.025Units/pl Taq Gold. (Inversion 16 dNTP and 
MgCl2 concentrations were slightly less as only 1.5pl of cDNA was used and was 
compensated for by adding more reagent buffer.)
Conditions for amplification were 94°C for 10 minutes, 35 cycles of 94°C for 30 
seconds, 65 °C for 60 seconds, 72°C for 60 seconds and then the block temperature was 
reduced and held at room temperature.
The second round master mix was composed of: 200pM dNTPs, ImM MgCl2, IX 
PCR Buffer II ([ImM] Tris-HCl, pH8.3, [5mM] KC1), 0.4pM of each primer in a total volume 
of 24pl (inversion 16 dNTP concentrations were slightly less). The master mix, minus the 
first round template, was made up in the pre PCR hood. When preparation was completed 
and 24pl was aliquotted to each sample tube, the tubes were taken to post PCR for the 
addition of lpl of first round product. Cycling conditions were the same as the first round. 
Samples were then electrophoresed on an agarose gel for analysis.
The only optimisations required for the biomed-1 primers were varying amounts of 
cDNA to be used in the first round PCR or MgCl2 concentrations in the second round; these 
are noted in the individual PCR sections.
2.6.La t(8;2l) with RUNX1-RUNX1T1
The t(8;21) PCR detects the fusion of the RUNX1 gene on chromosome 21 to the 
RUNX1T1 gene on chromosome 8 using a nested primer set. There are no known variant
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fusion transcripts from the area of this translocation. The estimated log sensitivity of the PCR 
was between lxlO '4 and lx l0 ‘5. This means the assay is able to detect 1 t(8;21) transcript in a 
total of between 10,000  and 100,000  transcripts.
For the first round amplification 5 pi of cDNA was added to a Biomed-1 master mix to 
equal 25pl. The first round primers were:
AML-1A: 5’- CTA CCG CAG CCA TGA AGA ACC-3’
ETO-B: 5’- AGA GGA AGG CCC ATT GCT GAA-3’
One microlitre of the first round amplification was added to the Biomed-1 second 
round master mix to give a total volume of 25pl. The second round primers are shown below. 
The expected sizes seen on an agarose gel were: t(8;21): 260bp (395bp first round).
AML1-C: 5’- ATG ACC TCA GGT TTG TCG GTC G-3’
ETO-D: 5’- TGA ACT GGT TTC TGG AGC TCC T-3’
2.6.Lb  t(15;17) with PML-RAR
The t(l 5; 17) PCR detected the fusion transcript of the PML gene on chromosome 15 
and the RARa gene on chromosome 17 using a nested set of primers. There are three 
different breakpoint regions in PML, bcr 1, bcr 2 and bcr 3, which can create a range of PCR 
product sizes. The bcr 1 and bcr 3 breakpoints make up the bulk of the transcripts seen with 
frequencies of 55% and 40% respectively. Both bcr 1 and bcr 3 are “stable” breakpoint 
regions and always produce the same size for their respective products. Bcr 2 on the other
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hand, has a range of 168bp where the PML break can occur and therefore the product can 
vary in size from patient to patient. To produce efficient and robust PCRs two different sets 
of PCR primers were designed, one for bcr 1 and 2 and another for bcr 3. By using these 
primer sets the products were kept under 500bp and could be amplified more efficiently. 
Initial patient analysis entailed two PCRs done using both of the primer sets so that any of the 
potential mutations could be detected. Subsequent PCRs were done using the primer set 
appropriate for the breakpoint seen in the primary analysis. The estimated log sensitivities of 
both PML-RARa PCRs were between lxlO '3 and lxlO '4. This means the assay is able to 
detect 1 t( 15; 17) transcript in a total of between 1,000 and 10,000 transcripts.
For the first round amplification 5pl of cDNA was added to a biomed-1 master mix to 
equal 25pi. The first round primers were:
Bcr 1 and bcr 2:
PML-A1: 5’- CAG TGT ACG CCT TCT CCA TCA-3’
RARa-B: 5’- GCT TGT AGA TGC GGG GTA GA-3’
Bcr 3:
PML-C1: 5’- TCA AGA TGG AGT CTG AGG AGG-3’
RARa-B: 5’- GCT TGT AGA TGC GGG GTA GA-3’
One microlitre of the first round amplification was added to the biomed-1 second 
round master mix to give a total volume of 25pl. The concentration of MgCL in the second 
round was adjusted to a final concentration of 2mM. The second round primers were:
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Bcr 1 and bcr 2:
Bcr 3:
PML-A2: 5’- CTG CTG GAG GCT GTG GAC-3’
RARa-D: 5'- CTG CTG CTC TGG GTC TCA AT-3'
PML-C2: 5'- AGC GCG ACT ACG AGG AGA T-3’
RARa-D: 5'- CTG CTG CTC TGG GTC TCA AT-3’
The expected sizes seen on an agarose gel were: 
Bcrl: 214bp (381 bp first round)
Bcr2: 43-211 bp (210- 378 bp first round) 
Bcr 3: 289 bp (376 bp first round)
2.6.l.c  Inversion (16) with CBFB-MYH11
This PCR reaction was designed to detect either the pericentric inversion of
chromosome 16 or the t(l 6 ; 16). There are three main “types” of aberration, A, D and E that
occur at a rate of 88%, 5% and 5% respectively. The type A PCR was to be run as a first
level of detection. If the type D or E product was present it was seen as a band at 1500-
1600bp, if detected the PCR was repeated using the D and E primer set to determine which of
these two mutations had occurred. The D and E primers are positioned to create a more
efficiently sized PCR product of between 300 and 600bp. On follow-up samples the primer
set appropriate to the type identified was used. The estimated log sensitivity of the assay for
all types was between lx l O’4 and lx l 0'5. This means the assay is able to detect one inversion
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16 transcript in a total of between 10,000 and 100,000 transcripts. For the first round 
amplification 1.5pl of cDNA was added to a biomed-1 master mix to equal 25pl. The first 
round primers were:
Type A:
CBFB-A: 5' -GCA GGC AAG GTA TAT TTG AAG G - 3’
MYH11-B2: 5'-TCC TCT TCT CCT CAT TCT GCT C -3’
If the patient was known to be type D or E, the primer MYH11-BX was used in place 
of MYH11-B2.
Type D or E: M Y H ll-B l 5’ -TGA AGC AAC TCC TGG GTG TC -3’
One microlitre of the first round amplification was added to the biomed-1 second 
round master mix to give a total volume of 25pl. The second round primers were:
Type A:
CBFB-C: 5’ - GGG CTG TCT GGA GTT TGA TG -3’
MYH11-D2: 5’- CCT GAG CGC CTG CAT GTT-3’
If the patient was known to be type D or E, the primer MYH11-BX was used in place 
oiM YH ll-D X.
Type D or E: MYH11-D1: 5’ -TCC CTG TGA CGC TCT CAA CT - 3’
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The expected sizes seen on an agarose gel if using the Type A primer set were:
Type A: 271 base pairs (1st round - 418bp)
Type D or E: ~1500bp
The expected sizes seen on an agarose gel if using the Type D and E primer set were:
Type D: 338 base pairs (1st round - 155bp)
Type E: 545 base pairs (1st round - 362bp)
2.6.1.d FLT3ITDPCR
The FLT3 PCR was used to detect ITDs occurring in exon 14 of the FLT3 gene on 
chromosome 13. The protocol was used as described by (Kiyoi et al. 1999) with 
modifications. The original PCR was designed to amplify DNA spanning the region where 
ITDs occur, this was adapted to work with cDNA to streamline the AML screening process 
by using the RT step to produce cDNA for use as template. The reagent concentrations of the 
PCR were optimised for use with cDNA template instead of genomic DNA. The product size 
of the FLT3 ITDs was variable, however, the mutation was rarely homozygous and the wild 
type (WT) product was present at a constant size of 237bp. To make the PCR product visible 
on a fluorescent detection system the forward primer was labelled on the 5’ end with the 
fluorescein dye 6 -fam. Using a semi quantitative method of analysis on the ABI Genescan
310, the FLT3 product can be expressed as a ratio of the amount of ITD expressed over the
total amount of FLT3 expression. This enabled a level of sensitivity of 1-2% of ITD to total 
FLT3 expressed to be reproducibly detected. A result was recorded as positive if the ITD 
level was higher than 1%. This level of sensitivity also allowed for the use of the FLT3 ITD 
PCR for MRD detection in follow-up samples.
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Five microlitres of cDNA was used in a reaction of total volume 25 pi with 2mM 
MgCl2, 50mM KC1, lOmM Tris-HCl, 200pM dNTPs, 0.625 Units Taq Gold, and 0.8pM of 
each primer. Samples were incubated at 95°C for 10 minutes followed by 30 cycles of: 94°C 
for 1 minute, 56°C for 1 minute, 72°C for 1 minute, and a final extension at 72°C for 10 
minutes. The primer sequences were:
FLT3 F: 5? -fr-fam GCA ATT TAG GTA TGA AAG CCA GC - 3’
FLT3 R: 5’ -  CTT TCA GCA TTT TGA CGG CAA CC - 3’
The expected sizes seen using capillary electrophoresis were:
FLT3 WT: 237bp
FLT3 ITD: the size of the ITDs ranged from 3-480bp, which was seen as a product
added to the size of the wt (240- 717bp).
2.6.1. d. i Expression o f  results
The percentage of FLT3 ITD was the amount of FLT3 ITD RNA expressed relative to the 
total amount of FLT3 RNA expressed:-
F IT 3 ITD % = (Area of FLT3 ITD/(Area FLT3 ITD+ Area FLT3 WT))*100
2.6.1.e M LL PTD
For analysis of the MLL PTD, occurring from exon 3 to exon 9,10, or 11 in the MLL 
gene, the region from exon 9 to exon 4 (Section 1.2.3.a), was amplified as previously 
described with modifications (Schnittger et al. 1998). The amplification detected only the 
PTD, no product was produced if the mutation was absent. Due to MLL PTDs being found in
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samples from healthy, non-leukaemic individuals (Marcucci et al. 1998; Schnittger et al. 
1998), the optimisation of the PCR sensitivity was critical. A number of modifications were 
systematically tested and the results are given in Chapter Three (Section 3.3.1). cDNA 
(0.5pl) was used in a reaction with ImM MgCl2, 50mM KC1, lOmM Tris-Cl, 200pM dNTPs, 
0.625 Units Taq Gold, and 0.2pM of each primer. Samples were incubated at 95°C for 10 
minutes followed by 35 cycles of: 94°C for 1 minute, 63 °C for 1 minute, 72°C for 1 minute, 
and a final extension at 72°C for 10 minutes. The results were analysed by gel 
electrophoresis. lOpl of product was run on a 2% agarose gel containing ethidium bromide 
(EtBr). The primer sequences were:
M LL  6.1:5’-GTC CAG AGC AGA GCA AAC AG-3’
M LL  E3AS: 5’-ACA CAG ATG GAT CTG AGA GG-3’
2.6.1.f ABL PCR
The ABL PCR was run for every sample to confirm that the RNA was amplifiable and 
determine whether there was contaminating DNA present. Any failure of the ABL PCR was 
attributed to improper sample handling, excessive time between collection and isolation or 
inhibitors present in the PCR resulting in degradation of RNA.
The ABL PCR from (Lion 1996a; Lion 1996b) was adapted by modifying the primer 
sequences to improve the PCR efficiency. 5pi of cDNA was used in a reaction with 2mM 
MgCl2, 50 mM KC1, lOmM Tris-Cl, 200 pM dNTPs, 0.625 Units Taq Gold, and 0.8pM of 
each primer. Samples were incubated at 95°C for 10 minutes followed by 36 cycles of: 94°C 
for 1 minute, 58°C for 1 minute, 72°C for 1 minute, and a final extension at 72°C for 10 
minutes. The results were analysed by gel electrophoresis. lOpl of product was run out on a 
2% agarose gel containing EtBr. The primer sequences were:
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ABL  S:5' -  AGC ATC TGA CTT TGA GCC - 3' 
ABL-A:5' -  TTA TAG CCT AAG ACC CGG - 3'
The expected sizes seen on an agarose gel were (overpage):
RNA 183bp
DNA ~600bp
2.6.2 Real Time Quantitative PCR (RQ-PCR)
Real time quantitative PCR is a technique whereby the amount of starting template 
can be calculated from the crossing point of the sample’s amplification compared to the 
crossing points of a standard curve. By normalising against a recognised control gene {ABL) 
samples are said to have a relative copy number calculated. This is in comparison to an 
absolute number which is calculated from a standard curve of a sample with a known value. 
Whereas in qualitative PCR the end point values are read as results that give a qualitative 
result, the RQ-PCR can not only determine whether a transcript was present but also how 
much of it was present. The disadvantage of this methodology was that some sensitivity was 
lost as the RQ-PCR was only a single round test compared to the nested protocol of many 
qualitative tests. Another danger when looking for an absolute number was that minor 
differences in the efficiency of the amplification can cause skewing of results between 
different samples and/or the sample and the control gene, leading to misinterpretation of the 
final copy number. This can be protected for with the use of a properly selected internal 
control (Sambrook & Russel 2001).
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All of the QPCRs were performed using the LightCycler version 1.2 and the 
LightCycler Faststart DNA Master Syber Green kit. In this system, the RQ-PCR assay 
determines the amount of DNA produced after every round of amplification by measuring the 
fluorescence emitted by Syber Green, a dye specific for double stranded DNA. The crossing 
point (Cp), the cycle number at which the level of fluorescence exceeds the background, was 
calculated. Samples with a greater amount of template will reach the Cp sooner and have a 
lower cycle number than samples with less template. It is important to note that the reason 
that this method is necessary is due to the plateau reached during most PCR reactions. As a 
PCR reaction proceeds with exponential expansion the availability of reagents becomes rate- 
limiting and hence the amount of product plateaus. Theoretically, this means that the same 
product endpoint can be achieved with a sample beginning with 200ng of DNA and a sample 
that started at 1 pg DNA.
The amount of product was determined from the quantity of fluorescence produced 
from double stranded (dsDNA) labelled with Syber Green. As any dsDNA would be labelled 
including non-specific amplification and primer dimers, the melting temperature (Tm) of the 
product was used to determine the specificity of the assay. To create specificity a melting 
curve analysis needed to be run where the Tm of the desired amplicon was determined. At 
the end of the amplification the products are allowed to renature and fluoresce as the 
temperature is slowly increased. The increasing temperature causes the dsDNA to denature as 
its characteristic Tm is reached. Features such as length, nucleotide composition, secondary 
structure and mismatches can all affect the Tm of DNA. When the Tm of a product is 
reached, the DNA denatures into single stranded (ssDNA) and ceased to fluoresce. This drop 
in fluorescence was calculated to be the Tm of the product. Any non-specific amplification 
can be identified by the different Tm exhibited, in the same way as size was used to 
differentiate between products run out on an agarose gel.
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2.6.2m  MLL PTD RQ-PCR
A two-step quantitative PCR (the RT and the PCR done in two independent reactions) 
was done to determine the gene dosage of the MLL PTD and S14 in AML patients. The 
benefits of performing a two-step RT-PCR procedure versus a one-step are: 1) the original 
cDNA from the AML screen could be used in the RQ-PCR for both the MLL PTD and the 
ABL assay and 2) the sensitivity of the assay was increased.
The MLL PTD RQ-PCR was performed according to the manufacturer’s protocol 
using the original cDNA from the AML screen. In brief, 0.5 pi of cDNA was added to a glass 
capillary that contained ImM MgCl2, 0.2pM of each primer Light Cycler Buffer and 2pl of 
Syber Green for fluorescent detection in a total volume of 20 pi. The glass capillaries used by 
the light cycler allows heat to transfer efficiently to the sample and the amount of 
fluorescence to be measured as the reaction takes place in the machine. The primers MLL 6 .1 
and MLL E3 AS from the qualitative PCR were used for the RQ-PCR. In the initial conditions 
samples were incubated at 95°C for 10 minutes followed by 45 cycles of: 95°C for 10 
seconds, 65°C for 5 seconds, 72°C for 10 seconds with fluorescent acquisition performed 
after the 72°C extension step. A melt programme of 95°C for 0 seconds, 65°C for 15 
seconds, then increasing to 95°C at a rate of 0.1°C/seconds was used to determine the Tm. 
Crossing point and Tm were calculated using LightCycler software. A detailed description of 
the optimisation and quantitation to achieve the final RQ-PCR protocol is described in 
Chapter 4.
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2.6.2.b S14 RQ-PCR
The expression data generated from the real-time PCR was normalised to a 
housekeeping gene, S14 (gene encoding for the 40S ribosomal subunit protein S I4) (Rhoads, 
Dixit. & Roufa 1986). The control gene was recommended by Roche for relative gene 
expression studies and used by the department in other publications (Guinn et al. 2005) et al, 
2005;(Walsby et al. 2008). The S14 RQ-PCR was performed using lpl of cDNA, 0.5pM 
primers and 4mM MgCb in a total volume of 20pl. The amplification conditions were 95°C 
for 10 minutes; 40x 95°C for 3 seconds, 60°C for 5 seconds, 72°C for 10 seconds; followed 
by a melt step of 70°C to 95°C at 0.1°C/second. Using the Cp as a measure of quantity the 
MLL PTD was then normalised against the Cp value for S I4.
2.6.2. c RQ-PCR fo r  Validation Genes
The details for the design and optimisation of primers used to amplify the validation 
genes in are given in the Materials and Methods of Chapter 5. ABL was used as a 
normalisation gene in the validation RQ-PCRs. The RQ-PCR conditions for all validation 
genes as well as ABL were lpl of cDNA, 3mM MgCb, 0.5pM forward and reverse primer and 
lpl of Syber Green in a total volume of lOpl. The amplification conditions were 95°C for 10 
minutes; 45x 95°C for 3 seconds, 60°C for 5 seconds, 72°C for 12 seconds; followed by a 
melt step of 60°C to 95°C at 0.1°C/second for all genes.
2.7 Electrophoresis
2.7.1 Gel Electrophoresis
Gel electrophoresis analysis was performed by loading PCR products onto an agarose 
gel and applying an electric current. The electric field generated causes the negatively
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charged DNA molecules to migrate towards the positive pole separating by size as it moves. 
Larger fragments move more slowly and smaller fragments move more quickly through the 
agarose matrix. Comparison to a DNA marker of known size allows for accurate sizing of 
PCR products. The DNA was visualised by staining the gel with EtBr, a fluorescent dye that 
intercalates with DNA so that it can be seen when exposed to ultra violet light. All of the 
PCRs and the QPCRs, with the exception of the FLT3 ITD assay, were run out on agarose 
gels containing EtBr to separate and visualise the DNA products.
A solution of 2% agarose (weight to volume) was made with 100ml 0.5x tris borate 
EDTA (TBE) (final concentration of 44mM Tris-borate and ImM EDTA, pH 8.3). The 
solution was heated to until the agarose was dissolved and then cooled to 55-60°C. EtBr 
(0.5pg/ml) was added and the agarose was poured into a casting tray followed by the insertion 
of a comb to created wells. After the gel had solidified, lOpl of sample was combined with 
loading dye, loaded into the well and an electric field of between 100 and 170 volts was 
applied for 20 to 40 minutes. DNA sizes were determined by comparison to a DNA size 
ladder. The DNA was then be visualised on an ultraviolet light box and photographed using 
Polaroid 667 film.
2.7.2 Capillary electrophoresis
The FLT3 ITD products were amplified with a 5’ fluorescently labelled primer and 
were then analysed by running lp l of the denatured product via capillary electrophoresis 
using an ABI prism 310 Genetic analyzer according to the manufacturers protocol. Briefly, 
the analysis was done using performance optimised polymer 4 (POP 4), lx  Buffer with 
EDTA, and 5 seconds injection time at 15 KV. lp l of PCR product was added to 15pl of 
highly deionised formamide with ROX 500bp marker, heat denatured for 3 minutes at 95°C,
cooled to 37°C and run at 15 KV, 60°C for 30 minutes.
2-94
2.8 Sequencing
All samples positive for the MLL PTD mutation were sequenced in the forward and 
reverse orientation to confirm the sequence. All sequencing was performed using the ABI 
Big Dye 3.1 Sequencing Kit according to the manufacturer’s instructions. The PCR products 
were run out on an agarose gel to verify the product and the number of bands.
Single band products were purified using the Qiagen PCR Purification Kit according 
to manufacturer's instructions. Five volumes of buffer PB was added to the PCR sample and 
applied to the QIAquick column and centrifuged at ~17,900xg for 45 seconds. After 
discarding the flow-through, the column was washed with 0.75 ml PE buffer and centrifuged 
for 45 seconds. The eluate was discarded and the column spun for an additional minute. To 
elute the purified DNA 50pl water was added to the centre of the membrane and centrifuged 
for 1 minute. If the amplification yielded multiple bands, the individual bands were cut out 
from the gel and purified using the Qiagen Gel purification Kit following the manufacturer’s 
protocol. Briefly, the DNA fragment was cut from the agarose gel using a clean scalpel. The 
sample was weighed and three volumes of Buffer QG to one volume of gel were added. The 
sample was incubated for 10 minutes at 50°C, and vortexed every three minutes to help 
dissolve the gel. One gel volume of isopropanol was added and the tube was mixed. The 
sample was applied to the QIAquick spin column and centrifuged at ~17,900xg for one 
minute. The eluate was discarded, 0.5ml of Buffer QG was added to remove all traces of 
agarose, and the spin was repeated. The DNA was washed with the addition of 0.75ml of 
Buffer PE and a one minute spin. Eluate was discarded and the spin repeated to remove all 
traces of ethanol. The DNA was eluted with the addition of 50pl and a 1 minute spin. The 
purified products were analysed on the spectrophotometer to determine the concentration
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(Section 2.4.3) using the formula of 50pg/ml per 1 OD for DNA. The amount of DNA used 
was relative to the size in base pairs of the DNA to be sequenced.
200-500bp 3-10ng
500-1000bp 5-20ng
The appropriate amount of template was added to 2pl of Ready Reaction mix, lp l of 
BigDye Sequencing Buffer, 1.6pmol MLL 6.1 and water added to a final volume of 20pl. The 
programme used for cycle sequencing was: 96°C for 30 seconds, 50°C for 15 seconds, 60°C 
for 4 minutes repeated for 25 cycles.
The Qiagen Dye Ex 2.0 Spin Kit was used to remove the unincorporated dNTPs from 
the sequencing reaction. The manufacturer’s instructions were observed as follows. The spin 
column was vortexed and then spun for 3 minutes at 2800 rpm on a Heraeus Biofuge to pack 
the resin. All 20pl of the sequencing reaction was dripped on to the centre of the resin bed 
and spun again for 3 minutes. The dNTPs remain in the column while the purified DNA 
elutes during centrifugation. The purified sequencing reaction was then taken to CBS to be 
electrophoresed on a 3130x1 Genetic Analyzer. The results were analysed to verify the type 
of mutation.
2.9 Collection of Clinical Data
Excel spreadsheets were designed and updated for over 386 patient samples. The 
clinical details were collected and collated for all patients after selecting for samples with 
satisfactory PCR controls. The non-trial information was collected manually from the 
Hospital Telepath System and trial data was provided by Dr. Rob Hills, Cardiff University. 
Information collected included the date of birth (DOB), date of collection, diagnosis, age at 
diagnosis, trial number if applicable, WBC and BM blast percentage at diagnosis, AML RT-
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PCR screen status, sample type, cytogenetic data, cytogenetic risk factor, sex, FAB, molecular 
marker data for FLT3 TKD, NPM1 and WT-1, as well as post diagnostic data for trial patients.
2.10 Data Obtained From Other Sources
A portion of the data analysed in this study was produced by other groups. This 
included NPMJ and FLT3 TKD results provided by the Cardiff University Department of 
Haematology and the WT-1 expression level results kindly provided by Professor John Yin, 
Manchester Royal Infirmary. The Department of Haematology at Cardiff University has 
collected GEP data that can be analysed for the determination of gene expression in AML. 
Around 300 AML patient GEPs are available, derived from two Affymetrix GeneChip 
platforms including the human genome HG 133A and the HG-U133 plus 2. These procedures 
are described in brief below and the protocols are provided (Appendix B).
The analysis of the variable mutation sites in NPM1 and FLT3 TKD are performed 
using the PyroMark ID (Biotage, Uppsala, Sweden) which provides quantitative mutation 
analysis by using pyrosequencing to analyse short sections of DNA directly from PCR 
templates. cDNA from the reverse transcription as described above (Section 2.5) was 
amplified using the same amplification conditions but with primers specific to the mutation 
being analysed; (94°C 10 min x l; 50x 94°C 30 seconds, 65°C 1 minute, 72°C 1 min; 72°C 10 
min). The success of the amplification is verified before the PCR products are analysed on a 
PyroMark ID programme individualised for the gene of interest. The region where mutations 
occur was sequenced and the mutation type was determined by comparison with a set of 
known mutation profiles.
The diagnostic expression level of WT-1 in 133 AML 15 trial patients was determined 
by quantitative PCR. The assay used primers and fluorescent hybridisation probes located in
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exon 7 and 8 of the gene to determine if the gene was overexpressed at presentation. WT-1 
copy number was normalised using the ABL gene (Liu-Yin et al. 2008)
2.11 Gene expression profiling
Mononuclear cells were isolated by Ficoll separation and then pelleted for RNA 
isolation. RNA isolation for the Affymetrix analysis was performed with either Trizol (HG- 
U133A) as described above (Section 2.4) or using the Qiagen RNeasy protocol (HG-U133 
Plus2) (Appendix B). Comparison of probe set expression levels between samples with RNA 
isolated by different methods indicated that biological variation due to acute leukaemia 
overrode any differences that arose from RNA isolation methodology (Campo Dell’Orto 
2007). The other slight modification in procedure between the chips was the in vitro 
transcription time. The RNA was quantified using a spectrophotometer and assessed for 
quality using the Agilent Bioanalyser which visualises and quantitates the RNA peaks 
(Agilent Technologies UK Ltd, Stockport, Cheshire, UK). RNA samples with insufficient 
concentration were to be efficiently transcribed were concentrated by re-precipitation. The 
first reverse transcription was performed with a poly-T oligomer to create the first strand 
cDNA (Figure 2.1). This was followed by the synthesis of the second strand so that a double 
stranded cDNA solution was produced. The solution was purified with a spin column and 
then an in vitro transcription (IVT) reaction was carried out to create biotin labelled cRNA. 
The cRNA was purified with a spin column and then fragmented for use in the hybridisation 
cocktail. Fragmentation was verified by visualisation using the Agilent Bioanalyser. The 
hybridisation cocktail was heat denatured before adding to the pre-hybridised Affymetrix 
GeneChip and incubated. The GeneChip was washed and stained on the fluidics station
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before being scanned and fluorescent data collected. The normalisation process used for the 
.cel files is described in Chapter 5, Section 5.2.2.
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Figure 2.1 Diagram of Affymetrix GeneChip Protocol
Brief description of the protocol for the standard eukaryotic gene expression assay. 
Affymetrix ™.
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3 Prognostic Significance of MLL PTD in
AML Patients
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3.1 Introduction and Objectives
Molecular markers are important in the accurate prognosis of CN-AML patients who 
are currently classified by their lack of a prognostic marker. Diagnostic karyotypes are used 
to stratify patients into three prognostic groups favourable, intermediate and adverse. 
However, the technique of karyotyping only identifies large chromosomal aberrations, which 
means that many underlying mutations go undetected. In fact, approximately 45% of all 
AML cases are described as cytogenetically normal and are then categorised as intermediate 
prognosis due to the absence of a karyotypic marker (Byrd et al. 2002; Grimwade et a l 1998; 
Grimwade et al. 2010). The clinical outcome for cytogenetically normal AML patients is 
variable, with the 5 year overall survival between 35% and 45% (Byrd et al. 2002; Grimwade 
et al. 1998; Slovak et al. 2000). New molecular markers would add further stratification to 
the intermediate group, so patients could be treated in a manner appropriate to their level o f 
risk (Grimwade & Hills 2009).
In recent years, molecular genetic techniques have been used to identify several new 
sub-microscopic mutations associated with normal karyotype AML. These include mutations 
in the FLT3 and NPM1 genes (Boissel et al. 2005; Dohner et al. 2005; Falini et al. 2005; 
Nakao et al. 1996; Schnittger et al. 2005b). The FLT3 ITD was one of the first markers to be 
identified and is found in approximately 25% of newly diagnosed AML and 30% to 35% of 
all CN-AML patients (Section 1.2.4.b) (Boissel et al. 2005; Chillon et al. 2004; Kottaridis et 
al. 2001; Whitman et al. 2001). The variable length duplication creates an in-frame transcript 
whose protein is constitutively activated and promotes survival and proliferation of leukaemic 
blasts (Gilliland & Griffin 2002). This marker is associated with leukocytosis, a high BM 
blast count, an increased risk of relapse and reduced survival (Kottaridis, Gale, & Linch 2003; 
Small 2006; Stirewalt & Radich 2003). NPM1 mutations are found in approximately 30% of
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all AML patients (Suzuki et al. 2005a; Verhaak et al. 2005a) and 50% of CN-AML patients 
(Section 1.2.4.c) (Falini et al. 2005; Schnittger et al. 2005a; Suzuki et al. 2005b; Verhaak et 
al. 2005b). The function of the NPM1 gene is not as well understood as the function of the 
FLT3 ITD. However, the NPM1 mutation is known to disrupt protein localisation and export, 
causing patients with this mutation to exhibit cytoplasmic rather than nucleic nucleophosmin. 
This altered expression pattern may disrupt the normal functioning of the protein leading to 
cancer pathogenesis (Falini et al. 2006). Patients with mutated NPM1 are reported to have a 
favourable prognosis in terms of achievement of complete remission (CR) relapse free 
survival (RFS) and overall survival (OS) (Dohner et al. 2005; Falini et al. 2005; Gale et al. 
2007; Schnittger et al. 2005b). The prognostic significance of these additional mutations is 
illustrated by the inclusion of the NPM1 mutation as a provisional entity in the 4th edition of 
the WHO classifications of AML with recurrent genetic abnormalities (Swerdlow et al. 2008). 
The MLL PTD is another sub-microscopic mutation that may provide further prognostic 
information, particularly to patients with CN-AML (Section 1.2.4.a). The duplication was 
originally identified as a recurrent abnormality in AML patients with trisomy 11 identified as 
the sole abnormality (Bernard et al. 1995; Caligiuri et al. 1994; Caligiuri et al. 1996; 
Schichman et al. 1994a). However, it was soon recognised that the duplication was also 
found in AML patients lacking trisomy 11 and that the majority occurred in CN-AML, with 
reported frequencies of 6%-21% (Caligiuri et al. 1998; Schnittger et al. 2000; Yu et al. 1996). 
The preliminary papers on MLL PTD indicated a reduced duration of complete remission and 
reduced overall survival for patients with the MLL PTD (Caligiuri et al. 1998; Schnittger et 
al. 2000; Yu et al. 1996). The majority of these early studies assessed small numbers of AML 
patients, less than 100, from limited subtypes including cytogenetically normal AML and 
trisomy 11.
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This chapter addresses the hypothesis that the MLL PTD is a poor prognostic indicator 
in diagnostic and CN-AML. In this study, the frequency and clinical characteristics of the 
MLL PTD were analysed in 386 (342 unselected diagnostic AML) patients with 
haematological disorders.
The specific objectives of the study were:
1) to determine the frequency of the MLL PTD in unselected and CN-AML
2) to assess the impact of the MLL PTD PCR assay on the proportion of patients without 
established prognostic markers (for cytogenetics and RT-PCR)
3) to determine the association of the duplication with cytogenetic abnormality, FAB 
classification, FLT3 mutations, NPM1 mutations and other characteristics of clinical 
presentation
4) to assess the prognostic impact of the MLL PTD on AML patients
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3.2 Materials and Methods
3.2.1 Patient Samples
A total of 386 patients and 20 healthy controls were tested for the presence of MLL 
PTD. The healthy control samples were obtained from donor samples collected for bone 
marrow transplant. The patient samples were derived from two groups, Medical Research 
Council AML Trial-United Kingdom (MRC-UK) patients and non-trial patients assayed by 
the Haematology department’s RT PCR AML screen assay. Of the 386 patients assayed, 
there were 342 AML, 18 AML follow up, 3 ALL and 23 that were not diagnosed as AML. 
The majority of the patients in the latter group were diagnosed with myelodysplastic 
syndrome (MDS) or myeloproliferative neoplasms (MPN) and were excluded from the 
primary analyses. The 342 diagnostic AML patients were composed of 302 de novo AML 
and 40 secondary AML (sAML) cases, these samples were analysed together unless otherwise 
stated. The clinical and molecular characteristics of these patients are shown in Table 3.1 and 
Table 3.2. The treatment protocols of the patients were described previously (Section 2.3.2 
Materials and Methods). The 342 diagnostic AML patients studied fell into two groups, 117 
were non-trial patients and 225 were enrolled into one of the MRC AML trials, 130 o f the 
trial samples were randomly selected from the stored material maintained by the Cardiff 
University trials unit and the remaining 95 were processed directly by the Haematology 
department. There was no significant difference observed between the results for the trial 
data alone and trial and non trial data combined in the majority of tests performed, therefore 
all results shown in this study are a combination of trial and non trial patients unless otherwise 
stated. Results requiring post-diagnostic information were performed on the trial samples 
only due to the lack of outcome data available on the non-trial patients.
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Characteristic
Sex n=342 n %
Male 187 54.7
Female 155 45.3
Age Group n=342 n %
<35 years 52 15.2
35-60 years 131 38.3
>60 years 158 46.2
Age n=342 years
Median 58.0
Range 1 -89
WBC xlO’/L
Median 15.7
Range 0.6-311.0
Bone marrow blasts count n=295 %
Median 65.0
Range 1-100
Type of AML n=342 n %
de novo AML 306 89.5
sAML 36 10.5
FAB type n=342 n %
M0 29 8.5
Ml 56 16.4
M2 86 25.1
M3 19 5.6
M4 46 13.5
M5 33 9.6
M6 6 1.8
M7 1 0.3
Bilineage 1 0.3
RAEB/RAEB-t 6 1.8
Not determined 59 17.3
Table 3.1 Clinical Characterisation of Diagnostic Patient Cohort
WBC: white blood count; L: litre; sAML: secondary AML (sAML included both AML that 
developed after a myelodysplastic syndrome and AML developed after therapy); FAB: 
French-American-British. Complete information was not available for some patients .RAEB: 
refractory anaemia with excess blasts; RAEB-t: refractory anaemia with excess blasts in 
transformation.
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Characteristic Patients (n) Patients (%)
CytogeneticAbnormalities n=342
t(15;17) 17 5.0
t(8;21) 15 4.4
inv( 16)/t( 16; 16) 20 5.8
+8 10 2.9
+11 8 2.3
-5 1 0.3
-7 11 3.2
3q 2 0.6
t(6;9) 1 0.3
t(9;22) 2 0.6
t(l lq23) 8 2.3
Complex karyotype (>5 chromosomal abnormalities) 29 8.5
Other chromosomal abnormalities 29 8.5
Normal karyotype 154 45.0
Not determined 35 10.2
Cytogenetic Prognostic Classification n=342
Favourable 52 15.2
Intermediate 201 58.8
Adverse 44 12.9
Not determined 45 13.2
Molecular Abnormalities
MLL PTD - no./total no. 17/342 5.0
FLT3 ITD - no./total no. 76/336 22.6
FLT3 TKD - no./total no. 25/200 12.5
NPM1 - no./total no. 52/181 28.7
WT1 over-expression - no./total no. 108/133 81.2
Table 3.2 Molecular Characterisation of the Diagnostic Patient Cohort
PTD: partial tandem duplication; n.: number; ITD: internal tandem duplication; TKD: 
tyrosine kinase domain.
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3.2.2 Molecular Biology Techniques
PCR conditions were optimised to prevent amplification of MLL PTDs that were not 
relevant to AML (as described in Introduction 3.1). When the MLL PTD PCR was performed 
as near to the conditions described by Schnittger et al. (1998) as possible (the MgCC 
concentration and buffer conditions were not stated) multiple PCR products were produced 
(Schnittger et al. 1998). The conditions for amplification were 50 ng/pl cDNA, 0.2 mM 
primers MLL 6.1 and MLL E3AS. 0.2 mM dNTPs, 2 mM MgCL, 1 mM Tris-HCl, pH8.3, 5 
mM KC1 and 0.025 units/pl Taq polymerase. The cycling conditions were 4 minutes at 94°C, 
followed by 35 cycles (1 minute at 94°C. 1 minute at 63°C, 1 minute at 72°C) then a final 
extension of 10 minutes at 72°C. Reducing the MgCC concentration to ImM and replacing 
Taq polymerase with TaqGold polymerase achieved more stringent results and prevented the 
amplification of products in MLL PTD negative patients (Figure 3.1). The final optimised 
conditions were described previously (Materials and Methods Section 2.6.1.e).
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A Standard RT-PCR conditions:
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 N Mri j p f j  '■ jj
K J
480 bp 
350 bp
B Optimised RT-PCR conditions:
M 1 2 3 4  5 6 7  8 N M
480 bp__
350 bp—
e11/e3
e 10/e 3
Figure 3.1 Optimisation of MLL PTD PCR
PCR products separated by size on an ethidium bromide stained agarose gel. A: 
Amplification of multiple MLL PTD transcripts from AML patients prior to PCR 
optimisation. Lanes 2 and 6 were positive for MLL PTD, all other numbered lanes are 
negative. B: Amplification of samples after PCR optimisation. Lanes 3 and 4 are positive for 
the duplication (lanes 2 and 6 in gel A), all other numbered lanes are negative. MLL PTD 
transcript types and sizes are indicated. M: Molecular weight standard; N: negative control 
containing water.
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3.2.3 Endpoints and Statistical Analysis
Clinical outcome data were analysed for trial patients with post diagnostic information 
available. Complete remission (CR) was defined as less than 5% blasts in a normocellular 
BM with no requirement for peripheral blood count recovery. The two classifications of 
remission failure were induction death (ID) (treatment related death and/or hyperplasia 
occurring within 30 days of diagnosis), or resistant disease (RD) (failure of treatment to 
eliminate the disease including partial remission (5% to 20% blasts)). Overall survival is 
defined as the time from trial entry to death, relapse free survival is the time from trial entry to 
first event either relapse or death and the risk of relapse is the cumulative risk of relapse 
discounting death in CR.
Statistical analysis was performed using the SAS System 9.1 statistical software 
package (SAS Institute, Cary, NC, USA). Differences in the clinical and demographic data 
for MLL PTD positives were assessed using the Wilcoxon rank sum test (for continuous data), 
Mantel-Haenszel test for trend (for ordinal data), x2 test and Fisher’s exact test. Odds ratios 
(OR) and hazard ratios (HR) with 95% confidence intervals were calculated. An OR or HR 
>1 indicated a worse outcome for the condition considered. Two tailed P-values below 0.05 
were accepted as a marker of significance throughout the study. The probability of RR, RFS 
and OS were determined using the Kaplan-Meier method and survival curves were compared 
using a double-sided log-rank test for univariate analyses and Cox regression for multivariate. 
If p<0.05. models were adjusted for two sets of additional variables using logistic regression. 
The first set were the basic clinical variables (age, sex, secondary disease, cytogenetic 
prognostic group and WHO performance status) followed by molecular markers (FLT3 ITD, 
FLT3 TKD and NPM1).
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3.3 Results
3.3.1 MLL PTD Qualitative PCR Optimisation
To identify MLL PTDs for use as positive controls, diagnostic AML samples were first 
screened with the PCR conditions described by Schnittger et al. (1998). The amount of 
cDNA used was increased from 25 to 50ng to ensure that amplification occurred, as some of 
the amplification conditions were not fully described (Section 3.2.2). These conditions 
amplified multiple bands in the majority of samples tested (Figure 3.1 A); such bands 
represented MLL PTD transcripts that are produced at high levels of amplification in MLL 
PTD negative AML patients and healthy controls. The majority of the transcripts have a 
different sequence to those identified in AML and are not considered to be related to the 
disease (Marcucci et al. 1998; Schnittger et al. 1998). Further explanation of these MLL PTD 
transcripts is covered in the Discussion (Section 3.5). Of the 18 samples tested, two of the 
samples showed greater product amplification at the expected sizes of the MLL PTD 
transcripts associated with AML. When the PCR was repeated using conditions optimised to 
increase the stringency of the amplification, only the recognised MLL PTD transcripts (el0/e3 
and el l/e3) were amplified. Three modifications were made to increase the stringency of the 
PCR; the template concentration was reduced to 25 ng, the concentration of MgCL was 
decreased from 2mM to ImM and Taq polymerase was replaced with TaqGold polymerase. 
TaqGold polymerase increases the specificity of PCR reactions by allowing a “hot start” 
technique to be employed. TaqGold was activated by a ten minute 94°C incubation (hot start) 
thus preventing non-specific amplification caused by low temperature amplification before 
the start of the cycling protocol (Chou et al. 1992). The specificity of the amplification was 
confirmed by sequencing each of the different transcripts and comparing with the MLL 
sequence. All three of the transcripts amplified matched the sequence of MLL and confirmed
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that the PCR identified the partial duplication by fusion of either MLL exon 9, 10 or 11 with 
exon 3, creating an in-frame protein for translation (Figure 3.2, Figure 3.3). These samples 
were used as positive controls for future assays and subsequent positives were verified by 
basepair size.
MLL WT
04d 1 2 3 4a 4b 4C 5 6 7 6 9 1011
1 2 3 4 5 6 7 8 9  10 11 12 1314
E3AS ^  6.1
MLL-PTD (exons 3-6)
Old 1 2 3 44 4b  4C 5 6 2 3 44 4b 4C 5 6 7 8 9 1011
N*w 1 2  3 4 5 6 7 8 9 3  4 5 6 7 8 9  10 11 12 1314
6.1 E3AS
Figure 3.2 Schematic Stucture of the MLL PTD
Schematic structure of the 5' region of the MLL gene and the exon 9/exon 3 MLL PTD. The 
primers used to amplify the duplications are indicated in blue and are named according to the 
“Old” nomenclature. The "New" exon nomenclature ((Nilson et al. 1996) is used to designate 
the PTDs in this study. BCR: breakpoint cluster region.
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C
Figure 3.3 Sequence Analysis of the MLL PTD Transcripts
Characterisation of the DNA sequence of the three partial tandem duplications identified in 
MLL-PTD. A: Exon 9/exon3; B: Exon 10/exon3; C: Exon 1 l/exon3.
2 8 02 5 0
C C A G T A G T G G G  C A  T G T A G A G
2 6 0 ^  2 7 0
G A  T G A  G C A A T T C T T A  G G T T T T C
Exon 1 1 - * >  Exon 3
A T C A G A G T G G A C T T T A A G G A T  G A G C A A T T C T T A G  G T T T  1 
169 176 183 190 197 204
Exon 10 * ------------► Exon 3
A A C A A A A A C C A A A A G A A A A G  
Exon 9  * —
G A T G A G C A A T T  C T T A G G T T T T G G  
— ► Exon 3
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3.3.2 Incidence o f MLL PTD
3.3.2. a MLL PTD Incidence fo r  all Diagnostic AML samples
In total, 386 patient samples and 20 healthy controls were analysed for the presence of 
the MLL PTD. All patients were either enrolled in MRC AML trials or were determined to 
need an AML PCR screen by their clinical details. The 20 healthy control samples were all 
negative for the duplication. There were 19 MLL PTD positives (4.9%) in the cohort of 386 
patients; however, after completion of all clinical tests, the final number of diagnostic AML 
samples was determined to be 342 and the final number of MLL PTD positives was 17 (two 
were from relapse samples). To gain a broad picture of the frequency of MLL PTD in AML, 
the assay was not limited to a particular subgroup of patients; therefore de novo AML, 
secondary AML and all FAB subtypes were included in the overall analysis. MLL PTD 
products were detected in 5.0% (17/342) of patients overall,the frequency was 5.2% (16/306) 
in de novo AML and 2.8% (1/36) in sAML (Section 3.3.2.i) (Table 3.3). The clinical details 
of the patients positive for MLL PTD are shown in Table 3.4. Three different transcripts were 
identified by sequence analysis, the majority of which were the fusion of exon 9 to exon 3 
(e9/e3 transcript). The e9/e3 transcript represented 70.6% (12/17) of the total positives, the 
el0+ell/e3 transcripts 23.5% (4/17) and the el0/e3 transcript 5.9% (1/17). In the 154 
patients who were cytogenetically normal, 6.5% (10/154) were positive for the duplication. 
Thus, the incidence of the duplication was increased in the cytogenetically normal subgroup 
compared to the overall group but was not significant (p=0.3). The duplication also occurred 
in samples with cytogenetic abnormalities, albeit at a lower frequency. The incidence was 
3.9% (6/153) with all aberrant karyotypes included, but dropped to 2.7% (4/150) when the 3 
samples with trisomy 11 as the sole karyotypic abnormality were excluded. In summary, 
5.0% (17/342) of the diagnostic AML patients had an MLL PTD. Six of the 17 cases had
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chromosomal abnormalities including trisomy 11 (2), monosomy 7 (2), complex karyotype 
with multiple abnormalities (1) and unusually, an t(8;21) (1). Ten of the remaining patients 
were normal karyotype and one was not determined (Table 3.4). These results indicated the 
duplication was not limited to patients with a normal karyotype or to the intermediate 
prognostic group.
AML Cohort
total no.
MLL PTD +ve 
n
Frequency
%
Overall 368 19.0 4.9
Diagnostic AML 342 17.0 5.4
de novo AML 306 16 5.2
sAML 36 1 2.8
CN-AML 154 10 6.5
Aberrant karyoty pe 153 6 3.9
Aberrant kary otype (minus +11) 150 4 2.7
Table 3.3 Prev alence of MLL PTD in Different AML Cohorts
Prevalence of the MLL PTD in different AML cohorts. PTD: partial tandem duplication; 
sAML: secondary AML; CN-AML; cytogenetically normal AML.
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9 F 66 59.8 66 9/3 M N/D N/D N/D Normal N/D ?ET to AML s AML
14 F 47 4.4 83 10/3 WT N/D N/D Ml -7 N/D ?AML de novo AML
17 F 62 4.8 N/D 10/3+11/3 WT N/D N/D M2 Complex N/D ?Relapse FU
41 M 64 60.0 63 10/3+11/3 WT WT WT M2 Normal CR AML 14 de novo AML
49 F 61 3.0 56 9/3 WT N/D N/D M2 Normal N/D ?AML de novo AML
68 M 38 8.0 73 10/3+11/3 WT N/D N/D M2 -7(q) N/D ?Relapse FU
77 M 61 0.8 60 10/3+11/3 WT WT WT M0 Normal CR AML 15 de novo AML
126 M 82 4.5 80 10/3+11/3 WT N/D N/D Ml + 11 N/D ?AML de novo AML
150 F 35 3.6 10 9/3 WT M WT N/D N/D CR AML 15 de novo AML
173 F 43 1.0 56 9/3 WT N/D N/D M2 Normal CR AML 15 de novo AML
188 F 72 1.9 50 9/3 WT N/D N/D M6 Normal N/D ?AML de novo AML
262 F 72 125.0 90 9/3 M WT WT M5 Normal CR AML 11 de novo AML
263 M 62 118.0 N/D 9/3 M WT WT Ml Normal CR AML 11 de novo AML
282 F 65 2.6 63 10/3+11/3 WT WT WT M2 -7 CR AML 14 de novo AML
296 M 76 46.2 84 9/3 M WT WT Ml Normal RES DIS AML 14 de novo AML
301 M 71 50.5 92 9/3 WT M WT Ml +11 CR AML 14 de novo AML
320 F 41 79.9 71 9/3 WT WT WT M2 t(8;21) CR AML 15 de novo AML
370 M 60 1.0 87 9/3 WT WT WT Ml Complex RES DIS AML 15 de novo AML
384 F 75 1.6 N/D 9/3 WT WT WT M2 Normal N ?AML de novo AML
Table 3.4 Clinical Characteristics of MLL PTD Patients
Clinical characteristics of patients with the MLL PTD. The two relapse patients UPN 17 and 
UPN 68 were not used in further analyses. UPN: unique patient number; M:male; F: female; 
N/D: not determined; M: mutant; WT: wild type; CR complete remission; RES DIS: resistant 
disease; and sAML: secondary AML.
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Karyotype data was available on 299 MLL WT AML patients, of these 2.7% (8/299) 
of patients had a trisomy 11; three of these as the sole abnormality and five in combination 
with other abnormalities. Trisomy 11 was present in 13.3% (2/15) MLL PTD patients and 
2.1% (6/284) MLL negative patients (p=0.06) (Table 3.5). Furthermore, two of the three 
cases of trisomy 11 as the sole abnormality were MLL PTD positive (p=0.02) indicating MLL 
PTD is significantly over represented in this group of patients.
Trisomy 11 (sole and 
other abnormalities)
MLL
WT
n=284
% MLL
PTD
n=15
% P-
value
- 278 97.9 13 86.7
+ 6 2.1 2 13.3 0.06
Trisomy 11 (sole 
abnormality)
MLL WT 
n=284
% MLL PTD 
n=15
% p-value
283 99.6 13 86.7
+ 1 0.4 2 13.3 0.02
Table 3.5 Frequency of MLL PTD in Trisomy 11 Patients
Co-occurrence of MLL PTD in patients with trisomy 11. A. MLL PTD association with all 
trisomy 11 patients. B. MLL PTD association with patients with trisomy 11 as the sole 
abnormality. WT: wild type; PTD: partial tandem duplication.
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3.3.2.b Stability o f MLL PTD in Relapse Samples
The stability of the MLL PTD as an MRD marker was assessed by the number of 
follow up samples that retained the marker upon relapse. Retention would increase the 
possibility of successfully using the duplication as an MRD marker. Eight of the 18 post­
treatment samples were relapse samples (BM blast counts greater than 5%) and two were 
positive for the MLL PTD. Unfortunately, only one of these patients had a diagnostic sample 
available for testing. In this patient the same duplication, el0/e3 + el l/e3, was identified in 
both the diagnostic and relapse sample, indicating that the mutation was retained (Figure 3.4). 
The MLL PTD screening identified 8 patients for whom follow up material could be obtained. 
These patients were followed through treatment to determine if the duplication was an 
effective marker for MRD. The results of these studies can be found in Chapter 4.
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Figure 3.4 MLL PTD PCR of Patient at Diagnosis and Relapse
Lane 1 and 2 are positive controls, lane 3 is UPN 68 at diagnosis and lane 4 is UPN 68 at 
relapse. Transcript type and size are indicated on the left. M: molecular weight marker; N: 
negative control using water. This is a composite gel.
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3.3.2.C MLL PTD Incidence in non AML Haematology Patients
Twenty-six of 386 patients originally thought to have AML were later determined to 
have other haematological diseases; three were diagnosed with ALL and 23 with non- 
leukaemic disorders. There were no cases of MLL PTD in diagnostic ALL patients (0%; 0/3) 
and no cases in the non-leukaemic patients (0%; 0/23). Interestingly, one of the ALL patients 
had trisomy 11 as the sole cytogenetic abnormality, which is associated with a higher 
frequency of MLL PTD in AML. The major groups in the non-leukaemic patients were MDS 
(11), MPN (5) and myeloid sarcomas (4). None of the myeloid sarcomas had any evidence of 
bone marrow involvement, as evidenced by the low blast counts observed; therefore AML 
abnormalities in the bone marrow would not be expected. Although the numbers tested were 
small, there was no evidence of the MLL PTD detected in any of the non-AML samples 
tested.
3.3.2.d MLL PTD Co-occurrence with Other Molecular Aberrations
The possible co-occurrence of MLL PTD with other molecular aberrations was 
examined in FLT3 ITD, FLT3 TKD, NPM1 and WT-1. The FLT3 TKD and NPM1 data was 
provided by Professor A. K. Burnett, Cardiff University Trials Unit and the WT-1 data on the 
Cardiff University MRC AML 15 samples was kindly provided by Professor John Yin, 
Department of Haematology, Manchester Royal Infirmary. The co-occurrence of the MLL 
PTD with the FLT3 ITD and TKD mutations was analysed in the 342 diagnostic patients due 
to the co-occurrence of MLL PTD with either a FLT3 ITD or TKD in 50% (6/12) of the MLL 
PTD samples. The FLT3 ITD mutation was detected in 22.6% (76/336) of the patients 
assayed; 23.5% (4/17) of MLL PTD positive patients were FLT3 ITD mutants compared with 
22.6% (72/319) of MLL negative patients (p=1.0) (Table 3.6). FLT3 TKD data was available 
for 200 patients and detected in 12.5% (25/200); 18.2% (2/11) of the duplication positive
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patients were positive for the TKD mutation versus 12.2% (23/189) of the MLL negative 
patients (p=0.6). The number of patients available for the overall FLT3 mutation status, 
dictated by the presence of either mutation, was 224 with 44.6% (100/224) mutants detected. 
Six patients positive for MLL PTD tested positive for a FLT3 mutation (6/12; 50%) and 
44.3% (94/212) of MLL negative patients had a FLT3 mutation (p=0.8).
Despite the high proportion of MLL PTD patients harbouring FLT3 mutations there was no 
significance associated with any of the aberrations. There was no significant correlation when 
the same analysis was performed in the CN-AML subgroup where there is a higher incidence 
of all three mutations. In summary, despite the high percentage of co-occurrence between 
MLL PTD and FLT3 mutations the frequency was no higher than expected.
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MLL WT 
n %
MLL PTD 
n % p value
FLT3 ITD n-319 a II
- 247 11A 13 76.5
+ 72 22.6 4 23.5 1.0
FLT3 TKD n=189 n = ll
- 166 87.8 9 81.8
+ 23 12.2 2 18.2 0.6
FLT3 overall n=212 n=12
- 118 55.7 6 50.0
+ 94 44.3 6 50.0 0.8
NPM1 n=170 n = ll
- 118 69.4 11 100.0
+ 52 30.6 0 0.0 0.04
WT1 Over-expression n=128 n=5
- 20 15.6 0 0.0
+ 108 84.4 5 100.0 1.0
Table 3.6 Co-occurrence With Other Molecular M arkers
WT: wild type; PTD: partial tandem duplication; no.:number; ITD: internal tandem 
duplication; TKD: tyrosine kinase domain; -: negative for mutation; +: positive for mutation.
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The co-occurrence of the NPM1 mutation and MLL PTD was analysed in the 
diagnostic AML cohort. The NPM1 mutation assay was performed on 181 patients and 
28.7% (52/181) were positive. Within the 11 MLL PTD patients there were no NPM1 
mutations detected (0/11; 0%) compared to 30.6% (52/170) NPM1 mutations in the MLL 
negative group. There was a significant negative association between the two mutations (p= 
0.04). Subsequent analysis of the CN-AML subgroup (n=93) reproduced this result (p=0.06). 
Taken as a whole, these results suggest that the mutations NPM1 and MLL PTD have a 
negative association, but a larger cohort of patients would be required to confirm this finding. 
WT-1 is generally over-expressed in AML and has been linked with poor prognosis (Liu-Yin 
et al. 2008; Paschka et al. 2007; Weisser et al. 2005a)(Garg et al. 2003b). The correlation of 
WT-1 expression level with the presence of the MLL PTD was analysed in 133 diagnostic trial 
patients. High expression levels of WT-1 were detected in all five MLL PTD positive patients 
(5/5; 100%) and in 108 MLL negative patients (108/128; 81.2%). The association of MLL 
PTD with over expression of WT-1 was not statistically significant (p=1.0).
3.3.2.e MLL PTD Incidence in Cytogenetic Prognostic Groups
The frequency of the MLL PTD was examined in relation to the cytogenetic 
prognostic groups in de novo AML patients, to determine if the duplication was associated 
with a particular prognostic classification. In the 297 patients analysed, the duplication 
positive patients had 6.7% (1/15) favourable, 73.3% (11/15) intermediate and 20.0% (3/15) 
adverse classification types. This compared to the MLL negative patients who showed 18.1% 
(51/282) favourable, 67.4% (190/282) intermediate and 14.5% (41/282) adverse types (Table 
3.7A). Despite the slightly higher proportion of intermediate classifications in the MLL PTD 
patients, there was no significant difference between the distribution of the MLL PTD and 
MLL WT patients in the cytogenetic prognostic groups (p=0.3). To determine if there was an
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association between MLL PTD and cytogenetically normal patients, the intermediate group 
was further stratified into cytogenetically normal and those with a cytogenetic abnormality. 
Although over half of the duplication positive patients (9/15; 60.0%) were in the 
cytogenetically normal group, there was no significant difference between the duplication 
positive and negative patients (p=0.6).
MLL
WT
n=282
%
MLL
PTD
n=15
% p value
Favourable 51 18.1 1 6.7
Intermediate 190 67.4 11 73.3 0.3
Adverse 41 14.5 3 20.0
MLL MLL
B. WT
n-282
% PTD
n=15
% p value
Favourable 51 18.1 1 6.7
Intermediate (normal) 143 50.7 9 60.0 0.6
Intermediate (abnormal) 47 16.7 2 13.3
Adverse 41 14.5 3 20.0
Table 3.7 Frequency of MLL PTD in Cytogenetic Prognostic Classifications
A: Prevalence of the MLL PTD in patients classified by cytogenetic prognostic classifications. 
B: Prevalence of MLL PTD when the intermediate prognosis group is sub-divided into those 
with normal karyotype (‘normal’) or with cytogenetic abnormalities (‘abnormal’). WT: wild 
type; PTD: partial tandem duplication.
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These data show that the proportion of patients classified with an intermediate 
prognosis due to the lack of a marker would be reduced by the inclusion of the MLL PTD 
assay. There were 201 patients classified as intermediate prognosis by using cytogenetic 
classification of which 75.1% (151/201) were cytogenetically normal. The MLL PTD assay 
increased the number of patients with a significant prognostic marker (Section 3.3.3) through 
detection of nine duplications (9/151; 6.0%) in the cytogenetically normal cohort. Therefore, 
the MLL PTD assay increased the number of patients with a prognostic marker when 
compared to cytogenetic testing alone. Addition of the FLT3 ITD to the 146 patients tested 
for both mutations added a prognostic marker to 39 more patients 32.8% (48/146).
3.3.2.f MLL PTD Incidence in Relation to RT-PCR o f Fusion Genes
The incidence of MLL PTD in the diagnostic AML screen cohort was analysed to 
determine how the inclusion of the MLL PTD assay would affect the number of non- 
informative results in the RT PCR AML screen assay. There were 231 diagnostic AML 
patients screened by RT PCR and only 18.2% (42/231) had a detectable mutation. Fourteen 
of the mutations were CBF$-MYH11 (14/231; 6.1%), 12 RUNXJ-RUNX1T1 (12/231; 5.2%), 
14 PML-RAR (14/231; 6.1%) and 2 BCR-ABL (2/231; 0.9%). This left 82% (189/231) of the 
patients without a marker detectable by these RT PCR tests. The MLL PTD was detected in 
10 (10/231; 4.3%) of the samples, with only one co-occurring with a detectable RT PCR 
translocation, a RUNX1-RUNX1T1. Therefore, the MLL PTD assay increased the number of 
informative RT PCR results by 21.4% (9/42). Inclusion of the FLT3 ITD assay, available on 
186 of the 189 negative samples, detected 35 positives and increased the positive results by 
68.6% (35/51) when combined with the results of the MLL PTD assay. The final proportion 
of informative markers detected when both tests were performed was 37.7% (86/228). The 
addition of the MLL PTD test whether independently or in conjunction with the FLT3 ITD
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assay increased the number of informative results obtained from RT PCR testing of de novo 
AML patients.
3.3.2.g Association o f  Clinical Features with MLL PTD
The demographic data on age, sex, FAB classification, presentation WBC and 
presentation blast percentage for the 342 diagnostic AML patients was analysed to determine 
if there were associations with MLL PTD.
In the only instance of a difference between trial and non-trial patients, elderly trial 
patients had a significantly higher incidence of the mutation (p=0.03). The median age of the 
MLL PTD negative patients was 53.5 years (range 15-87) while the median for the positive 
patients was 62 years (range 35-76). The addition of non-trial patient’s data raised the 
number of patients from 225 to 342 and increased the median of the MLL WT to 57 (range 1- 
89) and the MLL PTD patients to 64 (range 35-82) (Table 3.8). These data still demonstrated 
a higher frequency of MLL PTD in elderly patients, but were not significant (p=0.07).
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Age MLL WT 
(years) n=325 %
MLL  PTD
n=17 %  p value
0-14 11
15-29 29
30-39 24
40-49 37
50-59 80
60+ 144
3.4 
8.9
7.4
11.4 
24.6 
44.3
3
0
13
64 (35-82)
0
0
0.0
0.0
5.9
17.6
0.0
76.5
Median 57(1-89) 0.07
Table 3.8 Distribution of MLL PTD by Age
Distribution of the MLL PTD across age groups in the combined trial and non-trial cohort. 
WT: wild type; PTD: partial tandem duplication.
The greater proportion of MLL PTD were female 58.8% (10/17), and the occurrence of 
the mutation in females (10/155; 6.5%) was higher than in males (7/187; 3.7%), however, 
these differences were not significant (p=0.3).
The distribution of the FAB classifications for the 325 MLL WT and 17 MLL PTD 
patients are displayed in Table 3.9. Although the majority of the duplications occurred in Ml 
and M2, the distribution broadly mirrored that of the MLL WT and no statistical differences 
were seen (p=0.4).
3-126
FAB
MLL
WT
n=325
%
MLL
PTD
n=17
% p value
MO
n
28 8.6
n
1 5.9
M l 50 15.4 6 35.3
M2 80 24.6 6 35.3
M3 19 5.8 0 0.0
M4 46 14.2 0 0.0 0.4M5 32 9.8 1 5.9
M6 5 1.5 1 5.9
M7 1 0.3 0 0.0
Bilineage 1 0.3 0 0.0
RAEB/RAEB-T 6 1.8 0 0.0
N/D 57 17.5 2 11.8
Table 3.9 Incidence of MLL  PTD in FAB Classifications
Incidence of FAB subtypes in patients with and without the MLL PTD. RAEB: refractory 
anaemia with excess blasts; RAEB-t: refractory anaemia with excess blasts in transformation; 
N/D: not determined.
3-127
To determine if there was an association between the diagnostic WBC and MLL PTD, 
the data from 323 patients was analysed. The median WBC for MLL negative patients was 
16.2x109/L (range 0.6-311.0x109/L) while the median for the duplication positive patients was 
4.4x109/L (range 0.8-125.0xl09/L) (Table 3.10). There was no significant difference between 
the distribution of WBC for positive or negative MLL PTD patients (p=0.17). Additionally, 
the FLT3 ITD is associated with a significant increase in the WBC of MLL PTD patients
(p=0.02).
WBC
(x109/L)
MLL WT 
n=306 %
MLL PTD
n=17 % p value
0-9.9 125 40.8 10 58.8
10-49.9 95 31.0 1 5.9
50-99.9 42 13.7 4 23.5
100+ 44 14.4 2 11.8
Median (range) 16.2 (0.6-316.0) 4.4 (0.8-125.0) 0.17
Table 3.10 Association of MLL PTD with Presenting WBC
Comparison of the distribution of MLL WT and MLL PTD in presenting WBC. L: litre; WT: 
wild type; PTD: partial tandem duplication; WBC: white blood count.
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The proportion of blasts in the diagnostic analysis from 299 samples were generally 
similar between wild type and positive patients with the largest number of patients found in 
the >50% subset for both, 56.6% (184/325) for wild type and 82.4% (14/17) for the 
duplication (Table 3.11). The median and range were 65% (1-100%) in MLL WT versus 66% 
(range 10-92%) in the MLL PTD. There was no significant difference between the 
distributions of the two groups (p=0.7).
Blast MLL WT G/ MLL PTD
Percentage n=325_________ n=17
<20% 21 6.5 2 11.8
20-29% 26 8.0 0 0.0
30-49% 52 16.0 0 0.0
50%+ 184 56.6 14 82.4
Median (range) 65(1-100) 66(10-92)
Unknown 42 12.9 1 5.9
Table 3.11 Association of MLL PTD with Diagnostic Blast Percentage
WT: wild type; PTD: partial tandem duplication
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In summary, the MLL PTD patient cohort was not significantly different to the MLL 
WT cohort in terms of the baseline clinical characteristics of sex, FAB classification, WBC or 
blast percentage. However, evidence from this study suggested a higher incidence of MLL 
PTD in the elderly.
3.3.2.h Correlation o f MLL PTD with WHO Performance Status
Patients with the MLL PTD were studied to determine if there was an association 
between the duplication and the WHO performance status. The WHO performance status is a 
measure of the patients well being and is used as a factor in determining patient treatment 
(Oken et al. 1982). The status levels range from 0-5, with 0 being asymptomatic and 5 death. 
The distribution of patients in status level 0 to status level 4 (bed-bound or completely 
disabled) was compared in 225 trial patients with and without the duplication (Table 3.12). 
Of the MLL negative patients, 0.9% (2/214) were at status level 4, 2.3% (5/214) at level 3, 
2.3% (5/214) at level 2, 27.6% (59/214) at level 1 and 66.8% (143/214) at level 0. The MLL 
PTD distribution showed none (0/11) at level 4, 9.1% (1/11) at level 3, none (0/11) at level 2, 
54.5% (6/11) at level 1 and 36.4% (4/11) at level 0 (Table 3.12). Thus, the numbers of MLL 
negative patients increased as patient well-being increased from level 4 to level 0, whereas the 
greatest number of MLL PTD patients were in performance level 1. However, these data were 
not significant (p=0.09).
3-130
WHO
Performance
Status
MLL WT 
n=214 %
MLL
PTD
n - l l
% p value
0 143 66.8 4 36.4
1 59 27.6 6 54.5
2 5 2.3 0 0.0 0.09
3 5 2.3 1 9.1
4 2 0.9 0 0.0
Table 3.12 Association of MLL  PTD with WHO Performance Status
WT: wild type; PTD: partial tandem duplication; WHO: World Health Organisation; PTD: 
partial tandem duplication.
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3.3.2A Association o f MLL PTD With sAML
Within the total cohort of 342, the patient data were studied for an association between 
MLL PTD and sAML. The MLL negative patients exhibited a higher level of sAML than the 
positive cases, with 11% (35/325) compared to 6% (1/17) with the duplication. This 
difference was not significant (p=1.0).
3.3.3 MLL PTD Patient Outcome
3.3.3. a Association o f MLL PTD with Complete Remission
The MRC trial data from 220 intensively treated patients was used to determine if 
there was an association between the MLL PTD and one of three outcomes: induction death, 
resistant disease or complete remission. A total of 31 patients negative for MLL PTD died 
during induction (31/209; 14.1%) compared to no deaths for MLL PTD patients (0/11; 0%). 
Although fewer MLL PTD patients died during the induction stage of treatment the difference 
in death rate was not significant (Odds Ratio (OR), 0.30 [0.05-1.68]; p=0.17) (Table 3.13). 
The incidence of RD did not vary significantly between the positive and negative patients, 
10.5% (22/209) of negative patients had RD compared with 18.1% (2/11) of MLL PTD 
patients (OR, 2.19 [0.31-15.2]; p=0.4). The higher proportion of duplication positive patients 
reaching CR, 81.8% (9/11) versus 75.0% (156/209) MLL WT, was not significant (OR, 0.68 
[0.17-2.76]; p=0.6). Additionally, the treatment outcome of 103 normal karyotype patients 
demonstrated no difference in these three remission indicators for MLL PTD patients 
compared with MLL WT. In summary, there was no association between remission indicators 
and the presence of the MLL PTD.
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MLL WT 
n=209 %
MLL
PTD
n=ll
% OR 95% Cl p value
ID
+
178
31
85.2
14.8
11
0
100.0
0.0 0.3 0.05-1.68 0.17
RD
+
187
22
89.5
10.5
9
2
81.8
18.2 2.19 0.31-15.2 0.4
CR
+
53
156
25.4
74.6
2
9
18.2
81.8 0.68 0.17-2.76 0.6
Table 3.13 Comparison of Complete Remission Outcome
Complete remission outcome compared between patients with and without MLL PTD. WT: 
wild type; PTD: partial tandem duplication; OR: odds ratio; Cl: confidence interval; ID: 
induction death RD: resistant disease; CR: complete remission; -: negative for mutation; and 
+: positive for mutation.
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3.3.3.b Outcome o f MLL PTD Patients
The outcome indicators, relapse free survival (RFS), risk of relapse (RR), and overall 
survival (OS), were compared between patients positive and negative for the duplication using 
the post diagnostic MRC trial data of AML patients. The presence of the duplication had a 
significant negative influence on the five year RFS rate in the 165 patients with available data, 
the Kaplan Meier (KM) survival estimates were 38.4% for the MLL PTD negative patients 
versus 0% for the MLL PTD positive (Hazard Ratio (HR), 18.78 [5.11-69.09]; p<0.0001). In 
fact, only one patient with the duplication passed the one-year mark before relapsing (Figure 
3.5). The results remained significant (HR, 2.66 [1.19-5.91]; p=0.01) after RFS was adjusted 
for the influence of the baseline covariates (age, sex, secondary disease, cytogenetic prognosis 
status and WHO performance status). However, when adjusted for the molecular markers 
FLT3 ITD, TKD and NPM1 the influence of MLL PTD on RFS was no longer significant 
(HR, 1.72 [0.67-4.41]; p=0.3).
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Figure 3.5 MLL PTD influence on Clinical Outcome in diagnostic AML.
A. Relapse free survival, B. risk of relapse, and C. overall survival of MLL PTD WT 
compared to MLL PTD patients. HR: hazard ratio.
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Patients positive for the duplication demonstrated a significantly higher RR than 
negative patients (n=l56). The RR in MLL WT patients at five years post-diagnosis was 
46.7% compared to 100% of the eight MLL PTD patients (HR, 75.19 [15.12-373.9]; 
p<0.00001). One patient reached CR, yet died without relapsing; therefore this patient was 
not censored. The significance of the relationship between MLL PTD and a higher RR was 
maintained after the adjustment was made for baseline co-variates (p=0.005, HR=3.95 (17.2- 
9.10)) and remained highly suggestive after the influence of the molecular markers was 
included (p=0.06, HR=2.5 (0.93-6.72)). The presence of MLL PTD was correlated with the 
OS at 5 years post diagnosis in 220 patients. Patients with the duplication had a significantly 
lower rate of OS than MLL negative patients, with survival estimates of 9.1% and 33.9% 
respectively (p=0.04, HR=2.5 (1.05-5.97)). The MLL PTD patient that survived to five years 
post diagnosis had a favourable t(8;21) marker in addition to the duplication, which may have 
been dominant over the negative influence of the PTD. The negative relationship between 
MLL PTD and OS was not retained after baseline co-variate adjustments were made (p=0.6, 
HR=1.23 (0.58-2.59)), or with the additional adjustment that accounted for the impact of 
molecular markers (p=1.0, HR=0.99 (0.42-2.3)). In summary, the MLL PTD does not appear 
to add any prognostic information relating to the OS beyond the scope of the standard 
baseline prognostic variables (age, sex, secondary disease, cytogenetic prognosis 
classification and WHO performance status). In contrast, patients positive for the duplication 
fared significantly worse in both RFS and RR even after the baseline variables were included, 
thus demonstrating the negative impact of the MLL PTD on these outcomes.
The clinical outcome of CN-AML patients with and without the MLL PTD was 
investigated due to the high proportion of duplications that occur in this cytogenetic subgroup. 
Patients with an MLL PTD detected had a significantly lower level of RFS and a significantly 
higher RR (p=0.002, HR=15.4 (2.79-84.4) and p<0.0001, HR=145 (16.9-1242) respectively).
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There were 82 patients with relapse data, 36.4% of the MLL negative patients achieved RFS at 
five years compared with 0% of the MLL PTD patients (Figure 3.6). When comparing RR 
analyses, 48.1% of MLL negative patients relapsed compared to all of the patients with a 
detected PTD. Patients with a detectable MLL PTD exhibited a lower level of OS at 5 years, 
0% versus 34.7% of the MLL negative, but this result was not statistically significant (p=0.1, 
HR= 2.76 (0.79-9.73)). In summary, the presence of the MLL PTD within the cytogenetically 
normal AML subgroup had a significant negative affect on the relapse outcomes, relapse free 
survival and risk of relapse, but no significant effect on overall survival.
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Figure 3.6 MLL PTD influence on Clinical Outcome of CN-AML Patients
A. Relapse free survival, B. risk of relapse, and C. overall survival of MLL PTD WT 
compared to MLL PTD patients. HR: hazard ratio.
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As a large proportion of MLL PTD mutations co-occur with FLT3 mutations, the 
prognostic impact of the combination was compared by outcome analysis. The patients were 
divided into four groups, MLL PTD-/FLT3-, MLL PTD-/FLT3+, MLL PTD+/FLT3- and MLL 
PTD+/FLT3+ and the three outcome indicators RFS, RR and OS were estimated. The FLT3 
mutations were analysed in three categories, FLT3 ITD, FLT3 TKD and FLT3 overall, where 
FLT3 was considered mutant if either ITD or TKD was mutant and WT when both were WT. 
The low numbers in the co-incident groups were insufficient for statistical analysis of the 
associations, therefore the study can be considered primarily as a preliminary analysis of the 
trends which may encourage further investigations using greater numbers. The numbers of 
patients with mutation status and clinical outcome data are given in the figure legends.
The RFS and RR for the three FLT3 categories in conjunction with MLL PTD 
described similar scenarios, where MLL PTD+ patients fared worse than the others. In RFS, 
none of the MLL PTD+/FLT3+ and MLL PTD+/FLT3- patients were alive at five years, with 
the double positive patients surviving around half as long as the MLL PTD+/FLT3- patients 
(Figure 3.7). The KM plots for RR showed that all MLL PTD patients relapsed, with the time 
to relapse shorter for the double positive group (Figure 3.8). Interestingly, in both analyses, 
the MLL PTD-IFLT3 TKD+ was beneficial to the patient outcome in comparison to all other 
categories, while the MLL PTD+/FLT3 TKD+ was markedly detrimental.
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Figure 3.7 Influence of MLL PTD and FLT3 mutations on RFS
Relapse free survival in patients positive or negative for MLL PTD with A. FLT3 ITD 
mutations, B. FLT3 TKD mutations or C. either FLT3 mutation. MRC: Medical Research 
Council; PTD: partial tandem duplication; ITD: internal tandem duplication, TKD: tyrosine 
kinase domain.
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Figure 3.8 Influence of MLL PTD and FLT3 mutations on RR
Relapse risk in patients positive or negative for MLL PTD with A. FLT3 ITD mutations, B 
FLT3 TKD mutations or C. either FLT3 mutation. MRC: Medical Research Council; PTD 
partial tandem duplication; ITD: internal tandem duplication, TKD: tyrosine kinase domain.
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The MLL PTD appeared to decrease the overall survival more than either of the FLT3 
mutations alone. In fact, the KM graphs for the double negative, double positive and the MLL 
PTD+/FLT3- in all three graphs were similar, with the double positive faring the worst (0% 
survival), MLL PTD+/FLT3- (ITD, TKD or overall) at 13% or 20% and the double negative 
ranging from 30%- 37% (Figure 3.9). As shown by data for RFS and RR, the MLL PTD- 
IFLT3 TKD+ was beneficial to the OS with a KM estimate of 50% in comparison with 24% 
for MLL PTD-IFLT3 ITD+ and 30% for MLL PTD-/FLT3 + in FLT3 overall status. Although 
the numbers are low due to the low frequency in multiple mutation categories, the outcome 
results revealed a negative influence of MLL PTD in all three of the outcome indicators 
suggestive of a negative influence in combination with FLT3 mutations.
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Figure 3.9 Influence of MLL PTD and FLT3 mutations on OS
Overall survival in patients positive or negative for MLL PTD with A. FLT3 ITD mutations, 
B. FLT3 TKD mutations or C. either FLT3 mutation. MRC: Medical Research Council; PTD: 
partial tandem duplication; ITD: internal tandem duplication, TKD: tyrosine kinase domain.
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3.4 Discussion
The importance of molecular mutations in determining the prognosis and the response 
to treatment in AML patients was originally demonstrated in relation to cytogenetics 
(Grimwade et al. 1998). More recently, the importance of sub-microscopic mutations has 
been evaluated in AML, with particular emphasis on the sub-group of CN-AML. In this 
study, the frequency of the MLL PTD was investigated in 342 patients who were either in an 
MRC AML trial or being tested for AML markers using a standard AML RT PCR screen. 
The frequency of the MLL PTD in AML patients was 5.0% overall, 5.2% in de novo AML 
and 2.8% in sAML. The frequency within CN-AML rose to 6.5% while the 3.9% incidence 
observed in aberrant karyotypes was reduced to 2.7% when patients with +11 as the sole 
abnormality were removed, as there is a known association between MLL PTD and +11. 
Interestingly, the association of +11 patients with old age and few long term disease free 
survivals (Heinonen et al. 1998) may be due in part to MLL PTD. The frequencies of de 
novo, CN-AML and aberrant karyotypes registered in this study are in line with those reported 
in other large number studies assessed over the same time period (Steudel et a l 2003), 
(Dohner et al. 2002a), (Schnittger et al. 2000) (Bacher et al. 2005). Higher frequencies (10- 
21%) have also been reported (Munoz et al. 2003; Shiah et al. 2002; Yu et al. 1996), however 
most of these are in studies of less than 100 patients and the 21% was for CN-AML patients 
only. There is also the likelihood that variation in PCR sensitivity could affect the detection 
frequency, with amplified MLL PTD transcripts clearly detected in both healthy normal 
samples and AML patients not considered positive for MLL PTD when the PCR sensitivity is 
increased (Schnittger et al. 1998), (Marcucci et al. 1998). The first step in this study was to 
optimise the PCR protocol to prevent the amplification of the multiple fusion transcripts 
detectable in all AML patients clearly demonstrated in Figure 3.1. The effectiveness of the
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optimisation strategy was confirmed by the negative results of all 20 healthy control samples 
assayed in this study.
The incidence of the duplication in patients with sAML in this study, 2.8%, is lower 
than that reported elsewhere. The few early studies in which sAML and tAML were examined 
reported frequencies of 15.4% (4/26) and 3.8% (1/26) respectively (Christiansen & Pedersen- 
Bjergaard 2001; Schnittger et al. 2000). Apart from possible differences arising from the 
difference in sample size, the sAML frequency in this study may be reduced as a result of 
tAML patients being categorised as sAML in the trial studies. The higher frequency of MLL 
PTD in AML compared to MDS (0/11) observed in this study may indicate the duplication is 
an early mutation event that promotes the pathogenesis of AML over that of MDS. 
Furthermore, the reported increase in frequency as disease evolves from MDS 2.7% (9/238) to 
sAML 7.4% (28/378) suggests the MLL PTD may be an acquired event promoting the 
transformation of MDS to AML (Bacher et a l  2007a). A recent publication supports this idea 
with the same incidence of MLL PTD observed in +11 MDS as in +11 AML, resulting in a 
high rate of transformation to AML and poor prognosis (Wang et al. 2010).
The MLL PTD was detected in 11.1% (2/18) of the relapse patient samples. The 
el0+ell/e3  transcript was detected in both the diagnosis and relapse samples of the one 
patient where samples at both timepoints were available. This indicated that the marker was 
stable over the time course of the disease. The gain of cytogenetic aberrations not present at 
diagnosis, in addition to the marker stability, suggests the MLL PTD may be an early event 
leading to leukaemogenesis. Stability of a mutation at relapse would suggest potential as an 
MRD marker, but there are difficulties due to the levels of transcripts present in healthy 
volunteers and non MLL PTD AML patients (Schnittger et al. 1998). Further data and 
discussion of the stability of the duplication, MRD applicability and clonal evolution are 
presented in Chapter 4.
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Analysis of RT PCR AML screens and cytogenetic prognostic classification cohorts 
revealed the usefulness of the MLL PTD as a diagnostic and prognostic marker. Performance 
of the test alongside the traditional RT PCR AML screen, including RUNX1-RUNX1T1, PML- 
RAR and CBFB-MYH11 increased the number of informative results by 21.4%, as 6% o f CN- 
AML patients gained a marker. The proportion of informative results was raised further when 
combined with the FLT3 ITD assay. The use of the MLL PTD assay would provide an 
increased level of prognostic information for AML patients, information that may be used to 
alter treatment strategies and improve clinical outcome.
Investigation of the prevalence of MLL PTD and other molecular mutations revealed a 
significant difference between the occurrence of NPM1 in MLL WT and patients with the 
duplication. There were no NPM1 mutations present in MLL PTD positive cases versus 31% 
of MLL WT. This negative association fits with the grouping of mutations into 
complementary classes. It has been proposed that molecular mutations are divided into two 
groups in AML: class I mutations, which increase proliferation and survival through the 
activation of signal transduction pathways, and class II mutations that impair differentiation 
by disruption of transcription (Gilliland 2002). FLT3 mutations are class I mutations while 
MLL PTD and NPM1 are generally considered to be class II, and overlap is generally seen 
between mutations of different classes (Section 1.2.4.c) (Ishikawa et al. 2009; Schlenk et al. 
2008). The prevalence of the FLT3 ITD in duplication positive samples (23.4%) was not 
significant in the diagnostic cohort as a whole or in the CN-AML cohort. Previous results for 
this observation are varied with some finding significant association and others no 
significance at all (Olesen et al. 2005b; Steudel et al. 2003). The FLT3 TKD was found to 
co-exist with the duplication in 18.2% of MLL PTD positives and high expression of WT-1 
was found in 100% of duplication positives, however neither of these associations were 
significant. The presence of MLL PTD with other aberrations suggests that the duplication
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may require the proliferative and survival traits of complementary mutations before leukaemia 
develops.
Additional comparisons between MLL PTD and FLT3 ITD patients revealed further 
differences in the clinical characteristics. There was no significant association of MLL PTD 
with the WBC or FAB type. Although there was a lower WBC in patients positive for the 
duplication, this finding was not significant. These results were in agreement with previous 
studies, with the exception of a study that found the WBC significantly lower in duplication 
positive patients (Steudel et al. 2003). The duplication has been detected in all FAB types 
except M3 and M7, which indicates that it is not restricted to lineage or level of differentiation 
(Caligiuri et al. 1998; Dohner et al. 2002b; Schnittger et al. 2000; Steudel et al. 2003). Taken 
together, the lower WBC, difference in FAB type distribution and association with different 
cytogenetic abnormalities demonstrated different clinical characteristics for the MLL PTD and 
FLT3 ITD. In this study a significantly higher WBC in co-duplicated patients was observed 
compared to MLL PTD alone. A similar result has been reported and may indicate a dominant 
effect of FLT3 ITD on the proliferative capacity of the cells (Steudel et al. 2003). These 
differences suggest that the two mutations identify different AML subtypes with similarly 
poor prognostic outcomes. Despite the suggestion that the breakpoint regions of the two 
genes may be susceptible to a similar action of genotoxic stress (Libura et al. 2003), the 
association of each mutation with a specific cytogenetic abnormality would indicate a 
common mechanistic cause was unlikely (Steudel et al. 2003)).
These data show that neither sex nor blast percentage could be used as an indicator for 
MLL PTD, in accordance with previous studies (Schnittger et al. 2000), (Caligiuri et al. 1998; 
Dohner et al. 2002b). MLL duplication positive patients tended to be older than the negative 
patients (p=0.07) and the WHO performance status was poorer than negative patients, with a 
greater proportion of patients in status level one (p=0.09). Taken as prognostic indicators,
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both of these factors would suggest a poorer outcome. A significant association with higher 
age was also observed in previous studies, this would suggest a different mechanism of 
pathogenesis to that of balanced translocations, which were evenly distributed over all age 
groups (Bacher et a l 2005; Schnittger et a l 2000; Shih et a l 2006a)).
The MLL PTD cohort achieved a slightly higher level of complete remission in accord 
with other reports, but no significant association between MLL PTD and CR was 
demonstrated (Dohner et a l 2002b; Whitman et a l 2007). In addition, there was no 
significant difference between the incidence of the ID or RD rates between positive and 
negative patients. This would suggest that the poor outcome of these patients is not caused by 
a failure to reach remission, however, morphological determination of remission may not be 
sufficient to detect small populations o f malignant clones capable of causing patient relapse 
by repopulating the bone marrow.
The clinical outcome for patients with the MLL PTD was worse in the three clinical 
outcomes studied. The 100% RR and RFS in duplication positive patients were clearly 
significant (p=0.001 and 0.006 respectively) as well as the 9% OS (p=0.04). Previous 
investigations of the clinical outcome of duplication positive patients have shown varied 
results, though the consensus is an association with a generally worse overall outcome. 
Reduced complete remission duration without reduced overall survival, reduced disease free 
survival without reduced overall survival and reduced overall survival alone have all been 
reported in cohorts of unselected AML (Dohner et a l 2002b; Schnittger et a l 2000; Steudel 
et a l 2003). The differences in the reported outcome may be due to the low frequency of the 
mutation, although the sample sizes in the studies were all more than 387 patients. 
Consideration of other prognostic variables within the cohorts, in addition to MLL PTD, may 
be another reason for the discrepancies. For this reason, the clinical outcomes in the present 
study were adjusted to account for the impact of baseline clinical prognostic factors and
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molecular markers. Multivariable regression analysis adjusts for the influence of known 
prognostic variables on the population of patients being studied, thereby preventing over 
interpretation of the impact of the condition being studied. Adjustment for the basic factors 
age, sex, secondary disease, cytogenetic prognostic group and WHO performance status was 
done first, followed by adjustment for FLT3 ITD, FLT3 TKD and NPM1. After adjustment 
for other prognostic variables, the difference in OS between patients positive and negative for 
the duplication was not significant, which implied that the original difference was not due to 
MLL PTD. In contrast, while the numbers of positives are small, the analysis does suggest 
that the negative outcomes observed in RR and RFS reflect the influence of the duplication 
after the basic clinical prognostic factors are considered. Furthermore, the negative impact of 
the MLL PTD is maintained in the RR after adjusting for molecular markers as well as basic 
clinical prognostic factors, indicating it is an independent prognostic marker and provides a 
rationale for MLL PTD testing at diagnosis.
One of the objectives of this study was to determine the effect of the MLL PTD on the 
CN-AML cohort of patients. Although the number of positive patients is decreased, the 
results are similar to those seen in the group overall, with a significant negative impact on RR 
and RFS and no effect in OS. Adjustments were not made to these analyses due to the 
smaller starting numbers. In summary, the MLL PTD proved to be a useful independent 
prognostic marker that identified a subset of patients with a higher RR and lower RFS in CN- 
AML and AML with chromosomal aberrations.
In experimental models, the influence of MLL PTD in leukaemogenesis is unclear. In 
vivo studies using MLL PTD/WT mice show an increased number of haematopoietic 
progenitor cells and epigenetic alterations in the promoter region of Hoxa genes, however the 
mice never develop leukaemia (Dorrance et al. 2006). The duplication was detected in 
CD34+ progenitor cells, as well as myeloid and lymphoid subtractions of healthy cord blood
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samples which indicated it was present throughout life and occurred at an early stage of 
haematopoiesis (Basecke et al. 2006b). The high incidence of the mutation in a subtraction of 
cells prone to leukaemic transformation together with the low frequency o f AML patients 
with the mutation suggests that it is not an initiating event. These findings are similar to the 
reports of BCR-ABL (CML) and RUNX1-RUNXT1 (AML) transcripts being identified in 
healthy individuals, however both were found at lower frequencies than MLL PTD (Basecke 
et al. 2002; Bose et al. 1998). The MLL PTD transcripts detected in AML patients are 
restricted to three transcript types and are 3-4 magnitudes higher than in healthy donors, 
which may be relevant to the development of leukaemia (Chapter 4 data)(Basecke et al. 
2006b; Weisser et al. 2005b). Taken with the in vivo study, this may indicate that further 
alterations in addition to transcriptional up-regulation are necessary before leukaemogenesis 
occurs. In addition, the argument for the leukaemogenic potential of MLL PTD due to its 
appearance as a singular aberration in early studies should be revised with the identification of 
more co-occurring mutations (Basecke et al. 2006c). The current evidence would suggest the 
duplication may be an early event in leukaemic transformation that requires the co-operation 
of an additional mutation(s). Evidence that the co-expression of FLT3 ITD is necessary for 
the fusion gene MLL-SEPT6 to induce myeloid leukaemia in mice supports the hypothesis 
that multiple mutations may be needed to unlock the leukaemogenic potential o f MLL 
mutations (Ono et al. 2005).
The clinical outcome studies in MLL PTD patients indicated the high proportion of 
patients achieving complete remission was offset by the increased relapse free survival and 
risk of relapse resulting in a lower rate of overall survival. The multitude of theories 
regarding leukaemogenesis provides a number o f possible reasons for a relapsing population 
of cells. The short duration of remission coupled with the relatively insensitive definition of 
complete remission as less than 5% blasts in a normocellular BM may indicate that a
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substantial sub-population of MLL PTD positive cells survived treatment and rapidly 
repopulated the marrow to cause patient relapse. A subpopulation of quiescent MLL PTD 
cells located in the microenvironment of a BM niche would be unaffected by chemotherapy 
aimed at killing proliferating cell populations. A change in the niche environment promoting 
the re-expansion of these cells would result in patient relapse. This population could be 
intrinsically leukaemic or may be a “seeding” population that possessed the property of clonal 
expansion but required a co-operating mutation to become leukaemic. Furthermore, relapsing 
MLL PTD patients have a higher frequency of adverse molecular markers than MLL PTD 
patients that achieved long term disease free survival (Whitman et al. 2007). Lastly, a 
subpopulation of the leukaemic cells may have obtained a mutation that conferred drug 
resistance. Determining the cause of early relapse would be instrumental in the pursuit of 
treatment targeted for these poor outcome patients. Regardless of the cause, the stability of 
the MLL PTD upon relapse implies it could be used as a more sensitive method of MRD 
detection. Identification of patients harbouring positive cells despite reaching morphological 
remission may identify a subset of patients who would benefit from different treatment (e.g. 
bone marrow transplant). The application of MLL PTD RQ-PCR for detection of MRD is 
studied in Chapter 4. In a recent clinical trial, CN AML MLL PTD positive patients exhibited 
an improved rate of disease free survival rate, 41% (9/24). This improvement may be 
attributable to a treatment regime that included an autologous PBSCT transplant in CR1 for 
82% (18/22) of the duplication positive patients (Whitman et al. 2007).
The MLL duplication had a negative effect that was observed in all three clinical 
outcomes with all three FLT3 conditions. The numbers preclude statistical analysis, but the 
co-duplicated and the MLL PTD+/FLT3- patients exhibited a more negative outcome than the 
MLL PTD-/FX7’i+  and MLL PTD-IFLT3- in each of the three outcomes studied. The results 
of previous studies regarding the co-duplication of FLT3 ITD and MLL PTD reported no
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significant difference in OS, however, one group reported a lower OS for co-duplicated 
patients and MLL PTD+/FLT3- that was not significant and another showed significant 
difference between the co-duplication and all other combinations in DFS for patients over 60 
years of age. All of these studies were limited by low numbers of MLL PTD and co­
duplicated samples (Olesen et al. 2005b; Steudel et al. 2003)]. The prognostic impact of 
FLT3 TKD remains uncertain, with previous studies reporting significantly improved 
survival, poorer outcome or no impact at all (Bacher et al. 2007b; Mead et al. 2007; Yanada 
et al. 2005). A likely cause of these different conclusions may be due to the selection of the 
cohorts analysed. Recently, the prognostic impact of the FLT3 TKD was shown to be 
dependent upon its combination with other molecular markers (Bacher et al. 2007a). In 
regard to MLL PTD, the study reported a significant negative effect of the co-occurrence of 
the two mutations when compared to the double negative and the MLL PTD-IFLT3 TKD+ 
subset but not when compared to the MLL PTD+/FLT3 TKD- patients. This effect was 
amplified when FLT3 ITD patients were excluded. A recent report indicated that FLT3 ITD 
and TKD should be considered as two independent mutations occurring in the same gene due 
to the biological and prognostic differences (Bacher et al. 2007a). However, the outcome of 
patients harbouring co-occurring FLT3 and MLL PTD mutations in this study appears to be 
similarly poor. Clinical outcome is associated with the combined mutational status (e.g. 
NPM1, FLT3, CEBPA and MLL) of CN-AML patients (Schlenk et al. 2008). Several groups 
have proposed schema for mutational testing of AML and CN-AML to refine prognosis and 
assign risk-adapted post-remission therapies (Mrozek et al. 2007; Renneville et al. 2008).
The low frequency of the MLL PTD in AML patients makes the limited numbers of 
available positives an inherent problem in this and other studies of the duplication. The trial 
samples used in this study were AML 15 samples processed at Cardiff University or by the 
hospital Department of Haematology and considerable difficulties have been encountered
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previously even when trying to obtain sample numbers smaller than those needed by this 
study. Given the low incidence of the mutation, -2000 samples would be needed 
substantially increase the significance of the results. Therefore, the results presented in this 
study regarding the prognostic significance of the duplication should be considered as a proof 
of principle.
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3.5 Conclusion
The data support the hypothesis that the MLL PTD is an indicator of poor prognosis. 
Consideration of additional prognostic variables, including baseline variables and molecular 
markers, provided evidence that the duplication was an independent negative prognostic 
indicator for RR. The duplication gave additional information on relapse free survival beyond 
that obtainable with the baseline variables. Evidence of a higher rate of CR in the MLL PTD 
coupled with a high RR and low RFS would be consistent with a scenario in which the 
majority of leukaemic cells were killed yet a subpopulation of MLL PTD cells survived, 
possibly through quiescence or drug resistance, to repopulate the bone marrow causing 
relapse and in most cases, death.
The introduction of this assay would provide a forewarning of poor clinical outcome 
in around 5% of CN-AML patients who are presently without RT PCR or cytogenetic 
information. Ideally, other molecular markers would be included, not only for the prognostic 
information they would provide in isolation, but also because of possible changes in prognosis 
due to mutations that occur in combination. The most striking possibility would be the 
change from a favourable/intermediate prognosis in the case of a patient with FLT3 TKD to 
an that of adverse prognosis if an MLL PTD was also identified.
Difficulties in identifying large numbers of MLL PTD positives due to their low 
frequency dictates that these results should be considered a working hypothesis. Further work 
should be completed as an integrated molecular study in conjunction with a large scale 
clinical trial, thus eliminating difficulties arising from differences in molecular techniques, 
patient selection and patient treatment which are encountered when comparing results from 
different studies. A large scale clinical trial that included the MLL PTD assay could
3-154
determine whether changes in the treatment strategy would improve the clinical outcome for 
this cohort of patients.
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4 Assessment of MLL PTD RQ-PCR as a 
Marker for Minimal Residual Disease
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4.1 Introduction
Beyond the initial prognostic categories established by cytogenetic analysis at 
diagnosis, there are additional criteria affecting the outcome of the AML patient which 
subdivide the prognoses still farther and one of these is the level of minimal residual disease 
(MRD) detected as treatment progresses. MRD detected by PCR has been shown to be 
clinically relevant using gene fusions RU NXI-RU N XITJ , PML/RARA and CBFB/MYH11 to 
monitor the patient’s response to treatment and to predict early relapse (Grimwade et al. 2009; 
Perea et al. 2006; Scholl et al. 2005). Qualitative PCR can be an effective method for the 
detection of MRD and is still widely used, however the advent of RQ-PCR allows for a much 
more detailed picture of the response than simply a positive or negative result; this is 
especially important since a positive result need not indicate impending relapse (Buonamici et 
al. 2002; Jurlander et al. 1996; Lo et al. 1999c). The ability to measure precise levels of 
expression using RQ-PCR has led to the identification of many new prognostic parameters. A 
number of studies have shown the prognostic significance of decreased expression levels and 
the attainment of log reduction thresholds (e.g. 2 log reduction) in fusion genes (Buonamici et 
al. 2002) (Stentoft et al. 2006) (Leroy et al. 2005). RQ-PCR provides the means to study the 
kinetics of the changes in the levels of disease in patients, which has led to the development 
of prognostic scoring systems (Schnittger et al. 2003). This scoring system found that a 
decrease in the transcript of the fusion genes, R\JNX\/RUNX1T1, PML/RARA and 
CBFB/MYH11, between diagnosis and post consolidation could be used to identify a cohort of 
patients with favourable prognosis (100% EFS) from those with a significantly worse 
outcome. Conversely, consecutive substantial increases in the level of transcript invariably 
predicts for patient relapse. Relapsing patients with core binding factor leukaemia, 
RUNX1 /R UNX1T1 and CBYB/MYH11, were shown to have increasing levels of MRD
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(Krauter et al. 2003; Stentoft et al. 2006), often this increase was seen before the relapse was 
identified by morphology and cytogenetic analysis (Schnittger et al. 2003).
It is important to establish new markers of MRD because the most common gene 
rearrangements used to measure MRD in AML (RUNXI-RUNX1T1, PML/RARA and 
CBFB/MYHJ1) only occur in 21-37% of AML patients (van Dongen et al. 1999). Up to 50% 
of AML patients appear cytogenetically normal, ruling out the use of the “traditional” gene 
rearrangement markers or cytogenetic analysis for MRD. However there are a number of 
genes with mutations or changes in gene expression level which are specifically associated 
with CN AMLs; these have been studied for use as MRD markers and include FLT3 ITD, 
NPMJ and WT-1 (Barragan et al. 2008; Ostergaard et al. 2004; Schnittger et al. 2004). The 
MLL PTD also occurs in a sizeable proportion of CN patients, shown to be 5% in Chapter 3 
and reported to be 5%-10% in other publications, hence it may be a useful MRD marker 
(Caligiuri et al. 1998; Schnittger et al. 2000). Furthermore, while many of the previously 
mentioned fusion gene markers are categorised as favourable prognosis, the MLL PTD has 
been shown to indicate poor prognosis with a higher probability of relapse and a shorter 
period of complete remission (Chapter 3)(Dohner et al. 2002b). Early identification of 
unresponsive and relapsing patients using molecular MRD status would give the clinician 
time to make pro-active changes in the treatment strategy; this approach has been used 
successfully in acute promyelocytic leukaemia (Grimwade et al. 2009).
However, the use of the MLL PTD for MRD detection is not straightforward, due to 
the presence of low background levels o f MLL PTD transcripts detected in healthy donor PB 
and BM as well as progenitor subfractions (Basecke et al. 2006a; Marcucci et al. 1998; 
Schnittger et al. 1998). An effective assay requires the ability to identify the transcripts 
relevant to the leukaemia at as high a level o f sensitivity as possible while avoiding the 
amplification of transcripts in normal haematopoietic cells; alternatively there should be as
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much separation between the two sets of transcript levels as possible. Optimisation of 
conditions to preferentially amplify the relevant transcripts is critical if clinically relevant 
results are to be produced while preventing false positives.
The aim of these studies was to test the hypothesis that the expression level o f MLL 
PTD determined by RQ-PCR can be used as a marker for MRD, and is able to indicate 
remission and predict relapse.
The objectives of this study were:
1) to develop and optimise an MLL PTD RQ-PCR assay
2) to develop an analysis methodology
3) to determine the stability of the MLL PTD mutation
4) to evaluate patient data to determine efficacy of the MLL PTD RQ-PCR as an MRD 
marker.
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4.2 Results
4.2.1 MLL PTD RQ-PCR Optimisation
An ideal clinical RQ-PCR assay for MRD requires efficient amplification of the target 
template and clear differentiation of the positive and negative samples. The RQ-PCR assay 
protocol was optimised to meet these two criteria. The primers used for the quantitative MLL 
PTD RQ-PCR were the same as those used for the qualitative assay described in Chapter 2 
and were used at the same concentration (Chapter 2 Material and Methods Section 2.6.2.a). 
The RQ-PCR assay was performed using the LightCycler Faststart DNA Master SYBER 
Green I kit from Roche. Syber Green fluoresces in the presence of double stranded DNA 
(dsDNA) and the signal is proportional to the amount of dsDNA present. The reagents used 
for the qualitative and quantitative assays are not the same, which necessitated re-optimisation 
of the conditions for the RQ-PCR assay. The three variables optimised were MgC^, template 
concentration and primer annealing temperature. Three patient samples were used in this 
optimisation process; one sample positive for the e9/e3 MLL PTD, one positive for the 
el0/e3+el l/e3 MLL PTD and one AML sample negative for MLL PTD. The AML MLL WT 
sample was used in place of a donor sample because of the scarcity and high demand for the 
donor RNA. The amount of donor RNA used was minimised by delaying the determination 
of the level of MLL PTD expression in donor samples until after the RQ-PCR was fully 
optimised. According to the manufacturer’s recommendations M gCf concentration was 
optimised first, followed by template concentration and then primer annealing temperature. 
The efficiency of the assay was judged by the crossing point value (Cp), steepness of the 
curve, fluorescence intensity and melting temperature (Tm) as shown in the MgCL 
concentrations evaluated in Figure 4.1. On the LightCycler the software calculated the Cp 
using the “second derivative maximum” method. The Cp was defined as the maximum of the
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second derivative of the amplification curve, the point of the maximum rate of increase in 
DNA amplification. The “second derivative maximum” method was chosen for comparisons 
between runs because it allows the Cp to be calculated independent from user input and initial 
fluorescence value. The amount of starting template influences Cp, such that the value of the 
Cp is inversely correlated to the template concentration. The slope of the curve is a measure 
of the efficiency of the amplification, with steeper curves showing higher efficiency. 
Fluorescence intensity is an arbitrary measurement of the Syber Green dye fluorescence 
during the amplification. However, because the reaction of the Syber Green dye is non­
specific the amount of fluorescence detected is a result of all dsDNA produced in the reaction. 
The specificity of the amplification must be determined using the DNA melting temperature 
(Tm) to ensure that values arising from non-specific amplification such as primer dimers are 
not evaluated. The Tm of the DNA product was calculated from the negative derivative of 
fluorescence to determine the temperature at which the amplicon denatures. The temperature 
was gradually increased to a final temperature of 95°C and the Tm was calculated from the 
decrease in fluorescence that occurred when the DNA denatured. Every PCR product will 
have a characteristic Tm, in the same way as it has a characteristic size in base pairs. The Tm 
is determined by the GC content and the length of the PCR product.
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Figure 4.1 Light Cycler Traces of MLL PTD e9/e3 Sample
A. Real time Syber Green fluorescent history plotted against the cycle number of MLL PTD 
e9/e3 amplified with varying concentrations of MgCh. The three parameters used to assess 
RQ-PCR quality are shown (Cp, slope and intensity of fluorescence). B. Fluorescence history 
versus temperature. The fluorescence values were transformed and plotted against 
temperature to calculate the characteristic melting temperature of the PCR products. Cp: 
crossing point; Tm: melting temperature; mM: millimolar.
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4.2.2 Optimisation of MgCh Concentration
The MgCl2 concentration was optimised first because it is a critical factor for primer 
binding and also affects the activity level of Taq polymerase. Higher concentrations of MgCl2 
are known to have an inverse affect on the stringency of primer template binding and as 
Mg2" is a cofactor for Taq polymerase, low concentrations limit the efficiency of the enzyme 
(Figure 4.1) (Kramer & Coen 2001). The range of MgCl2 concentrations tested for 
optimisation was l-5mM. Table 4.1 shows the results of altering MgCl2 concentration on 
RQ-PCR efficiency, with cDNA template volume and primer annealing temperature held 
constant at 1 (a.1 and 55°C respectively. Amplification was not observed in any of the samples 
using ImM, the lowest MgCl2 concentration. The highest MgCl2 concentration, 5mM, 
showed no improvement in any of the measured variables when compared to 4mM MgCl2. 
Low Cp values indicated 3-4 mM MgCl2 were improved amplification efficiency compared 
with 2mM. The specificity of the amplification was confirmed by using agarose gel 
electrophoresis to calculate the size of the products in base pairs (described in chapter 2). The 
size of the RQ-PCR products was identical to that amplified using the qualitative assay, which 
confirmed that the correct products were being produced. The Tm values generated for the 
two positive samples were within one degree Celsius of each other. Each positive sample had 
one major Tm indicating a specific amplification with the larger el0/e3+ell/e3 mutation 
having a slightly higher final temperature. Multiple Tm peaks were calculated for the 
negative sample indicating that non-specific binding produced more than one product. The 
intermediate concentrations showed the most efficient amplification.
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UPN MLL PTD 
Status
MgCI2
(mM)
Cp Fluor. Intensity 
(Arbitrary Units)
Slope Tm
(°C)
1 n/a n/a n/a n/a
2 >41 n/a ++ 85.6
49 e9/e3 3 25.9 12.0 +++ 85.0
4 25.3 9.0 ++ 85.3
5 25.1 8.0 ++ 85.3
1 n/a n/a n/a n/a
2 29.8 15.0 +++ 85.7
77 el0/e3+el l/e3 3 31.0 14.0 ++ 85.7
4 27.5 9.0 ++ 86.0
5 27.6 9.0 ++ 86.0
1 n/a n/a n/a n/a
2 35.7 14.0 +++ 81-89
250 Negative 3 35.4 12.0 +++ 81-89
4 33.4 10.0 ++ 81-89
5 33.8 8.0 ++ 81-89
Water 3 n/a n/a n/a n/a
Table 4.1 Optimisation of RQ-PCR Using a Range of MgCh Concentrations.
The MLL PTDs e9/e3 and elO+el 1/3, and an AML patient negative for the MLL PTD were 
amplified with cDNA template and annealing temperature held constant at lpl and 55°C 
respectively. UPN: unique patient number; Cp: crossing point; Tm: melting temperature; 
Fluor. Intensity: fluorescence intensity. Cp, Tm, fluorescence intensity and slope are 
measures of amplification efficiency while Tm indicates specificity.
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As the highest levels of amplification were apparent at the intermediate 
concentrations, these assays were repeated to demonstrate reproducibility and to determine 
one optimum concentration for each mutation (Table 4.2). The high amplification was 
represented by the low Cp values determined in all (Table 4.2A). Consistent Tm values for 
the MLL PTD positive samples were produced using 3 and 4mM MgCC but the Tm value 
produced in 2mM M gCf was 1.5°C lower indicating poor amplification specificity at this 
lower concentration. Tm values generated for the positive samples were similar, with the 
larger el0/e3+el l/e3 mutation having a final temperature approximately 1°C higher than the 
e9/e3 mutation. The MLL PTD negative sample showed a similar pattern to the positive 
samples, with decreasing Cp values as MgCh concentrations increased. However, the number 
of different PCR products increased as MgCh concentration increased as indicated by 
multiple Tm values. The trend of decreasing Cp as MgCh concentration increased was 
reproducible between Table 4.1 and Table 4.2 and can be seen in all samples despite the 
variation in individual Cps. The results of all three of the parameters of efficiency (Cp, 
fluorescent intensity and the steepness of the curve) showed 3mM to be the optimum 
concentration for the e9/e3 MLL PTD and 4mM the most efficient for el0/e3+el l/e3 MLL 
PTD. The MgCb concentration of 3.5mM was chosen because it provided the lowest Cp and 
consistent Tm for both positive MLL PTD samples (Table 4.2A) and generated the largest 
difference in Cp values between the positive and the negative samples (Table 4.2B).
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UPN MLL PTD MgCl2 Cp Fluor. Intensity Slope Tm
Status (mM) (Arbitrary Units) (°C)
A.
2 35.7 14.0 ++ 83
49 e9/e3 3 27.9 19.0 +++ 84.9
4 25.8 15.0 ++ 85.5
2 42.6 17.0 ++ 84.5
77 el0/e3+el l/e3 3 32.5 17.0 +++ 86
4 28.2 16.0 +++ 86.5
„
2 >51 n/a +++ 78-90
250 Negative 3 36.3 13.0 +++ 78-90
4 34.8 10.0 ++ 78-90
Water 3 n/a n/a n/a n/a
B.
49 e9/e3 3.5 24.2 15.0 +++ 85.4
77 el0/e3+el l/e3 3.5 26.8 14.5 +++ 86.5
250 Negative 3.5 33.7 13.0 +++ 78-90
Table 4.2 Reproduciblity of MgCl2 Optimisation
The MLL PTDs e9/e3 and el0/e3+el l/e3, and an AML patient negative for the MLL PTD 
were amplified with cDNA template and annealing temperature held constant at lpl and 55°C 
respectively. Cp, Tm, fluorescence intensity and slope are measures of amplification 
efficiency while Tm indicates specificity. A. Repeat of intermediate MgCl2 concentrations to 
show reproducibility of Table 4.1. B. Optimised assay using 3.5mM MgCl2. Cp: crossing 
point; Tm: melting temperature; Fluor. :fluorescence intensity.
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4.2.3 Optimisation of Template Concentration
The optimisation of template concentration was important for establishing a successful 
RQ-PCR because high levels of the template cDNA, can inhibit amplification and low levels 
can reveal evidence of inhibitors in the sample (when a decrease in the amount of template 
shows an unexpected increase in amplification it can be an indication of a PCR inhibitor being 
diluted out). An additional reason for testing the template concentration for MLL PTDs is the 
fact that the transcripts were found in normal samples if the sensitivity was too high (Chapter 
3). The volumes of template used were 0.01 pi, lp l and 2pls. The lowest volume of 0.01 pi 
was used to test for evidence of inhibitors and to establish if it would create a greater 
difference between MLL PTD and MLL PTD WT Cp values. All three conditions worked in 
the assay, amplifying MLL PTD product; these results are summarised in Table 4.3. The 
greatest discrimination between the positive and negative Cps, calculated by subtracting the 
Cp of the negative sample from the Cp of the positive, was seen using 1 pi template, with a 
resulting difference in Cps of 9.4 for e9/e3 MLL PTD and 6.9 for el0/e3+el l/e3 MLL PTD. 
The 0.01 pi sample showed comparable discrimination between the positive and negative 
samples, and had a greater difference than with the 2pl sample for the e9/e3 and the 
el0/e3+ell/e3 MLL PTDs. However, the lp l sample is more useful because its higher 
starting concentration of cDNA, as measured by a lower Cp, would enable detection of lower 
amounts of transcript before the lowest detection level (sensitivity) of the assay was reached. 
Therefore the optimal template volume was set at 1 pi.
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UPN MLL PTD cDNA Temp. Cp Fluor. Intensity Slope Tm
Status (pi) (Arbitrary Units) (°C)
2 23.6 15 +++ 85.4
1 24.2 15 +++ 85.4
49 e9/e3 1 (1:10) 29 15 +++ 85.4
2 26.1 15.5 +++ 86.5
1 26.8 14.5 +++ 86.5
77 e10/e3+e11/e3 1 (1:10) 30.9 13.5 +++ 86.5
2 30.7 10.5 +++ 78-90
1 33.7 13 +++ 78-90
250 Negative 1 (1:10) 37.7 14 +++ 78-90
Water 1 46.9 9 ++ 82
Table 4.3 cDNA Template Volume Optimisation
The MLL PTDs e9/e3 and el0/e3+el l/e3, and an AML patient negative for the MLL PTD 
were amplified with MgCh concentration and annealing temperature held constant at 3.5mM 
and 55°C respectively. Cp, Tm, fluorescence intensity and slope are measures of 
amplification efficiency while Tm indicates specificity. Cp: crossing point; Tm: melting 
temperature; Fluor: fluorescence intensity.
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4.2.4 Optimisation of Primer Annealing Temperature
Whereas the MgCl2 and the template concentration were the first to be optimised 
because they affect multiple aspects of the PCR, the primer annealing temperature, which 
only affects the stringency of primer binding, was optimised last and used strictly to maximise 
the difference in Cp value between the positive and the negative MLL PTD samples. A 
second AML patient sample negative for the MLL PTD was used in this optimisation, to take 
into account for possible variations in the Cp values of negative samples. Raising the 
annealing temperatures from a starting temperature of 55°C to 69°C gradually increased the 
difference between the Cp values for the positive and negative MLL PTD samples. Table 4.4 
shows how increasing the annealing temperatures from 65 °C to 69°C increased the difference 
in Cp between the positive and negative MLL PTD samples, while the other measures of 
efficiency remained largely unchanged. At 69°C, the average difference in Cp was >9 for 
both the e9/e3 and the el0/e3+ell/e3 mutations (Table 4.5). However, the previously 
moderate rate of increase in the Cp value observed as the temperature was raised, increased to 
a >1°C change in Cp as the temperature rose from 67°C to 69°C for the el0/e3+el l/e3 MLL 
PTD. This large increase indicated the beginnings of loss of efficiency for the RQ-PCR. 
Therefore, the temperature of 69°C was selected as the optimum primer annealing 
temperature because the separation between the positive and negative samples was nearly 
equivalent to a 3-log difference and the Cp of the positives was starting to increase indicating 
that a further increase in temperature would be detrimental.
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UPN MLL PTD Annealing Temp. Cp Fluor. Intensity Slope Tm 
Status (°C) (Arbitrary Units) (°C)
49 e9/e3
65
23.1 19.5 +++ 85.7
77 e10/e3+e11/e3 25 19.5 +++ 86.9
250 Negative 32.3 17.5 +++ 85.7+86.9+90.5
125 Negative 33.4 17.0 ++ 84.9+87.75+90.5
Water n/a n/a n/a n/a
49 e9/e3
67
23.3 17.0 +++ 85.7
77 e10/e3+e11/e3 25.6 17.5 +++ 86.9
250 Negative 34.3 16.0 +++ 87.7+88.9+91.0
125 Negative 33.3 14.5 +++ 86.4+89.5
Water n/a n/a n/a n/a
49 e9/e3
69
24 17.0 +++ 85.8
77 e10/e3+e11/e3 26.7 19.5 +++ 87.0
250 Negative 36.9 14.5 +++ 86+89.5
125 Negative 34.8 15.0 +++ 86.3+90.5
Water n/a n/a n/a n/a
Table 4.4 Optimisation of Primer Annealling Temperatures
The MLL PTDs e9/e3 and el0/e3+el l/e3, and two AML patients negative for the MLL PTD 
were amplified with MgC^ concentration held constant at 3.5mM. Cp, Tm, fluorescence 
intensity and slope are measures of amplification efficiency while Tm indicates specificity. 
Cp: crossing point; Tm: melting temperature; Fluor.: fluorescence intensity.
Annealing Temperature
I 65°C 67°C 69°C 65°C 67°C 69°C
UPN - 250 250 250 125 125 125
MLLPTD Status Negative Negative
49 e9/e3 9.7 11 12.9 10.7 10 10.8
77 el0/e3+ell/e3 7.8 8.7 10.2 8.9 7.7 8.1
Table 4.5 Cp Difference Between MLL PTD Positive and Negative Samples
Discrimination of RQ-PCR assay between positive and negative samples determined by Cp 
value at 3 primer annealing temperatures. The Cp difference=Cp(MLZ Negative)-Cp(ML£, 
PTD). Cp: crossing point.
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4.2.5 Final Optimisation of the Assay
The results of the final optimisation conditions can be seen in Figure 4.2. The 
superior reproducibility of the MLL PTD Cp and Tm compared to MLL WT is shown by the 
proximity of the duplicate traces. Evidence of the separation between the starting levels of 
template is shown by the positive samples having lower Cp values (shifted to the left) than the 
MLL WT samples. The ability to discriminate positive samples at this level, without 
encountering competing non-specific amplification from WT cDNA would enable testing for 
MRD to be clinically useful. The level of 3-log reduction from diagnosis was the original 
gold standard for CML patients being treated with Imatinib, after which there is a 95% chance 
of disease free progression for the following year (Hughes et al. 2003). Detection of MRD to 
that level would make this assay more sensitive than morphology, cytogenetics and many 
flow cytometry leukaemia associated immunophenotypes (LAIPs).
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Figure 4.2 RQ-PCR Assays Using Optimised Conditions
A. Real time Syber Green fluorescent history plotted against the cycle number of the MLL 
PTDs e9/e3 and el0/e3+el l/e3, and two AML patients negative for the MLL PTD. B. and C. 
Fluorescent history versus temperature. The negative derivative of fluorescence over time 
was plotted against temperature to calculate the melting temperature of the PCR products. B. 
MLL PTD positives. C. MLL PTD negatives.
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4.2.6 Test for Non-specific Amplification of DNA
Both primer sets were tested for the ability to amplify DNA, to ensure that DNA 
amplification would not result in a false positive for RNA expression. Despite the use of 
RNA as starting template described in the protocol in Chapter 2, small levels of DNA 
contamination can sometimes occur in the sample. To test this hypothesis, a known 
concentration of DNA was assayed using MLL PTD or S14 primers. The amplification 
product for MLL PTD had a Cp >41 cycles and a higher Tm than that produced by the MLL 
PTD positive samples, therefore it would not be misread as a false positive. The control gene 
S14 did amplify DNA at a range comparable to that of RNA samples but produced a lower 
Tm that would prevent it from being used in normalisation calculations.
4.2.7 Normalisation of MLL PTD Expression
The S14 housekeeping gene was used to normalise the MLL PTD RQ-PCR assay, 
correcting for run variations as well as sample to sample variations in quality and quantity by 
subtracting the Cp of the S14 RQ-PCR from the Cp of the MLL PTD RQ-PCR in each assay. 
S14 encodes for the 40S ribosomal subunit protein and is used routinely as a control gene in 
RQ-PCR assays in the Haematology department (Guinn et a l 2005; Walsby et al. 2008). As 
the quantification was dependent upon the difference between the target gene and the 
normalisation gene, it was important that the comparison of these two genes was as accurate 
as possible. The slope of the two PCRs was used as a measure of efficiency to allow 
comparison of the assays, because it is possible for a difference in efficiency to affect the 
calculation of expression level. PCR efficiency was calculated using the following the 
formula from Roche Diagnostic technical notes (overpage):
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E = 10(-l/slope) [4 ^
Where E is the efficiency and the slope is calculated from a relative standard curve of 
the log concentration of the standard dilutions vs. cycle number.
In an ideal PCR reaction, a 10-fold dilution series would have a slope o f -3.3 and an 
efficiency of 2, meaning that the amount of PCR product would double after the completion 
of every PCR cycle. This means that every 10-fold increase in starting template concentration 
would decrease the Cp by a value of 3.3. For the purpose of quantification the slope o f a PCR 
that fell within the range of -3.0 and -3 .9  and had a coefficient of determination (i.e. a 
measure of the association between the dilution points and the calculated trend line) o f >0.95 
should be acceptable (Van, V et a l 2003b). The slope of the MLL PTD RQ-PCRs was 
calculated by plotting the Cp value against the log of a relative standard curve of the two 
MLL PTD samples used in the optimisation assays. cDNA from both positives was serially 
diluted 1:10 from 100% to 0.1%. Tm values indicated successful amplification down to 1%, 
and the corresponding Cp values were plotted on a scatter graph to calculate the slope (Figure
4.3). The e9/e3 mutation had a slope of -3.4+0.4 (n=3) and a coefficient of determination of 
0.99. The slope of the el0 /e3+ell/e3  MLL PTD was slightly lower, -3.8+0.5 (n=3), and a 
coefficient of determination of 0.99. S14 was retrospectively analysed and showed a
reproducible but lower slope for both samples with a slope of -4.7+0.1 (n=4) and a coefficient 
of determination of 0.99. Due to the difference between the slopes of the target gene and the 
control gene, the slope of the target gene was used because, by its nature as the unknown 
variable, its expression level will display a wider range of Cp values (Beillard et al. 2003). 
Therefore, despite the different assay efficiencies, the narrow range of Cp values displayed for 
S14 as a control gene should have minimal impact on the calculation.
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Figure 4.3 RQ-PCR Slopes for Serial Dilutions of MLL PTD Compared to S14
The slope of the expression levels of a serial dilution series from 100-1% for RQ-PCR MLL 
PTD transcripts was compared to the slope of a dilution series 100-1% for the control gene 
SI4. The log value of the dilution was plotted against the Cp value. A. Slope of e9/e3 (blue) 
dilutions compared to S14 dilutions (pink). B. Slope of el0/e3+el l/e3 dilutions (blue) 
compared to S14 dilutions (pink). Cp: crossing point; R2: Coefficient of determination.
4.2.8 Analysis Methodology
Steps were taken to verify the specificity of the RQ-PCR amplifications. A protocol 
for the analysis of MLL PTD RQ-PCR assays was developed to prevent reporting false 
positive due to non-specific amplification of S14 or MLL PTD (Figure 4.4). Due to the non­
specific nature of Syber Green fluorescence, any amplified product, including primer dimer 
formation or non-specific amplification (caused by low template), created fluorescence and 
generated a Cp value. The reproducibility of Tm values between the duplicates was assessed, 
to verify that a specific product was amplified. Reproducibility of the Tm values was checked 
visually using the LightCycler histogram that plotted the first negative derivative of the 
fluorescence vs.temperature. Reproducibility of Cp between duplicates was defined on a
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sliding scale with the strictest definition being applied to the lower Cp values; to be accepted, 
the difference had to be <0.75 Cp for Cp values under 30 and <1.50 Cp for Cp values between 
31 and 40. The stringency for reproducibility was relaxed as the Cp increased because greater 
variability in Cp was observed as the concentration of the starting template decreased and the 
assay reached its limit of detection (Hughes et al. 2006; Van, V et al. 2003a). The highest 
priority was whether S14 had amplified specifically and did the level of amplification 
represent a sufficient level of starting template for MRD calculations? Samples that did not 
have a Tm of 89°C and a Cp lower than 41 were classified as “no result”. An S14 reaction 
with a melting temperature other than 89°C represented non-specific amplification and was 
not used for further analysis. If the S14 amplification was satisfactory the same analysis was 
repeated with the MLL PTD product data. The MLL PTD amplification required a 
reproducible Tm equal to 85 or 86°C and a Cp value less than 41 in both duplicates to 
continue analysis; samples that failed these criteria were classified as negative for the MLL 
PTD and assigned a ACp of 0.
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Figure 4.4 Analysis Methodology
Steps taken to verify the specificity of RQ-PCR amplifications. The Tm and Cp values were 
used to validate the amplification before calculating and plotting the ACp. Tm: melting 
temperature; Cp: crossing point and ACp: change in Cp.
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The following formula was used to calculate the ACp in samples with proven 
amplification of both the control gene and the target gene:
ACp=CpMLL PTD-Cpsi4 [4.2]
Where Cp=crossing point, C p MLL p t d =  crossing point of the MLL PTD RQ-PCR and 
Cpsi4=crossing point of the S 14 RQ-PCR.
The ACp is the crossing point of the target gene, MLL PTD, normalised by subtracting 
the crossing point of the control gene, S I4. This normalisation corrects for different 
efficiencies of cDNA synthesis and different amounts of starting template. The ACp produces 
a normalised calculation of expression level that can be used to compare different samples.
4.2.9 Development of ACpK value
S14 produced more PCR product and therefore had a lower Cp value than MLL PTD 
due to its higher level of constitutive expression. This resulted in the MLL PTD expression 
level being inversely correlated to the difference in the crossing point values i.e. lower ACp 
values represent higher expression levels of MLL PTD. To make the expression levels 
correlate directly to the ACp points on the graph, the ACp was subtracted from a constant, K, 
so that the highest points on the graph would represent the highest levels of MLL PTD 
expression. The highest ACp calculated was 14.3, so the constant was assigned the value of 
15 to make all ACp values greater than 0. The new variable was designated ACpK and was 
determined using the following formula (overpage):
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ACpK=K-(CpMLLPTD-Cpsi4) [4.3]
Where Cp=crossing point, C p m l l  ftd=  crossing point of the MLL PTD RQ-PCR, 
Cpsi4=crossing point of the S14 RQ-PCR and the constant K=15.
All results were analysed using this methodology. The change of expression level for 
minimal residual disease was plotted on a log scale. The ACpK value equivalent to 1 log was 
calculated. The average slope for the two mutations was -3.6; therefore every 10-fold 
increase in starting template concentration would decrease the Cp by a value of 3.6. To 
facilitate this understanding the y-axis of all graphs plotting ACpK were marked in increments 
of 3.6, with each increment representing a 1 log difference in the expression level o f MLL 
PTD.
The fluorescent history o f Syber Green as a function of the cycle number for the MLL 
PTD samples shown in Figure 4.2 were analysed using the methodology flow chart (Figure
4.4), and the calculated ACpK values were plotted for each sample (Figure 4.5). The results 
for the positive MLL PTD samples had acceptable Cp and Tm values for both genes so the 
ACpK was calculated and plotted. The large ACpK values (UPN 77,49) are indicative o f high 
levels of MLL PTD expression. The negative sample, UPN 250 passed all S14 criteria and 
was categorised as ACpK=0 due to the lack of reproducibility in Tm values produced from the 
MLL PTD RQ-PCR. However, negative sample UPN 125 passed the criteria for both assays 
with a calculated ACpK of 4.8; this value is 7.2 units below UPN 77 and 9.6 units below UPN 
49, making it at least of 2 logs lower than the positive samples. This indicated that there is 
clear separation between the expression levels seen in MLL PTD positive samples and the 
levels seen in MLL WT AML samples.
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Figure 4.5 CpK Values of Optimised RQ-PCR
ACpK normalised expression values of MLL PTD of the samples shown in Figure 4.2. UPN 
49 and 77 are MLL PTD positive, UPN 250 and 125 are MLL WT AML samples.
4.2.10 Inter Run Reproducibility of the Assay
The reproducibility of a RQ-PCR assay designed for the detection of MRD is essential 
if it is to be used as the determining factor for changing patient therapy. The inter and intra 
run reproducibility was assessed for both MLL PTD and AML MLL WT samples and was 
found to be consistent. Three separate positive samples were tested to determine the inter-run 
reproducibility of the assay. The samples were run on different days and used separately 
prepared reagent mixes to provide the best measure of independence. The results can be seen 
in Table 4.6. UPN 77 and 17 were run twice and showed a 1.3% and a 4.7% difference from 
the mean ACpK respectively. Patient sample 49 was run four separate times with a mean 
ACpK of 9.8+0.6 (n=4). Repeat runs using the AML MLL WT optimisation samples showed 
inconsistency, this was expected of samples that have template concentrations near the limits 
of detection of the assay. The samples produced positive and negative results on subsequent 
runs; all of the positive results had a low ACpK- The donor samples were not tested because 
no positives were observed.
Run UPN No. MLL PTD 
__ c P S14 Cp
Delta Cp 
(MLLPTD-S14)
Delta
CpK Mean SD
1 49 27.11 21.00 6.11 8.89
9.75 0.64
Duplicate 27.17 21.28 5.89 9.11
2 49 28.04 22.41 5.63 9.37Duplicate 27.79 22.71 5.08 9.92
3 49 27.10 22.76 4.34 10.66Duplicate 26.99 22.77 4.22 10.78
4 49 26.60 21.23 5.37 9.63Duplicate 26.81 21.43 5.38 9.62
1 17 23.85 20.13 3.72 11.28
11.56 0.27Duplicate 23.82 20.12 3.70 11.30
2 17 24.17 20.94 3.23 11.77Duplicate 24.23 21.12 3.11 11.89
1 77 27.48 21.01 6.09 8.91
8.86 0.22Duplicate 27.00 21.11 5.89 9.11
2 77 27.13 21.04 6.09 8.91Duplicate 27.52 21.03 6.49 8.51
Table 4.6 Inter-run Reproducibility of MLL PTD RQ-PCR
Inter run reproducibility shown in three ML PTD positive samples. All samples were run in 
duplicate. UPN: unique patient number; No.: number; Cp: crossing point; SD: standard 
deviation.
4.2.11 Intra Run Reproducibility of the Assay
Assessment of the intra-run reproducibility showed a very high correlation between 
the duplicates for both assays. To measure the level of intra run variation for the MLL PTD 
RQ-PCR, the mean Cp of the duplicates was plotted against the minimum and maximum 
values (Figure 4.6). For the MLL PTD data, all samples that passed the methodology criteria 
for S14 and had reproducible Tm for MLL PTD were plotted, resulting in 40 samples. The 
Cp values ranged from 23.2-37.7 due to the differences in the expression level of MLL PTD, 
yet the mean difference between the minimum and maximum value remained low at 0.3±0.3 
(n=40). A gradual loss of reproducibility occurred in parallel with the increase of mean Cp 
values as the assay approached the maximum level of sensitivity. Still larger variations were 
observed at higher Cp values, but these samples were not plotted because they failed to pass 
the Tm reproducibility checkpoint (non-specific amplification) flowchart.
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Figure 4.6 MLL PTD Intra Run Reproducibility
The minimum and maximum Cp values of the duplicates of all MLL PTD samples that met 
analysis criteria, n=40. Cp: crossing point; Max: maximum; Min: minimum.
A gradual increase in the difference of the duplicates in the S14 assay was observed as 
Cp value increased and was used in combination with the analysis methodology to establish a 
low template (high Cp) cut-off value for poor quality samples. In Figure 4.7A, the mean Cp 
value was plotted against the minimum and maximum duplicate values of all S14 samples if 
they met the reproducible Tm criteria for the S14 methodology, resulting in 73 samples. A 
slight difference in slope (Cpmax=L03, Cpmin=0.97) is observed with a greater separation 
between duplicates after the Cp of 25. When the criterion of reproducible Cp was applied to 
this set of samples, 3 of 11 (27.3%) samples with Cp>25, failed compared to 1 of 62 (1.6%) 
samples with Cp<25, indicating a higher percentage of poor quality samples in the Cp>25 
group. Many of the samples that failed to meet the reproducible Tm criteria for S14 also 
exhibited high variation in the Cp duplicates as the result of non-specific amplification. After 
the reproducible Cp criteria was applied the remaining samples were plotted as shown in
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Figure 4.7B and the linear trend lines graphed for the minimum and maximum Cp values are 
more parallel (Cpmax=1.01, Cpmin=0.99).
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Figure 4.7 S14 Intra Run Reproducibility
The minimum (blue) and maximum (red) Cp values of the duplicates of S14 samples. A. All 
samples with a reproducible melting temperature (Tm), n=73. B. Samples with reproducible 
Tm and Cp values, n=67. C. Samples with Cp<27 and reproducible Tm and Cp. Cp: crossing 
point; Max: maximum; Min: minimum.
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4.2.12 Setting of S14 Maximum Threshold for Cp Value
To prevent the interpretation of low template concentration and poor quality samples 
as false negatives, a maximum acceptable Cp value (low template) was derived from the mean 
Cp of all samples that met the S14 criteria (Figure 4.4). There is the potential for falsely 
declaring low template (high Cp value) MRD samples as negative, when the high Cp may be 
the result of low sensitivity due to the low amount of starting material or inefficient reverse 
transcription. To avoid such errors, all samples with a high Cp value that placed them farther 
than 1 log from the calculated mean of all S14 samples shown in Figure 4.7B were excluded. 
The mean Cp value was 22.4 and the Cp value equal to a 1 log change in starting template 
was 4.7 which gave a maximum value of 27.1 (22.4+4.7). All samples with a Cp>27 were 
excluded from further MRD analysis. Follow up samples, in particular, would be prone to 
false negative results as the amount of starting material is often low due to the low WBC 
observed in patients recovering from chemotherapy. Figure 4.7C shows the final range of Cp 
value and variation after all criteria were applied to the data.
4.2.13 Establishing a Reproducible and Maximal Sensitivity Level
Two levels of sensitivity were established; firstly a lower, yet highly reproducible 
sensitivity at which the quantification of the expression level can be reliably calculated and, 
secondly, a maximal sensitivity at which the sample is clearly positive but quantification is 
not possible due to the lack of reproducibility (Van, V et al. 2003b). The idea of two levels of 
sensitivity was first suggested by van Velden et al. (2003) and is also used in the proposed 
BCR-ABL guidelines for reporting disease levels for CML patients. In the BCR ABL 
guidelines, the level of “confidence” in the result is reduced as the copy number of the control 
gene decreases, until eventually the lowest level positive is reported as a positive of
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undetermined quantity. The reproducible sensitivity was calculated as 10'2 using the cDNA 
dilution experiment (Section 4.2.15). The lack of reproducibility observed in low-level MLL 
PTD positives was reflected by variation in the duplicate values of the Cp and, more 
frequently, in the visualisation of the Tm, where samples failed because they had more than 
one Tm peak. These double peak positive (DPP) MLL PTD samples were identified by the 
appearance of two Tm peaks instead of one; with one major reproducible peak at a recognised 
MLL PTD Tm and a minor peak at a slightly higher Tm. The major peak was defined as the 
taller of the two peaks present. A sample designated ACpK=0 because of a high or varied Cp 
value was re-classified if it met the definition of a DPP. DPPs were easily distinguished from 
the donor samples, which showed either no amplification, no reproducibility in Tm or had 
more than two peaks with one below the expected Tm of MLL PTD. The use of maximal 
sensitivity to detect DPPs potentially increased the detection of a MLL PTD positive sample 
by an order of 10, to 10'3 .
The use of the amended analysis methodology, including the maximum Cp value for 
SI4, resulted in fewer samples being analysed overall and a higher number of positives. All 
of the incorporated amendments to the protocol can be seen in Figure 4.8. The higher 
stringency for SI4, to prevent analysis of poor quality samples, excluded 5 samples from 
analysis. All 5 samples were ACpK=0. Six samples previously classified as ACpK=0 were re­
classified as low positives (DPPs) using the guidelines for maximal sensitivity. Three of the 
samples were from MLL WT AML patients and 3 were from MLL PTD positive patients. No 
donor samples changed from ACpK=0 to DPP. As expected, the amended guidelines excluded 
poor samples, which may have led to false negative reporting, left samples with high ACpK 
values unchanged and reclassified some low positive samples previously excluded due to low 
reproducibility to DPP.
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Figure 4.8 Amended Analysis Methodology
Analysis protocol with S14 Cp threshold and maximal sensitivity amendments incorporated. 
The Tm and Cp values were used to validate the amplification before calculating and plotting 
the ACp. Tm: melting temperature; Cp: crossing point and ACp: the change in Cp; DPP: 
double peak positive.
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4.2.14 MLL PTD Expression levels
In order to prevent false positive results a clear separation of Cp values was required 
between the expression level of the mutant transcript being assayed and any non-specific or 
low-level amplification of the transcript in normal donors. This is critical in MRD studies 
where the gene has a known level of expression in normal patients, as in WT-1, or where the 
mutation has been easily detected in normal samples, as in the case of the MLL PTD (Garg et 
al. 2003a; Marcucci et al. 1998; Schnittger et al. 1998). The minimum acceptable difference 
between the positive and normal ACps would be 1, but ideally the difference would be >3 to 
prevent a negative sample being misinterpreted as positive (Van, V et al. 2003b). As shown 
in Figure 4.9, the MLL PTD expression levels were assessed in donor samples and diagnostic 
samples from AML MLL WT and MLL PTD patients to determine the difference in ACpK. 
Using the criteria outlined above (Section 4.2.13), all of the donor samples had sufficient S14 
Cp values but failed to meet the MLL PTD criteria and were plotted as ACpK=0. The fact that 
all 6 donor samples were negative indicated that the optimisation of the RQ-PCR was 
successful and gave confidence to interpret all positive results as clinically relevant levels of 
MLL PTD transcript. Three of the 10 MLL WT samples were positive, but only one could be 
quantified, the other two were positives but had more than one Tm and variable Cp values and 
so were classified as DPPs. The sample that was quantified had a low ACpK of 3.0 and the 
remainder had a ACpK=0. There was a significant difference between the ACpic values of the 
clinically relevant MLL PTD positives and the MLL WTs (p<0.001). The 9 AML diagnostic 
samples with MLL PTD all tested positive with a median ACpK of 9.8 (range, 8.0-12.4). 
Using a ACpK of 3.6 as an equivalent to 1 log, the range of the positives was 1.2 logs and with 
a median value of 9.8 the assay should provide nearly 3 log of sensitivity for MRD follow up 
samples.
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Figure 4.9 MLL PTD Expression Levels in Different Populations
Scatter graph of MLL PTD expression levels using delta Cpk values. MLL WT AML 
patients, MLL PTD positive patients and healthy donors. Cp: crossing point; A Cp: change in 
Cp.
4.2.15 Sensitivity of the RQ-PCR Assay
The sensitivity of an MRD RQ-PCR is important for determining the clinical 
relevance of the assay. The type of RQ-PCR assay has a bearing on the achievable 
sensitivity; a level of 1:10,000 to 1:1,000,000  is a desirable level to aim for in most cases 
(Grimwade & Hills 2009). However, in the case of the MLL PTD assay a much lower level 
of sensitivity would be clinically relevant for two reasons: 1) the majority of MLL PTD AML 
cases are cytogenetically normal and so have no straightforward MRD marker other than 
morphology, and 2) an assay that is made too sensitive will begin to amplify MLL PTD 
transcripts that are not clinically relevant. The sensitivity of the MLL PTD RQ-PCR assay in 
follow up samples was estimated by diluting a positive diagnostic sample representative of
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each of the MLL PTD mutations into a pool of AML WT cDNA (Figure 4.10). The pooled 
dilution mixture of cDNA was composed of the samples used to calculate the expression level 
of MLL PTD in MLL WTs, where one sample displayed a low level of MLL PTD expression, 
ACpK=3.0, and two samples were DPP. There were no detectable MLL PTD transcripts in the 
pooled mixture run without added MLL PTD positive cDNA or the 0.01% dilutions of the 
e9/e3 or the el0/e3+el l/e3 mutation. This observation supported the idea that any MLL PTD 
expression detected was the result of the amplification of input positive cDNA. Because there 
was no amplification of the donor samples (Figure 4.9), there was no point at which the 
dilution series would trespass into the range of “normal” expression levels and have to be 
disallowed. The e9/e3 mutation dilution series produced a reproducible sensitivity of 1% and 
a maximal sensitivity of 0.1%. The maximal sensitivity was calculated using the DPP 
criteria. Despite the lower initial ACpK value of the 100% sample, the el0/e3+ell/e3 mutant 
obtained the same sensitivity levels as the e9/e3 mutation. Taking into consideration that 
these were patient samples that did not have the MLL PTD in every cell, both samples had a 
blast count of around 60%, the maximum sensitivity would be expected to be greater.
4-190
10.80
a,
U
<u
Q
7.20 --
3.60 -
0.00
e9/e3 el0 /e3+ ell/e3
100% 50% 10% 5% 1% 0.10% 0.01% 100%WT 100% 50% 10% 5% 1% 0.10% 0.01% NC
9.63 921 7.63 6.87 4.56 0.00 0.00 0.00 8.71 7.92 5.42 4.74 2.29 0.00 0.00 0.00
Dilutions
Figure 4.10 Sensitivity of MLL PTD RQ-PCR
Series of 9/3 and 10/3+11/3 positive patient samples diluted into MLL WT AML cDNA. 
Negative control used water as template. indicates a sample that was positive by maximal 
sensitivity (DPP). Cp: crossing point; WT: MLL wild type; NC: negative control.
4.2.16 Calculation of MRD Using AACp
The data from the sensitivity test was used as a mock MRD case to determine if The 
AACp formula developed by the Europe Against Cancer network for the calculation of MRD 
could be applied to the MLL PTD RQ-PCR assay (Gabert et al. 2003). The AACp method 
was developed to allow the level of fusion genes transcripts detected in a patient during the 
course of cytoreductive treatment to be presented graphically in an intuitive format. Using 
this method, the follow up Cp of the target gene, MLL PTD, was first normalised by 
subtracting the Cp of the control gene, SI 4, from the fusion gene to give the ACpFup.
A C pFU P= CpMLLPTD-CpS14 [4 -4 ]
Where A C p f u p  was the normalised value of the follow up sample, C pm ll ptd  was the Cp value 
of the follow up MLL PTD RQ-PCR and the Cpsi4 was the follow up S14 Cp value of the 
follow up sample.
4-191
The normalised value for the diagnostic sample, ACpox, was calculated in the same 
way; the Cp of the MLL PTD assay was subtracted from the Cp of the S14 RQ-PCR.
ACpox= CpMLLPTD-Cpsi4 [4.5]
Where ACpox was the normalised value of the diagnostic sample. Cpmllptd and Cpsi4 were 
the respective Cp values of the MLL PTD and S14 RQ-PCR of the patient at diagnosis.
To determine the amount of change between the follow up and diagnostic sample the 
ACpFup was normalised by subtracting the value of the ACpDx resulting in the AACp. The 
MRD value was then calculated using the formula:
MRDv=10((ACpFUP'ACpDX)/(-S)) [4.6]
Where MRDv is the minimal residual disease value, ACpfup and ACpox are the normalised 
values for the follow up and diagnostic samples respectively, and S is the slope of the RQ- 
PCR assays.
As outlined above (Section 4.2.7), when there is a difference between the slopes of the 
fusion gene and the control gene, the slope of the fusion gene should be used because the Cp 
values of the control gene occur in a narrower range and therefore would have only a minimal 
impact on the result. The smaller range of S14 Cp values were due to the equal amount of 
RNA as template for the cDNA reaction and the exclusion of high Cp values representative of 
poor quality samples. The two mutation types created by the MLL PTD have slight 
differences in their relative slopes, so to increase the accuracy at low levels of MRD the 
individual slope values of each mutation were used in the calculation. The results plotted in 
Figure 4.11 show concordance between the dilutions made and the level of MRD calculated 
using the AACp method despite the difference in slopes between the MLL PTD and S14
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assays and between the MLL PTD assays themselves. The lowest reproducible sensitivity for 
both mutations was between 2% and 3%, and the maximal sensitivity was detected down to 
the level of 0.1%. No product was detected in the 0.01% dilution for either mutation. There 
was a slight increase in the level of S14 Cp values (decrease in template concentration) as the 
concentration of MLL PTD cDNA decreased; this may cause the MRD value to be higher 
than the dilution value. The assay sensitivity achieved was 2 logs with the reproducible 
sensitivity and 3 logs overall using the maximal sensitivity.
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Figure 4.11 MRD Plot of MLL PTD Transcript Sensitivity Dilutions
Dilution series of e9/e3 and el0/e3+ell/e3 positive patient samples diluted into MLL WT 
AML cDNA plotted using the delta delta Cp method. indicates a sample that was positive 
by maximal sensitivity (DPP). MRD: minimal residual disease; Cp: crossing point.
4.2.17 Stability of the MLL PTD Marker
To determine if the MLL PTD was a stable molecular marker, 4 paired samples were
tested at diagnosis and relapse. All four of the markers were positive at both time points and
all relapsed with the same transcript type seen at diagnosis, which suggested the marker was
stable and that it was a potential marker for MRD. The diagnostic average using ACpK was
9.2+1.2 (n=4) and the average relapse using AACp was 186+133.2 (n=4). The ACpK values
indicate variation in the diagnostic samples, these were normalised using the AACp method so
differences in levels at diagnosis between individual patients are not apparent in the figure.
All of the relapse samples showed a substantial level of transcript; none were more than one
log from the diagnostic level, as shown in Figure 4.12. Three of the four patients relapsed
with expression levels higher than that seen at diagnosis and the fourth was lower, at 27% of
the diagnosis value. Expression levels of this magnitude may indicate a more rapid rate of
relapse, which would require more frequent monitoring to detect the relapse onset. In
addition, a positive result from the sample of a patient who failed to reach remission showed
the marker was stable in patients with resistant disease.
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Figure 4.12 MLL PTD Expression Level at Diagnosis and Relapse
MRD values of expression levels of patients at diagnosis and relapse. The level of MRD was 
calculated using the AACp MRD method therefore the diagnostic level is set at 100%.
4.2.18 Patient MRD Data
The MRD status of eight AML patients with MLL PTD was monitored longitudinally 
to assess the value of RQ-PCR for detecting levels of disease and predicting relapse. The RQ- 
PCR assay was compared against the “standard” measures of disease available to the patients: 
BM morphology and, if applicable, immunophenotyping and cytogenetic analysis.
4.2.19 Timepoints for MRD Analysis
The time points used to determine the progress of the patient are aligned to the 
administration of the treatment regime. The standard time points for measurement are at 
diagnosis and then following induction and consolidation treatments subsequent to the 
recovery of the WBC. The frequency of follow up samples after consolidation is reduced for 
patients in complete remission (CR). A BM sample is collected for analysis at the each of
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these points, however, if at any time in a patient’s treatment there is a lack of response to 
chemotherapy or relapse is suspected an additional BM sample is sent for analysis. The 
presentation samples were assessed by all methodologies to determine the diagnosis and the 
optimal marker for detection of MRD. When MRD markers were detected by multiple 
disciplines, the most sensitive and stable of these was chosen for follow up samples. Ideally, 
a marker for MRD would have a minimal sensitivity of 1:1,000 which would allow the 
detection of one AML cell in a background of 999 normal cells. This level of sensitivity is 
unavailable to cytogenetically normal patients who do not have a clearly aberrant 
immunophenotype; a patient with this profile is limited to a sensitivity of around 5%, 
obtained from morphological assessment of BM (Liu Yin 2002b). Follow up samples were 
sent for analysis to the departments determined to offer the best MRD method available to the 
patient. Due to the lack of a standard molecular marker for PCR at diagnosis, the samples at 
some time points were not sent for molecular analysis so the data sets are incomplete.
4.2.20 Patient Characteristics
The samples from 8 MLL PTD patients, selected for the availability of follow up time 
points, were analysed to evaluate the MLL PTD MRD assay. The patient characteristics at 
diagnosis are listed in Table 4.7. The criteria given in the 2001 WHO classifications were 
used to diagnose 7/8 patients as de novo AML (Vardiman, Harris, & Brunning 2002). One 
patient was diagnosed with MDS transforming to AML and was treated according to the 
AML 15 protocol as described previously (Chapter 2 Section 2.3.2). All 8 patients were 
determined to have the MLL PTD by the qualitative PCR as described in Chapter 3 and this 
was confirmed by RQ-PCR. There was an average of 2.8 samples received per patient 
(n=22). There were 4 male and 4 female patients with a median age of 60 years (range 35- 
72). The patients had a number of similarities; of the seven patients with available data, all
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but one presented with pancytopenia and the blast counts, as determined by BM morphology, 
of the AML samples were tightly grouped with a median of 56% (range 56-63%). All of the 
samples except for one were cytogenetically normal and were therefore categorised as 
intermediate prognosis, using cytogenetic guidelines (Grimwade et al 1998). The one sample 
with an aberrant cytogenetic karyotype was a 7q(del), which is also classified as intermediate 
prognosis. None of the molecular markers used in the AML RT-PCR screen (PML-RAR, 
RUNX1-RUNXT1, or CBFB/MYH11) were observed. These characteristics were in line with 
the results presented in Chapter 3 and with published reports of MLL PTDs association with 
cytogenetically normal samples and a lack of association with favourable risk cytogenetic 
translocations (Caligiuri et al. 1998; Schnittger et al. 2000). Surprisingly, none of the 
samples were positive for the FLT3 ITD, which can co-occur with the MLL PTD (Chapter 3) 
(Olesen et al 2005a; Steudel et a l 2003). The MLL PTD transcripts were the two most 
commonly observed types, e9/e3 and elO /ell + e3/ell, with 5/8 (63%) and 3/8 (37%) 
respectively. All patients received intensive treatment.
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UPN Sex Age
WBC
(x109/L)
FAB
BM Morphology 
Blast (%)
Cytogenetic
Marker
Cytogenetic
Prognosis
MLL PTD 
Type
FLT3-ITD
Status
Clonal
Evolution
77 M 61 0.8 M0 60 No Intermediate el0/e3+el l/e3 WT No
173 F 42 1.0 M2 56 No Intermediate e9/e3 WT Yes
41 M 63 60.0 M2 63 No Intermediate e9/e3 WT Yes
188 F 72 1.9 M6 50 No Intermediate e9/e3 WT No
68 M 37 n/d M2 n/d Yes (del 7q) Intermediate el0/e3+el l/e3 WT Yes
49 M 60 3.0 M2 56 No Intermediate e9/e3 WT Yes
150 F 35 3.6 MDS 10.0 No Intermediate e9/e3 WT Yes
17 F 60 2.6 M l 57 No Intermediate el0/e3+el l/e3 WT Yes
Table 4.7 Diagnostic Characteristics of MLL PTD
Characterisation of the MLL PTD positive patients assayed for MRD monitoring. UPN: unique patient number; L: litre; ITD internal tandem 
duplication; M: male; F: female; n/d: not determined; WT: wild type.
The number of samples exhibiting clonal evolution either at relapse or in 
refractory samples was higher than expected. When both relapsing and refractory 
patients were included clonal evolution was detected in 75% (6/8) of the samples. 
71% (5/7) percentage of CN MLL PTDs showed clonal evolution and despite the low 
number of patients tested this was substantially higher than the range of 25-51% 
reported in previous studies (Estey et a l 1995; Garson et al 1989; Kern et al 2002; 
Testa et al 1979). Comparison of karyotypes at diagnosis and relapse revealed 
evidence of clonal evolution (Table 4.8). All of the changes involved unbalanced 
translocations and mutations considered to be secondary abnormalities when found at 
diagnosis. The cytogenetic classification of two of the six patients changed from an 
intermediate to an adverse prognostic classification as a result of >5 cytogenetic 
aberrations, while the other four patients remained intermediate, despite changing 
from normal to aberrant karyotypes. One of the six patients that exhibited clonal 
evolution was considered to have refractory disease; supporting the theory that 
karyotype instability may promote the acquisition of a phenotype that is resistant to 
anti-leukaemic treatment (Kern et a l 2002).
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UPN Karyotype at diagnosis Prognosis Karyotype at Relapse Prognosis
A from Diag. 
Prognosis
173 46,XX[301 Intermediate 47,XX,+21 [5] Intermediate No
41 46,XY[20] Intermediate 46,XY,add( 1 Xq4? 1 ),add( 17Xq24)[3]/46,X Y[47] Intermediate No
68 46,XY,del(7)(q23q22)[81/46,XY[2] Intermediate 47,X Y,add(5Xp 13),-6,-9,-17,+4mar[3]/46X Y[3] Adverse (5) Yes
49 46,XX Intermediate 47,XX,+8[ 1 ]/46,XX[29] Intermediate No
150 46,XX Intermediate 46,XX,?add(6Xq2?5)[31/46,XX[ 171 Intermediate No
17 46,XX Intermediate 47,XX,-4,inv(7Xq22q36),-17,+22,+mar 1 ,+mar2[2]/46,XX,- 4,t(5;9Xq 13;p2?2),inv(7Xq22q36),add( 12Xq24),t( 13;22Xq 1 ?2;q 13),- Adverse (5) Yes
Table 4.8 Evidence of Clonal Evolution (Karyotypic ) Instability) iin Cytogenetically Normal Patients
Karyotypes of patients with clonal evolution. The diagnostic karyotype and relapsed or refractory karyotypes are shown with prognosis based 
on cytogenetic analysis. Column 6 indicates whether the change in karyotype changes the cytogenetic prognosis group. A:Change; “Adverse 
(5)” signifies adverse prognosis due to 5 or more cytogenetic aberrations. UPN: unique patient number.
4.2.21 Correlation of MRD Methods
The results of the MLL PTD RQ-PCR assay were compared against the 
standard measures of MRD that were available for each patient (BM morphology, 
immunophenotyping and cytogenetic analysis), to prove correlation with existing 
methods, to compare sensitivity and to determine if early detection of relapse was 
possible. The results of the BM morphology report were used to determine remission 
using the WHO criteria of <5% blasts to define morphological remission. Relapse 
was also determined from analysis of the BM morphology. Concordant results were 
observed between the MLL PTD RQ-PCR and all standard MRD methods when 
diagnostic, relapsed and refractory samples were analysed (Table 4.9). All 
presentation samples exhibited a high level of expression with a ACpK median of 9.3 
(range, 8-10.7, n=7). Follow up samples from each patient were normalised relative 
to the value at diagnosis. The samples that were designated as relapse or refractory by 
BM morphology, immunophenotyping or cytogenetic analysis all had substantial 
MLL PTD expression levels and were within 1 log of the diagnostic value. In four 
samples where morphological remission was indicated standard MRD markers did not 
detect disease while MLL PTD RQ-PCR was able to detect a decreased amount of 
transcript (between 1 and 2 logs below the diagnostic level). The alternative values 
were a result of the higher sensitivity of the MLL PTD RQ-PCR. The level of MRD 
was determined in three of the samples with values of 2, 3 and 4%; the fourth was 
found to be a DPP. The detection of MRD by MLL PTD RQ-PCR in samples 
designated as remission samples by standard methods demonstrated that a higher level 
of sensitivity was obtained using the new RQ-PCR assay. There were no instances 
where the MLL PTD RQ-PCR was negative and a standard MRD method showed
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evidence of disease. The only sample that showed a discordant result was the 2 
month sample for UPN 77. However, the marrow was described in the morphology 
report as a hypocellular sample and, as such, it may not have been representative of 
the whole and the fraction of blasts was calculated as 2% by morphology, while the 
level of MRD calculated was 52%. The quality of the RNA isolated was acceptable 
in both concentration and quality as determined by spectrophotometry and all of the 
criteria for the MLL PTD assay were met. Two subsequent marrows that were not 
received by molecular diagnostics substantiated the original MLL PTD MRD result 
with increased levels of blasts seen in each sample. In this example, it appeared that 
the RQ-PCR assay detected the underlying level of disease despite the poor quality 
and low quantity of the sample received, while the standard BM morphology result 
was ambiguous and had to be repeated. Concordance between the results of the RQ- 
PCR assay and the standard methods of MRD occurred in 77% (17/22) of samples. In 
the remaining 23% (5/22) of samples, the higher sensitivity of the RQ-PCR assay 
detected MRD in samples declared to be free of disease by other methods.
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UPN
Time from Diagnosis (months)
77
0 2* 4 16
173
0 3 5 8
41
0 1 5
WBC (xKP/L) 0.8 0.8 5.9 3.4 1 0.7 1.6 1.2 60 4.7 3.7
BM Blast Count (%) 60 2 4 22 56 59 4 n/d** 63 2 21
Immunophenotyping Blast Count (%) 58 n/d <0.5 10 30 65 0 n/d*** 65 n/d 22
Cytogenetic Analysis Cell Count n/a n/a n/a n/a n/a 5/5 0/200 17/20 n/a n/a 3/50
MLL PTD QPCR - Delta Delta Cp (%) 100 52 2 128 100 165 4 269 100 DPP 27
UPN
Time from Diagnosis (months)
188
0 1 2
68
0 27
49
0 4
150 
0 2
17
10 12
W BC (x109/L) 1.9 0.5 n/d n/d 8 3 1.7 3.6 n/d 2.9 6.1
BM Blast Count (%) 50 25 4 n/d 73 56 52 10 n/d 85 n/d
Immunophenotyping Blast Count (%) 40 20 5 n/d n/d*** n/d*** n/d 34 n/d n/d*** n/d***
Cytogenetic Analysis Cell Count n/a n/a n/a 8/10 3/6 n/a 1/30 n/a 3/20 7/10 n/d
MLL PTD QPCR - Delta Delta Cp (%) 100 464 3 100 319 100 582 100 15 100**** 130
Table 4.9 Comparison of Standard Methods of MRD for MLL PTD Patients Over the Course of Treatment
All results in red are refractory disease or relapse. UPN: unique patient number; WBC: white blood count; L: litre; BM: bone marrow; n/d: not 
determined; Cp: crossing point. *Hypocellular sample, may not be representative, BM and flow done at 2.5 and 2.8 months and showed 
increasing blasts; **BM trephine observed infiltration of myeloblasts - no percentage given; ***Majority of cells are blasts - no percentage 
given; ****Relapse sample, assigned 100%;
4.2.22 Prediction of Relapse and Attainment of Remission
Although neither molecular remission nor prediction of relapse was 
demonstrated with the MLL PTD RQ-PCR, this is likely to stem from inadequate 
sampling frequency rather than lack of sensitivity of the assay. The assay has clearly 
shown healthy donor samples to have no detectable levels of MLL PTD transcript, but 
none of the patients positive for the MLL PTD reached this point during their course 
of treatment. The molecular MRD data for all 8 patients are shown in Figure 4.13. 
The sample closest to reaching negativity was the one month time point of UPN 41, 
which reached a >2 log reduction to DPP, only to relapse 4 months later. No samples 
showed clear evidence of relapse prior to detection of relapse by other methods. 
However, the failure to clear the disease was apparent in four patients who 
subsequently relapsed and this, combined with the higher sensitivity of the RQ-PCR 
assay, suggests the ability to detect early relapse if samples were collected at more 
frequent time points. The paucity of longitudinal patient monitoring at regular 
intervals limits the interpretation of this study’s findings. A greater number of 
samples from patients with longer event free survival (EFS) may have demonstrated 
whether the MLL PTD transcript became undetectable and whether the assay was 
capable of predicting relapse. Many of the samples received from patients with 
longer EFS were sent for molecular diagnostics only because the relapse was already 
suspected so the opportunity to predict an early relapse was lost.
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Figure 4.13 Time Course M onitoring of MRD in Eight Patients with AML
Longitudinal MRD monitoring of MLL PTD positive patients over the course of 
treatment. MRD values were calculated using the AACp MRD method. Patients 188, 
49 and 173 had refractory disease. Patients 41, 77 and 173 had initial reductions of 
greater than 10% before relapse. The level of 1 represents DPP for patient 41. The 
two samples plotted for patient 17 are successive relapse samples, the diagnostic 
sample was not available, UPN: unique patient number.
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4.2.23 Demonstration of MRD in UPN 173
Samples from one patient (UPN 173) exemplified the potential clinical 
usefulness of the MLL PTD RQ-PCR MRD assay. The diagnostic MLL PTD 
identified the patient as having a poor prognosis (Chapter 3), the RQ-PCR assay 
demonstrated the presence of MRD when all other markers indicated remission and 
within three months the patient had relapsed (Figure 4.13, Table 4.9). These results 
indicate that the knowledge of persistent MLL PTD expression may have been useful 
in determining whether a different form of treatment was needed to achieve a durable 
remission.
The patient was a 42 year old woman who was pancytopenic with a WBC of 
1.0xl09cells/l, a blast level of 56% and 30% respectively for BM and 
immunophenotyping: she was diagnosed as AML FAB type M2. The MLL PTD RQ- 
PCR analysis detected a diagnostic level of disease with a ACpK of 10.7 (diagnostic 
range 8-12.4). No markers were found for cytogenetics or molecular diagnostics, 
therefore immunophenotyping was recommended as the most useful method for the 
detection of MRD. On the basis of cytogenetic analysis, the patient was classified as 
intermediate prognosis. The patient was entered into the AML 15 trial and received 
standard treatment. Following the first course of chemotherapy, the patient was in CR 
with less than 3% blasts by morphology and less than 1% with flow cytometry. The 
next sample for molecular diagnostics was received 3 months post diagnosis with the 
clinical details “?relapse” and WBC of 0.7x109cells/l. The BM morphology showed 
normal cellularity and 59% blasts; the conclusion was relapsed AML. The 
immunophenotyping detected blasts comprising 65% of the nucleated cells and the 
loss of the TdT marker seen at diagnosis. Cytogenetic analysis provided confirmation
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of relapse, with the observation of trisomy 21 in 5/5 cells, confirmed with TEL/AML 1 
fluorescent in situ hybridisation (FISH). Due to the poor quality of the cells, the 
possibility of further cytogenetic abnormalities could not be ruled out. MLL PTD 
RQ-PCR indicated definitive relapse with a AACp MRD higher than that found at 
diagnosis at 165%. The next sample followed in 2 months, after the patient had 
undergone a third course of therapy. The WBC was 1.6xl09cells/l and morphology 
on the BM showed normal cellularity and 4% blasts; the patient had responded well to 
treatment and was in complete remission. Immunophenotyping found no blasts with 
the presentation phenotype and stated, “If there are any leukaemic blasts they are 
beyond our limit of detection.” TEL/AML 1 FISH found no evidence of trisomy 21 in 
200 nuclei examined. In contrast, the RQ-PCR assay detected MLL PTD transcripts 
with the AACp MRD at 4%, less than a 2 log reduction from the diagnostic level. 
Unfortunately, no further samples were received for molecular analysis until the final 
sample was received 3 months later; 8 months post diagnosis. The clinical details 
were, “AML second remission. Still pancytopenic.” All of the methods used for 
MRD detection found evidence of relapse. The WBC was 1.2xl09cells/l, with an 
observation of circulating blasts, and an infiltration of myeloblasts was seen in the 
analysis of the BM trephine sample. The majority of cells observed by 
immunophenotyping were TdT positive blasts as seen at diagnosis. Cytogenetic 
analysis of the BM found that 17/20 cells had an abnormal karyotype with trisomy 21, 
as observed at first relapse and FISH analysis confirmed this result. Additionally, 4 of 
these cells showed monosomy 7, an additional marker on the short arm of 
chromosome 11 and a marker chromosome of unknown origin. The remaining 3/20 
cells showed no cytogenetic abnormalities. These results confirmed relapse, along
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with the possibility of further clonal evolution. The MLL PTD RQ-PCR confirmed 
the relapse with the AACp MRD rising clearly above the diagnostic level to 269%. 
No further samples were received for molecular diagnostics. The patient went on to 
receive palliative treatment and died of septicaemia, liver failure and AML 11 months 
after diagnosis.
The greater sensitivity of the MLL PTD RQ-PCR and the stability of the MLL 
PTD as a marker compared to the other MRD methods available to the patient suggest 
it would be a clinically useful assay. The standard methods of MRD, flow cytometry 
and cytogenetic analysis, were not sensitive enough to detect MRD in the 5 month 
post diagnosis sample from patient UPN 173. Analysis by immunophenotyping 
showed the phenotype changing from TdT +ve at diagnosis to TdT -ve and back 
again, while clonal evolution was observed in the cytogenetic analysis. Whether this 
was due to two separate cell lines populating the marrow at different time points or a 
phenotypic switch within one cell line was unclear. Clonal evolution was observed as 
the karyotype changed from cytogenetically normal to trisomy 21 at first relapse, and 
then progressed to trisomy 21, monosomy 7 with additional aberrations at second 
relapse. The disadvantage to using markers of MRD prone to change is that at relapse 
the new phenotype may not be detected or may be detected but not recognised as 
leukaemia. The stability of the MLL PTD marker was evident from detection of 
MRD at every time point tested, from diagnosis through morphological remission to 
relapse. Increasing the frequency of molecular testing for MRD, i.e. following every 
course of chemotherapy, has the potential to predict impending relapse and to identify 
the patient as a poor responder who may be benefit from a different treatment 
strategy. Furthermore, the presence of the MLL PTD throughout patient monitoring
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suggested that it may be necessary for maintaining the leukaemic phenotype and was 
possibly an early event in the transformation of the cell.
4.3 Discussion
The measurement of MRD has become increasing important in the treatment 
of patients with AML. Studies have proven that MRD levels are associated with the 
prognosis and clinical outcome of patients and can be used to guide the course of 
treatment. Unfortunately, as the majority of MRD markers detected by PCR are 
based on fusion genes, 63-79% of all AML patients are left with no sensitive method 
of following the course of disease after reaching morphological remission. The MLL 
PTD mutation occurs in approximately 6%-10% of CN patients and was tested as a 
potential marker for MRD using RQ-PCR.
The optimisation of the RQ-PCR assay was paramount because the MLL PTD 
transcript has been shown previously to be detectable in healthy donors and in MLL 
PTD negative AML patients (Chapter 3) (Schnittger et al. 2000), (Marcucci et al 
1998). The experiments conducted for the optimisation used MLL PTD negative 
AML samples and the two most commonly occurring MLL PTD mutations. 
Optimised concentrations of MgCl2, cDNA template and the primer annealing 
temperature created a separation of nearly 3 logs between the positive and negative 
samples. With conditions optimised, healthy donor samples showed no specific 
amplification of MLL PTD, thereby eliminating the possibility of misinterpreting a 
healthy normal as a false positive.
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The effect of different expression levels at diagnosis has been studied by a
number of groups with contrasting conclusions; diagnostic levels were shown to have
a significant effect on prognosis for the fusion genes, RUNX1 -R UNX1T1,
PML/RARA and CBFB/MYH11, (Leroy et al. 2005; Schnittger et al 2003) and no
correlation in a separate study on PML/RARA in APL (Gallagher et al. 2003). The
diagnostic range of expression level for the MLL PTD was reported as being >21og,
with the median value approximately 3 log above the level detected in both MLL PTD
negative AML and healthy donors (Weisser et al. 2005b). In this study the diagnostic
range was narrower, all samples were within 1.2 logs, and the donor samples showed
no amplification. The discrepancy in the diagnostic level may be due to the lower
number of samples used, or to the relatively narrow range of blast cell levels in the
samples, (all within 50-63%, apart from one MDS sample at 10%). The Weisser
(2005) study used the same amplification primers as the current study in combination
with hybridisation probes to demonstrate the specific amplification of the MLL PTD
transcript, whereas this study used Syber Green to identify the amplification of any
double stranded product independent of specificity. The ability to visualise samples
that produced non-specific amplification provided additional information, unavailable
if using specific hybridisation probes, used to exclude them from further analysis.
This may explain the negative results for the healthy donors in this study, since false
positives are avoided. Another possibility is that the difference was due to the higher
stringency for amplification in this study compared to the Weisser (2005) study,
arising from the higher primer annealing temperature, 69°C vs. 64°C, and the smaller
concentration of cDNA template. Evidence of this was the increase in the Cp of the
MLL PTD positive samples as annealing temperature and template volume were
increased (Table 4.3 and 4.4) and the increase in the Cp difference in positive and
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negative samples when annealing temperatures were increased (Table 4.5). The result 
would be a lower overall sensitivity for the RQ-PCR assay, offset by the fact that 
donor samples were not amplified. The median difference of just over 3 log between 
MLL PTD positive samples and healthy donor samples reported in the Weisser (2005) 
study adds support to this theory, as that would place the transcript level of donor 
samples just below the sensitivity of the present assay.
Despite the alternative strategies of detection and the resulting differences, the 
sensitivity range for both assays are broadly similar with the sensitivity of this study 
at 2-3 log and a 2-4 log sensitivity, dependent upon diagnostic levels, reported by 
Weisser (2005). Likewise, samples presenting with a higher diagnostic ACpK level 
would also be expected to have a higher sensitivity as previously outlined (Figure 
4.10). The stability of the MLL PTD was demonstrated by the detection of the 
marker in 4 paired samples tested at diagnosis and at relapse. The stability of MLL 
PTD, even in cases with clonal evolution, may indicate that the marker is an early 
event in leukaemogenesis. However, as the mutation is found in healthy donors as 
well as the progenitor sub-fraction of cord blood samples the likelihood that it is 
independently leukaemogenic is low. MLL PTD positive cells may need further 
mutations or an increase in transcription level before leukaemic progression begins 
(Basecke et al. 2006b). All of the relapse samples had substantial levels of MLL PTD 
transcript at relapse, within 1 log of the diagnostic level. Interestingly, three of the 
four relapse samples relapsed at a higher level than that detected at diagnosis; this has 
previously been reported for both NPM1 and WT-1 (Barragan et al. 2008; Tamaki et 
al. 1996). The data shown here demonstrate that the sensitivity, stability and 
specificity of the assay make it a suitable candidate for further evaluation as a method 
for measuring MRD.
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The MLL PTD RQ-PCR measurements calculated using the AACp MRD 
formula showed correlation with the “traditional” MRD methods down to the level of 
morphological remission. Only one of the patients with follow up data available had 
a cytogenetic abnormality available for use as a MRD marker, the remainder were 
monitored using morphology and occasionally an aberrant immunophenotype, 
however, none of these phenotypes were exceptionally sensitive. No correlation was 
shown in four patients where standard methods had declared the patient to be in 
remission, yet the higher sensitivity achieved with the RQ-PCR demonstrated 
lingering disease in these patients. Overall, the data show that the RQ-PCR assay for 
detection of MLL PTD is capable of measuring MRD in patients harbouring the MLL 
PTD and may offer greater clinical relevance due to the higher level of sensitivity 
compared to other available methods.
Leukaemia-associated aberrant phenotypes (LAIPs) are being used more
frequently for MRD because they are useful in a large proportion of AML patients,
especially those that are CN. In this study, the LAIPs identified were not as sensitive
as the MLL PTD RQ-PCR, but this may not always be the case as LAIP MRD
analysis has a reported sensitivity of up to 4 logs (Campana & Coustan-Smith 1999;
Freeman, Jovanovic, & Grimwade 2008). LAIPs have been used to detect MRD in
MLL PTD positive patients and were able to detect MRD in patients in morphological
remission, however the sensitivity of the assay was not determined (Munoz et al.
2003). In contrast to RQ-PCR analysis, which measures the level of transcript
expression from an individual gene, LAIP analysis is a measurement of the number of
leukaemic cells present in a sample. Approximately 25% of LAIPs present at
diagnosis may not be found at relapse and studies have shown variation in the
intensity of the antigen at relapse (Oelschlagel et al. 2000; Voskova et al. 2004). Due
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to the different information provided by LAIPs and the possibility of marker 
instability, AML patients may be best served by a combination of the two techniques 
presented in a multidisciplinary report.
None of the patients’ follow up samples reached molecular remission, 
however the principle was demonstrated clearly in the sensitivity test where the 0 .1% 
dilution was negative. Further studies are needed to evaluate whether the 
achievement of molecular remission is significant to the long term disease free 
survival of MLL PTD positive patients. The data from previous studies are not 
conclusive. Several reports have demonstrated that long term complete remission was 
obtainable despite PCR positivity in the fusion genes RUNX1 -R UNX1T1, 
PML/RARA and CBFB/MYH11 (Gallagher et a l 2003; Krauter et a l 2003; 
Schnittger et al 2003). It has been proposed that immunological intervention may 
able to hold low levels of LSCs in balance, preventing proliferation that would lead to 
the patient’s eventual relapse (Grimwade & Lo 2002). This in possible combination 
with the concept that the translocation itself is not enough to cause leukaemia, could 
explain positive MRD results for patients in long term remission (Grimwade & Lo 
2002). On the other hand, it was also reported that molecular remission was a 
requirement for long-term complete remission in CBFB/MYH11 and PML/RARA 
(Chillon et al 2004; Martin et a l 2000). The most likely explanation for the 
conflicting findings is that all groups are correct within the context of their respective 
tests, but the inconsistencies are a result of different sensitivities between the assays.
An improvement in the sensitivity of the assay may be possible by an
adaptation of the hybridisation probe methodology used in the Weisser (Weisser et al
2005b). The difference in amplification stringency due to the higher primer annealing
temperature may provide a greater separation between the MLL PTD positive samples
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and the healthy donor samples. This would be helpful in increasing the range of 
sensitivity to include samples with low initial diagnostic levels, which currently have 
a sensitivity of 2 logs. While this would give the advantage of making the assay more 
objective by removing the requirement for Tm analysis, it would also remove the 
benefit of being able to identify the amplification of non-specific products thereby 
preventing false positives. Another disadvantage is the considerable cost of 
synthesising hybridisation probes. While the current sensitivity is less than might be 
considered ideal for a molecular MRD marker, the patient cohort in question is 
populated with individuals with normal karyotype who often lack any markers at all 
beyond BM morphology so this assay provided additional useful information.
The importance of MRD monitoring in predicting the clinical outcome in 
AML has meant an increase in the study of mutations that occur preferentially in CN 
AMLs as potential markers of MRD. Cases of the MLL PTD and the FLT3 ITD 
occurring in the same patient have been shown in Chapter 3, as well as in previously 
published reports (Libura et al. 2003; Steudel et al. 2003). FLT3 ITD is often used as 
an MRD marker because of its high frequency of 40% in AMLs with a normal 
karyotype and 25% in AMLs (Schnittger et al. 2002). However, the instability of 
FLT ITD at relapse may lead to false negative results. In addition, unless patient and 
mutation specific primers are used, the sensitivity remains 2-3 log, so this MLL PTD 
assay may be an alternative method of MRD detection in patients with both mutations 
(Schnittger et al. 2004).
Clear evidence supporting the early prediction of relapse was not possible due
to the paucity of follow up samples available. However, the remission samples
showed the presence of MLL PTD transcripts in patients that later relapsed suggesting
that a higher frequency of sampling time points may allow such predictions. The
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ability to predict early relapse in APL coupled with an early treatment response in 
APL resulted in an improved clinical outcome (Diverio et al. 1998; Lo et al. 1999b). 
Additional studies are needed to see if this would prove to be true with MLL PTD 
patients.
The previously reported fraction of CN patients undergoing clonal evolution is 
substantially lower than that of karyotypically normal patients with the MLL PTD 
mutation in this study (Estey et al. 1995; Kern et al. 2002). Although FLT3 ITD and 
MLL PTD status was determined in a previous study of karyotypic instability, only 
four MLL PTD patients were found and the results were given in terms of the two 
mutations together (Kern et al. 2002). There is no previous data published on the 
observation of higher clonal evolution in MLL PTD patients. The suggestion that 
clonal evolution increased the risk of acquiring a mutation that confers resistance to 
leukaemia chemotherapy has been made previously (Kern et al. 2002). This 
hypothesis was supported by the poor response of the patients in this study and 
warrants further studies into the high level of clonal instability in MLL PTD patients.
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4.4 Conclusion
In conclusion, the hypothesis that the expression level of the MLL PTD as 
determined by RQ-PCR can be used as a marker for MRD was supported by the 
results shown in this study. The RQ-PCR would be beneficial to the 6%-10% of CN 
AML patients who present with the MLL PTD mutation and for whom there is often 
no sensitive method of MRD available. The assay is potentially a beneficial tool, 
despite its relatively low sensitivity, because the refractoriness and short duration of 
remission seen in many MLL PTD positive patients would make monitoring the 
response to therapy and the prediction of relapse in poor responders clinically useful. 
As MLL PTD patients have a high risk of relapse, long term MRD monitoring could 
also be improved by implementing this assay for detection of impending relapse, 
however, it may be less useful in this group of patients due to the low sensitivity level. 
Early identification of poor responders may enable intervention through more targeted 
treatment or an allogeneic bone marrow transplant, resulting in an improved clinical 
outcome.
The data in this study show a higher than expected level of clonal evolution 
from diagnostically normal karyotypes and may be a factor in the high level of relapse 
seen in MLL PTD positive patients.
Although the results of the study suggest the ability to predict relapse and 
determine molecular remission, future studies using established time points for MRD 
analysis and a much larger cohort of patients are needed to confirm this. The 
inclusion of MLL PTD MRD testing in a major AML trial would allow threshold
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levels, and the relapse kinetics, to be studied so that the important time points for 
MRD analysis could be determined. Early prediction of relapse or failure to reach a 
threshold level could be followed by studies to determine whether a change in 
treatment could influence the outcome of these patients.
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5 Gene Expression Profiling of MLL
PTD
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5.1 Introduction
The use of gene expression profiling (GEP) for investigating the pathobiology 
of AML is well established. GEP is used to discover new categories of AML, to 
develop predictors (i.e good versus poor outcome) and to understand the biological 
processes associated with the disease using the three respective applications: class 
discovery, class prediction and class comparison. The technique has advanced from 
the milestone study by Golub et al. (1999), where GEP demonstrated a gene signature 
that could distinguish ALL from AML samples, and is now used to distinguish 
smaller less well defined subgroups within the disease(Golub et al. 1999). AML 
subdivision has developed in step with technical advancement, from morphology to 
cytogenetics to molecular genetics; the capacity for global analysis of gene expression 
now allows previously unrecognised characteristics to be identified by unique gene 
signatures.
New subgroups have been identified from the large heterogeneous group of 
cytogenetically normal AML samples using the technique of class discovery, whereby 
similarities and differences between the profiles of AML samples are sought. 
Unsupervised hierarchical analysis, which is analysis performed without 
consideration of sample characteristics, found gene signatures coinciding with 
established cytogenetic groups and cytogenetically normal AML (CN AML). The 
cytogenetically normal samples were divided into two subsets with unique gene 
signatures suggestive of different methods of AML progression. Outcome prediction 
used 133 genes significant to the duration of patient survival and found the
5-228
designation of good or poor outcome in the CN AMLs correlated with the 2 gene 
signature groups (Chapter 1.4.2) (Bullinger et al. 2004).
GEP analysis has been used to determine the expression patterns of MLL 
chimeric fusion genes in paediatric and adult AML leading to a better understanding 
of the biological features of this subgroup. The group of leukaemias defined by 
chimeras at the llq23 locus show unique gene signatures, which allow them to be 
segregated from other AML translocations (Kohlmann et al. 2005). When paediatric 
AML and ALL patient samples were combined, signatures derived from MLL 
translocations grouped the MLL leukaemias by translocation instead of lineage (Ross 
et al. 2004; Zangrando et al. 2009). This indicated that similar transcriptionally- 
linked processes, regardless of the cell lineage involved, could establish MLL 
leukaemogenesis. Genes commonly expressed in both lineages included homeobox A 
(HOXA) cluster genes, in addition to the HOX  co-regulators, myeloid ecotropic viral 
integration site 1 homeobox (MEIS1) and pre B cell leukaemia transcription factor 3 
(PBX3) (Bullinger et al. 2004; Kohlmann et al. 2005). However, unsupervised 
analysis of combined acute leukaemia showed the MLL translocations grouping by 
lineage (Kohlmann et al. 2005; Ross et al. 2004; Zangrando et al. 2009). 
Unsupervised analysis conducted exclusively on MLL chimeric samples clearly 
separated the AML and ALL lineages, yet failed to further segregate the cases into 
groups according to the fusion partner or, for AML cases, according to FAB 
classification (Kohlmann et al. 2005). Subsequent attempts to identify unique gene 
signatures and predict class according to the fusion partner failed. In summary, gene 
expression signatures derived from microarray technology increased the 
understanding of the relationship between MLL fusion genes within AML and 
between acute leukaemias.
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The MLL PTD occurs primarily in AML and affects the same region of the 
MLL gene as the translocations yet no partner gene is involved. The overarching 
hypothesis of this chapter is that MLL PTD has a gene signature that is unique to other 
AMLs and can be used to add understanding to the aetiology of the disease.
The objectives of the chapter were:
1) to determine whether MLL PTD alters the overall gene signature from 
AML MLL PTD WT and can be used to predict for MLL PTD through 
GEP
2) to establish if molecular pathways or biological function correlations 
between the identified gene lists add insight to the pathogenesis of MLL 
PTD and can be used to discover potential therapeutic options
3) to validate the microarray data by correlation with RQ-PCR analysis
4) to ascertain if identified genes can be used as markers of minimal residual 
disease
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5.2 Materials and Methods
5.2.1 Patients and Control Samples
In this study bone marrow aspirates from 181 samples were analysed; 162 
were presentation samples from AML patients and 19 were obtained from transplant 
samples provided by healthy control subjects . All AML samples were from patients 
enrolled in MRC-UK AML clinical trial protocols and were processed at University 
Hospital Wales, Cardiff. Clinical characteristics of the patients are listed in Appendix 
A. RNA was isolated as described in Chapter 2 Materials and Methods (Section 2.4).
5.2.2 Affymetrix Microarray Analysis
The process of sample preparation, hybridisation and scanning of the 
Affymetrix GeneChips is covered in the Materials and Methods (Section 2.10). 
Affymetrix numerical cell (.cel) files were imported into Partek Genomics Suite 
(Partek Inc., St. Louis, MO, USA), a statistical program designed for microarray 
analysis, using the default normalisation parameters. Robust multi-chip averaging 
(RMA) was used to pre-process the perfect match probe data using background 
correction, quantile normalisation across all chips, log2 transformation and median 
polish summarisation. RMA normalised the background intensity of the perfect 
match probe values across each GeneChip and then normalised data across 
GeneChips with quantile normalisation. Two different GeneChips were used in this 
study, the HG-U133A and the HG-U133 Plus 2. The HG-U133A array is a human 
genome microarray containing >22 ,000  probe sets, analysing the expression level of
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over 18,400 transcripts and variants that code for over 14,500 genes. The HG-U133 
Plus 2 is an improved higher density GeneChip that evolved from the original HG- 
U133A, enabling the analysis of an additional 32,000 probe sets, 28,600 transcripts 
and 24,000 genes.
Analysis of variance (ANOVA) (p<0.05) was used to determine differentially 
expressed probe sets due to the MLL PTD with a false discovery rate (FDR) of less 
than 5%. The resulting list was filtered to exclude all sets that changed within a 2- 
fold change window in MLL PTD expressing cells when compared to AML MLL PTD 
WT (Figure 5.1).
To increase the statistical power, the sample number was increased by 
combining data from the common probe sets from the HG-U133A and the HG-U133 
Plus 2 cohorts. To prevent batch effects created by the different GeneChips and 
protocols from obscuring the biological effects of the MLL PTD the Partek Batch 
Remover programme was used. For information on protocol differences between 
HG-U133A and HG-U133 Plus 2 see Chapter 2 Material and Methods (Section 2.10). 
The results of Partek Batch Remover are demonstrated in Figure 5.2, which shows the 
samples from both chips combining into one common cluster.
For the validation of microarray data the log2 values of the genes of interest
(GOIs) were plotted against the ACp values. The log2 data for each gene of interest
was retrieved from the combined sample group data set. When multiple transcripts
identified a single gene, the transcripts with significant (p<0.05) and >2 fold
expression levels up or down between MLL PTD and MLL WT were used and the
mean taken. This ensured expression levels of variant genes, if present, were taken
into account. All of the data sets showed Gaussian distribution so Pearson’s
correlation coefficient was used. GraphPad Prism version 3.02 (GraphPad Software
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Inc., La Jolla, CA, USA) was used to perform the statistical analysis, and the null 
hypothesis was rejected when p<0.05.
5.2.3 Statistical Analysis for Determining Significant Probe Sets
The following strategy was applied to each of the GeneChip cohorts. To 
identify statistically significant changing genes due to the presence of the MLL PTD 
mutation, supervised differential expression analysis (an analysis that considers 
external factors) was performed using ANOVA followed by exclusion of probe sets 
that exhibited <2-fold change in expression level up or down (Figure 5.1). The list of 
probe sets was generated with a false discovery rate (FDR) of less than 5%. Principal 
component analysis (PCA) and hierarchical clustering was used to show how the 
increase in the stringency of the analysis caused a decrease in the number of 
transcripts and increasingly separated the MLL PTD samples from the MLL PTD WT 
samples. The 2-fold change in expression level was chosen to maximise the chance 
that the gene product had an appreciable affect via its function and was not exhibiting 
a normal level of variation. If an MRD marker is constitutively expressed in normal 
patients, it must be significantly up-regulated in patients with AML in order to be 
clinically useful. If it is not expressed highly enough above the normal background 
range the lack of sensitivity raises the possibility of false positives thereby limiting 
the clinical relevance. The sensitivity level for identification is dependent upon the 
MRD target and the technique used, RQ-PCR is up to 2 logs more sensitive than 
multiparameter flow cytometry (Liu Yin 2002b). However, the sensitivity required is 
determined by the clinical application of the assay, for example in ALL a sensitivity 
of 10"4 is required to detect low risk patients and 10’2 may be sufficient for detection
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of high risk patients (Van, V et al. 2003b). Given that many MLL PTD patients will 
be cytogenetically normal and have no other marker available, sensitivity greater than 
that of morphology (approximately 1:20) would be an improvement(Liu Yin 2002b).
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Figure 5.1 Data Analysis Flow Chart
Decision tree for analysing Affymetrix microarray data. Data are processed through 
ANOVA (MLL PTD vs. AML WT) (significance defined by p<0.05) and then 
expression level change to identify a significant gene list.
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5.2.4 RT-PCR Analysis of Genes of Interest
The standard conditions used for all RQ-PCR assays can be found in Chapter 
2 (Materials and Methods). Before designing primers, NCBI and Entrez Gene were 
used to determine if the Affymetrix probe sets detected variants of the genes of 
interest. By entering the base pair range of the gene, the Primer3 programme 
(http://ffodo.wi.mit.edu/primer3/input.htm) was able to design primers that amplified 
all of the variants detected by the probe sets (Rozen & Skaletsky 2000). The default 
parameters of the software were used, with the size of the product limited to 600bp to 
promote efficient amplification associated with smaller amplicon sizes. A mispriming 
library within Primer3, based on human interspersed repeats was used to screen out 
possible mismatches. All of the primer pairs were selected to have a Tm of 60°C so 
that RQ-PCR conditions could be made as similar as possible. The highest scored 
primer set was chosen from the list of possible primers produced by the Primer3 
software (Table 5.1). To prevent the misinterpretation of DNA amplification as RNA 
expression, all of the primers except TPD52 and TWIST 1 were intron spanning. 
TPD52 has a high number of alternative splice sites causing all of the Affymetrix 
probes to be located in exon 9, therefore in an effort to replicate the microarray data, 
the primers selected were also chosen from exon 9. The potential for intron spanning 
primers for TWIST1 was limited by the fact it has only two exons and the software 
identified no intron spanning pairs. The ability to amplify DNA was evaluated in all 
primer sets before validation tests were conducted. To prevent misleading results due 
to mismatched bases in primer sets, each was checked for the presence of single 
nucleotide repeats (SNPs) using the web based software SNPCheck
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http://ngrl.manchester.ac.uk/ SNPCheckV2/snpcheck.htm). All primers were found to 
be free of SNPs.
GenBank Acc. No. Gene Forward Primer (y -31) Reverse Primer (5'-3t) Amplicon Length (bp)
NM 001233.3 CAV2 acgactcctacagccaccac cgtcctacgctcgtacacaa 402
NM 078626.2 CDKN2C tgcacaaaatggatttggaa gggcaggttcccttcattat 223
NM 014608.2 CYFIP1 atgcatgtggacgagtgtgt cagaaatccagcacagcaaa 184
NM 006209.3 ENPP2 caccagctgtctggatttca gtccaggctggtgagatgtt 196
NM 001025253.1 TPD52 ttgaattcggctgcaaat tcatggcaatgcatgttg 158
NM 000474 TWIST1 tccgcagtcttacgaggag ggaggacctggtagaggaa 196
NM 007313.2 ABL cccaaccttttcgttgcactgt cggctctcggaggagacgtaga 386
Table 5.1 Primers for Validation RQ-PCR
The forward and reverse primers sequences for each gene selected for validation. The 
GenBank accession number and amplicon length are also provided. Acc: accession; 
no: number; bp: basepairs.
The specificity of the selected PCR primers to the genes of interest and their 
variants was confirmed by testing each primer with the NCBI Blast programme 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi)(Altschul et a l 1990). Every primer returned 
the genes and gene variants expected and all amplicons entered produced the base pair 
size predicted by Primer 3. ABL was chosen for use as the control gene for the RQ- 
PCR validation experiments and is shown as the seventh gene in Table 5.1. The ABL 
primer sequences chosen were used to amplify ABL as the control gene for the 
quantification of BCR-ABL in the estimation of disease in CML patients (Emig et al. 
1999).
To prevent batch variation affecting the results of RQ-PCR analysis, the total 
amount of cDNA needed for all assays was calculated and a single batch of each 
cDNA was produced. Due to the limited capacity of the light cycler (32 capillaries), 
the 28 samples used for gene validation of each GOI were assayed in groups of 14 
with a positive and negative control, equalling 32. This enabled all cases to be
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analysed in two assays. Every assay for one gene, i.e. 2 sets of 32 capillaries each, 
was assayed consecutively using the same master mix.
The RQ-PCR data showed a Gaussian distribution therefore ANOVA was 
used with the Tukey method applied used as a post test to determine significant 
differences between the means of the groups.
5.3 Results
5.3.1 Identification and Analysis of Significant Gene Lists
5.3.1.a Patient and sample characteristics
GEP was used to identify significant genes associated with the MLL PTD for
their potential as MRD markers, identifiers of pathways for therapeutic intervention
and predictors of MLL PTD positive AML. The AML subtypes in the 162 bone
marrows analysed included normal karyotype, t(8;21), t(15;17), inv(16), MLL
chimeric fusion genes and complex cytogenetic karyotypes. The clinical
characteristics of the seven MLL PTD positive samples analysed are given in Table
5.2. The cytogenetic karyotypes represented were varied with the expected normal
karyotypes (3/7), a trisomy 11 (1/7) previously associated with the MLL PTD
(Caligiuri et al. 1996; Caligiuri et al. 1997), a complex karyotype (1/7), a monosomy
7 (1/7) and a surprising co-occurrence with t(8;21) (1/7) which is an infrequent event
(Ishikawa et al 2009; Schnittger et a l 2000). The resulting prognoses based on
cytogenetic analysis were as follows: one favourable, four intermediate and two
adverse (Grimwade et a l 1998). Three of the samples had co-occurrence of the MLL
PTD and FLT3 mutations, two with FLT3 ITD and one with FLT3 TKD. All healthy
control samples were wild type for the MLL PTD.
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UPN Sex Age WBC(xl09/L)
BM Blast 
(%)
FAB
subtype Cytogenetics
Cytogenetics
Prognosis MLLPTD
FLT3
Mutant FLT3ITD/TKD
282 F 65 2.6 63 M2 -7 Adverse el0/e3+ell/e3 WT WT
296 M 76 46.2 84 Ml Normal Standard e9/e3 Mutant ITD
370 M 60 1 87 Ml Complex Adverse e9/e3 WT WT
320 F 41 79.9 71 M2 t(8;21) Favourable e9/e3 WT WT
41 M 64 60 63 M2 Normal Standard el0/e3+ell/e3 WT WT
262 F 72 125 90 M5 Normal Standard e9/e3 Mutant ITD
301 M 71 50.5 92 Ml +11 Standard e9/e3 Mutant TKD
Table 5.2 Clinical and Molecular Characteristics of MLL PTD Positive Patients.
Characterisation of MLL PTD positive samples in relation to different clinical variables. UPN: unique patient number; M: male; F: female; BM: 
bone marrow; WBC; white blood count; FAB , French-American-British; e: exon; PTD: partial tandem duplication; ITD: internal tandem 
duplication; TKD: tyrosine kinase domain; WT: wild type.
5.3.2 Patient Cohorts and Microarray Chips
To maximise the likelihood of identifying novel genes differentially expressed 
due to the MLL PTD mutation, data from both microarray GeneChips designed for 
transcriptional regulation studies were used (HG-U133A and the HG-U133 Plus 2). 
The Department of Haematology at University Hospital Wales has an extensive set of 
GEP data that can be analysed for the determination of gene expression in AML. 
There are 328 different AML GEPs analysed on the 3' expression arrays currently 
available, however RNA for some of the samples had been expended, thus preventing 
MLL PTD analysis. Data was collected from two Affymetrix GeneChip platforms 
including the human genome HG-U133A and the HG-U133 Plus 2.0. Initially, 
diagnostic AML samples were tested on the HG-U133A, however as the technology 
evolved and the feature size of the GeneChips increased, analysis was subsequently 
performed using the HG-U133 Plus 2 because of the greater gene coverage.
The 93 diagnostic AML samples and the 7 healthy samples assayed using the 
HG-U133A chips were tested for the presence of the MLL PTD (Table 5.3). Three of 
the samples were positive, giving a frequency of 3.2%. The MLL PTD PCR detected 
4 positive samples from the 69 diagnostic AML samples assayed with the HG-U133 
Plus 2 chip, giving a frequency of 5.8%. The combined frequency of MLL PTD from 
both data sets was 4.3%, which is consistent with the incidence seen in Chapter 1 and 
that reported in other studies (Bacher et al. 2005; Schnittger et al. 2000). There was 
no duplication of samples between the two cohorts.
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Affymetrix GeneChip
Patient Groups 
AML Samples MLL PTD Positive MLL PTD Frequency (%)
HG-U133A 93 3 3.2
HG-U133 Plus 2 69 4 5.8
Total 162 7 4.3
Table 5.3 Gene Chip Cohorts.
Total numbers of diagnostic samples tested on the different Affymetrix chips and the 
incidence of MLL PTD. The numbers of healthy donors tested on HG-U133A and 
HG-U133 Plus 2 were 7 and 12 respectively.
5.3.3 Cohort Merging for Increased Sample Number
Data from the HG-U133A and the HG-U133 Plus 2 cohorts were combined to 
increase the sample number and then analysed together. This set of samples was 
referred to as the “combined cohort”. Partek Batch Remover™ was used in order to 
reveal the effects of the MLL PTD mutation on gene expression in isolation from any 
batch effects. Such batch effects can be large relative to the effect of the condition 
being studied and this may cause the experimental effects to be obscured. The Batch 
Remover effectively normalises any differences between batches while leaving the 
effects of the experimental condition unaffected. The PCA of the combined cohort 
prior to analysis is shown in Figure 5.2A. Although each set of samples clustered in a 
parallel plane, the two groups were separate from one another. The batch effect 
caused by the different types of GeneChips and protocols were removed using the 
software and the two sets of data merged into one congregation on PCA (Figure 
5.2B). The success of the procedure was demonstrated by the tight clustering of MLL 
PTD and healthy control samples from the two different cohorts using ANOVA. This 
allowed subsequent analysis to be performed treating the data as one uniform group.
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•  MLL PTD
•  MLL WT 
O Healthy Donor
Figure 5.2 Principal Component Analysis of Batch Effect on the Combined 
Cohort.
The samples are projected in a three-dimensional space, plotted on the basis of the 
three principal components that best capture the variance of the data. Each case is 
represented by a coloured sphere. A) HG-U133A (right) and HG-U133 Plus 2 (left) 
are separated due to batch effects. B) After application of Batch Remover the two 
groups are merged into one common cluster. Samples were colour coded as indicated 
in legend. PCA, principal component analysis; pos, positive; wt, AML WT; Dwt, 
healthy control.
5-242
A significant gene list was generated from each of the cohorts. The combined 
cohort list was used for the majority of the downstream analysis due to the larger 
sample size (Figure 5.3); the other two lists were used to increase the gene numbers 
for pathway analysis and as qualifiers for the selection of the genes for validation 
(Section 5.3.12).
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Figure 5.3 Combined Cohort Analysis Flow Chart Illustrating Combined Cohort Origin and Downstream Analysis
The flow chart demonstrates the sample composition of the combined cohort and illustrates the analyses performed on the different cohorts. 
PCA: principal component analysis, HC: hierarchical cluster analysis; CMAP: connectivity map.
5.3.4 Significant Probe Sets Identified from Combined Cohort
The application of the above analysis strategy to the 162 samples in the 
combined cohort resulted in a gene signature composed of 65 probe sets; the resulting 
PCA map is shown in Figure 5.4. Although the grouping of the MLL PTD samples 
was not as cohesive as when displayed in the independent cohorts (Section 5.3.5 and 
5.3.6), the samples are clearly grouped in one quadrant of the map (discussed further 
in Section 5.4). The increase in sample size resulted in a smaller number of probe sets 
significantly associated with MLL PTD compared to the individual GeneChips 
(Section 5.3.5 and 5.3.6), indicating a higher level of discrimination was obtained. 
The hierarchical clustering shown in Figure 5.5 shows the samples occurring in 
different regions. Interestingly, three of the MLL PTD samples, two with FLT3 
mutations, flanked an AML MLL WT sample on an isolated branch of the 
dendrogram. The seven MLL PTD samples together presented a more diverse picture 
of gene expression using PCA than PCA of the individual GeneChips, due to the 
diversity of gene expression within the positive group.
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Figure 5.4 Principal Component Analysis of the Combined Cohort.
The samples are projected in a three-dimensional space, plotted on the basis of the 
three principal components that best capture the variance of the data. Each case is 
represented by a coloured sphere. The MLL PTD group (n=7) showed accurate 
separation from AML MLL WT (n=162) using 65 discriminating probe sets. Samples 
were colour coded as indicated in legend. PCA: principal component analysis; pos: 
positive; wt: AML WT.
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Figure 5.5 Hierarchical Cluster Analysis of Combined Cohort.
Hierarchical cluster analysis of AML (n=162) versus 65 MLL PTD discriminating 
probe sets. Probe sets are shown by rows and samples by columns. The normalised 
expression value of the probe sets are shown, with colour coding representing 
deviation from the mean, with the higher expression in red and lower expression in 
blue. Indicated below the samples is the MLL PTD and FLT3 ITD classification. The 
green colourings for FLT3 indicate that no data were available. MLL PTD 
abbreviations pos: MLL PTD; wt: AML MLL WT. FLT3 mutant abbreviations, wt: 
FLT3 wild type.
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The significant gene list contained 65 probe sets and identified 54 genes. The 
top 20 probe sets selected by lowest p value are shown in Table 5.4. 81.5% (53/65) of 
the probe sets differentially regulated by MLL PTD are up-regulated. The gene 
ontology biological processes links genes with operations or molecular events related 
to cell function. The genes identified were associated with processes including cell 
mobilisation, proliferation as well as transcriptional regulation. The complete list of 
all probe sets is compiled in Appendix C.
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Affymetm ID Common Name Gene Title GcnBaak Acc No. Gene GO:BP p-value(pos vs. wt) FoidChaaKe(pos vs. wt)
205048 s at PSPH phosphoserine phosphatase NM 004577 L-serine metabolic process 1.98E-06 4.7
211122 s at CXCL11 chemokine (C-X-C motif) ligand 11 NM 005409 chemotaxis 3.98E-06 2.7
210839 s at ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 NM 001040092 phosphate metabolic process 7.61E-06 2.4
204751 x at DSC2 desmocollin 2 NM 004949 cell adhesion 8.03E-06 2.1
203324 s at CAV2 caveolin 2 NM 001233 negative regulation o f endothelial cell proliferation 1.68E-05 3.2
219479 at KDELC1 KDEL (Lys-Asp-Glu-Leu) containing 1 NM 024089 . . . 5.54E-05 2.3
203323 at CAV2 caveolin 2 NM 001233 negative regulation o f endotielial cell proliferation 7.44E-05 2.8
201689 s at TPD52 tumor protein D52 NM 001025252 anatomical structure morphogenesis 7.62E-05 2.5
209392 at ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 NM 001040092 phosphate metabolic process 9.47E-05 3.3
204779 s at HOXB7 homeoboxB7 NM 004502 transcription 1.08E-04 2.1
210163 at CXCL11 chemokine (C-X-C motif) ligand 11 NM 005409 chemotaxis 1.60E-04 2.0
204159 at CDKN2C cyclin-dependent kinase inhibitor 2C (p i8, inhibits CDK4 NM 001262 regulation of cyclin-dependent protein kinase activity 2.73E-04 2.6
213943 at TWIST 1 twist homolog 1 (Drosophila) NM 000474 negative regulation of transcription from RNA polymerase II promote 2.91 E-04 2.3
212097 at CAV1 caveolin 1, caveolae protein, 22kDa NM 001753 MAPKKK cascade 5.99E-04 2.6
201688 s at TPD52 tumor protein D52 NM 001025252 anatomical structure morphogenesis 6.91 E-04 2.1
208923 at CYFIP1 cytoplasmic FMR1 interacting protein 1 NM 001033028 multicellular organismal development 7.43E-04 2.1
201690 s at TPD52 tumor protein D52 NM 001025252 anatomical structure morphogenesis 1.25E-03 2.4
215017 s at FNBP1L formin binding protein 1-like NM 001024948 endocytosis 1.48E-03 2.1
202833 s at SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase NM 000295 response to h>poxia 1.51E-03 -4.7
203761 at SLA Src-like-adaptor NM 001045556 . . . 1.93E-03 -2.0
Table 5.4 Genes Differentially Regulated In Combined Cohort MLL PTD Samples
The top 20 dysregulated probe sets representing 15 genes are listed according to their significance (p value). Fold change is given with respect 
to AML MLL WT mean expression level. Acc: accession; no: number; GO:BP: Gene ontology biological process; pos: MLL PTD; wt: AML 
MLL WT.
5.3.5 Significant Probe Sets Identified from HG-U133A
A significant gene list from the HG-U133A GeneChip, differentiating MLL PTD 
from MLL PTD WT was identified by ANOVA and >2 fold difference in expression 
level for further analysis. The successive PCAs show how the variance from the 
decreased number of genes increasingly separated the MLL PTD samples from the 
MLL PTD WT and donor samples. In the sequence of PCA diagrams (Figure 5.6, A- 
C), the MLL PTD samples clearly become further separated from both the AML MLL 
WT and the healthy controls as the stringency of analysis is increased and the number 
of significant genes reduced. The ability of the 167 significant probe sets to segregate 
the MLL PTD samples demonstrated the uniqueness of their expression levels 
compared to the other groups. In Figure 5.7, hierarchical clustering shows the MLL 
PTD samples grouped together on the right side of the diagram in a small discrete set 
separated from the bulk of the other samples. The samples grouped together despite 
the fact that 2 of the 3 samples had a co-occurring FLT3 mutation in addition to the 
MLL PTD. This may indicate that the MLL PTD expression profile was preserved 
despite the presence of the FLT3 mutation or a similarity in the profiles of the two 
mutations.
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Figure 5.6 Principal Component Analysis of HG-U133A Samples.
The samples are projected in a three-dimensional space, plotted on the basis of the 
three principal components that best capture the variance of the data. Each case is 
represented by a coloured sphere. The MLL PTD group (n=3) show further separation 
from AML MLL WT (n=93) and healthy controls (n=7) as the number of probe sets is 
reduced through statistical analysis. A) PCA with compete gene list, probe 
sets=22,283, B) PCA with genes discriminating MLL PTD from AML WT probe 
set=4731, and C) PCA with genes discriminating MLL PTD positive from AML WT 
and greater than 2 fold expression, probe sets=167. Samples were colour coded as 
indicated in legend. PCA, principal component analysis; pos, positive; wt, AML WT; 
Dwt, healthy control.
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Figure 5.7 Hierarchical Cluster Analysis of HG-U133A Samples.
Hierarchical cluster analysis of AML (n=93) samples versus 167 MLL PTD 
discriminating probe sets. Probe sets are shown by rows and samples by columns. 
The normalised expression value of the transcripts are shown, with colour coding 
representing deviation from the mean, with the higher expression in red and lower 
expression in blue. Indicated below the samples is the MLL PTD and FLT3 mutant 
classification. MLL PTD abbreviations: pos, MLL PTD; wt, AML MLL WT. FLT3 
mutant abbreviations, wt FLT3 wild type.
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The significant probe sets and corresponding genes identified for the 93 HG- 
U133A samples are shown in Table 5.5. The top 20 significant probe sets (as 
determined by the p value of the transcripts) are listed. The biological processes 
associated with the genes identified include transcription and mobilisation. Further 
analysis of the genes identified by the significant probe sets is addressed later in the 
chapter, Sections 5.3.7-9 and 5.12. Additional lists of the complete probe sets 
identified are compiled in Appendix C.
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yjymetrix II Common Name Gene Title GeaBank Acc No, Gene GO:BP p-valne(pos vs. wt) FoldChange(pos vs. wt)
211122 s at CXCL11 chemokine (C-X-C motif) ligand 11 NM 005409 chemotaxis 1.69E-08 4.6
210163 at CXCL11 chemokine (C-X-C motif) ligand 11 NM 005409 chemotaxis 2.85E-08 3.9
203915 at CXCL9 chemokine (C-X-C motif) ligand 9 NM 002416 chemotaxis defense respo 4.13E-08 3.5
201083 s at BCLAF1 BCL2-associated transcription factor 1 NM 001077440 transcription 1.18E-07 2.4
209392 at ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 NM 001040092 phosphate metabolic process 1.44E-07 8.1
210839 s at ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 NM 001040092 phosphate metabolic process 1.45E-06 3.1
221530 s at BHLHE41 basic helix-loop-helix family, member e41 NM 030762 transcription 1.55E-06 2.2
216016 at NLRP3 NLR family, pyrin domain containing 3 NM 001079821 apoptosis; indue 5.32E-06 2.1
204779 s at HOXB7 homeobox B7 NM 004502 transcription 9.68E-06 2.8
206500 s at C14orfl06 chromosome 14 open reading frame 106 NM 018353 cell cycle; mito 1.60E-05 2.2
103505 a“ F13A1 coagulation factor Xlll, Al polypeptide NM 000129 blood coagulation; blood 2.32E-05 8.5
216973 s at HOXB7 homeobox B7 NM 004502 transcription 3.38E-05 2.4
204438 at MRC1///MRC1I mannose receptor, C type 1 I I I  mannose receptor, C type 1-like 1NM 001009567 endocytosis; rec 3.99E-05 5.3
213943 at TWIST 1 twist homolog 1 (Drosophila) NM 000474 negative regulation of transcription from RNA polymerase II promo 1.84E-04 2.5
201462 at SCRN1 secemin 1 NM 001145513 exocytosis 2.12E-04 3.6
222154 s at SPATS2L spermatogenesis associated, serine-rich 2-like NM 001100422 — 2.91E-04 2.6
213734 at WSB2 WD repeat and SOCS box-containing 2 NM 018639 intracellular signaling cascade 3.41 E-04 2.4
202314 at CYP51A1 cytochrome P450, family 51, subfamily A, polypeptide 1 NM 000786 steroid biosynthetic process 4.61 E-04 2.4
201951 at ALCAM activated leukocyte cell adhesion molecule NM 001627 cell adhesion 8.54E-04 2.8
203324 s at CAV2 caveolin 2 NM 001233 negative regulation of endothelial cell proliferation 9.84E-04 3.5
Table 5.5 Genes Differentially Regulated In HG-U133A MLL PTD Samples
The top 20 dysregulated probe sets representing 18 genes are listed according to their significance (p value). Fold change is given with respect 
to AML MLL WT mean expression level. Acc: accession; no: number; GO:BP: Gene ontology biological process; pos: MLL PTD; wt: AML 
MLL WT.
5.3.6 Significant Probe Sets Identified from HG-U133 Plus 2
The same analysis rationale was applied to the 69 samples analysed with the 
HG-U133 Plus 2 chip to identify a significant gene list associated with the MLL PTD. 
The results of the analysis reduced the number of probe sets from >54,000 to 293; the 
final results are shown on the PCA map in Figure 5.8. The isolated grouping of the 
MLL PTD samples showed that the 293 transcripts were able to discriminate these 
samples from the AML MLL PTD WTs. The result is similar to that observed with 
the greater number of samples in the HG-U133A experiment. When the samples were 
displayed using hierarchical clustering, the MLL PTD samples associate on one half 
of the dendrogram with three of the four located together on an independent branch 
(Figure 5.9). One of these three clustered samples had a co-occurring FLT3 mutation 
yet still matched the expression pattern of the MLL PTD positives. The PCA and the 
hierarchical dendrogram demonstrated separation of MLL PTD from the MLL WT 
samples using the significant list o f probe sets.
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Figure 5.8 Principal Component Analysis of HG-U133 Plus 2 Samples.
The samples are projected in a three-dimensional space, plotted on the basis of the 
three priniciple components that best capture the variance of the data. Each case is 
represented by a coloured sphere. The MLL PTD group (n=4) showed accurate 
separation from AML MLL WT (n=69) using 293 discriminating probe sets. Samples 
were colour coded as indicated in legend. PCA: principal component analysis; pos:, 
positive; wt: AML WT.
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Figure 5.9 Hierarchical Cluster Analysis of HG-U133 Plus 2 Samples.
Hierarchical cluster analysis of AML (n=69) samples versus 293 MLL PTD 
discriminating transcripts. Transcripts are shown by rows and samples by columns. 
The normalised expression value of the transcripts are shown, with colour coding 
representing deviation from the mean, with the higher expression in red and lower 
expression in blue. Indicated below the samples is the MLL PTD and FLT3 mutant 
classification. The purple colourings for FLT3 indicate that no data were available. 
MLL PTD abbreviations: pos, MLL PTD; wt, AML MLL WT. FLT3 mutant 
abbreviations, wt, FLT3 wild type.
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The significant gene list is composed of 293 transcripts; the top 20 transcripts 
have p-values ranging from 2.95xl0 'n to 3.1 lxlO"4 (Table 5.6). The lack of common 
genes observed between the cohorts is investigated in the selection of genes for 
validation where common genes are identified (Section Venn 5.3.12.a) and discussed 
further in Section 5.4. Further analysis of the genes identified by the significant probe 
sets is addressed later in the chapter (Sections 5.10-5.13 and 5.16). Complete lists of 
the probe sets are compiled in Appendix C.
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Affymetrix ID Common Name Gene Title GenBank Acc No. Gene GO:BP p-value(pos vs. wt) FoldChangefpos vs. wt)
242054 s at — Transcribed locus — — 2.92E-11 5.09
239552 at FLJ14712 hypothetical protein FLJ14712 NM 001135924 — 8.19E-08 2.94
205048 s at PSPH phosphoserine phosphatase NM 004577 L-serine metabolic process 7.90E-06 15.19
1557280 s at ITSN1 intersectin 1 (SH3 domain protein) . . . . . . 1.40E-05 2.10
225619 at SLAIN 1 SLAIN motif family, member 1 NM 001040153 — 1.59E-05 4.30
206634 at SIX3 SIX homeobox 3 NM 005413 eye development 3.36E-05 3.12
1555564 a at CFI complement factor I NM 000204 proteolysis 3.62E-05 2.17
205830 at CLGN calmegin NM 001130675 protein folding 5.20E-05 3.03
222462 s at BACE1 beta-site APP-cleaving enzyme 1 NM 012104 proteolysis 5.43E-05 2.20
227036 at RASAL2 RAS protein activator like 2 NM 004841 signal transduction 6.85E-05 2.02
204751 x at DSC2 desmocollin 2 NM 004949 cell adhesion 7.29E-05 2.55
206693 at IL7 interleukin 7 NM 000880 T cell lineage commitment 8.13E-05 2.69
244740 at MGC9913 Hypothetical protein MGC9913 — — 8.69E-05 3.55
243918 at — Transcribed locus — — 8.81E-05 2.18
218898 at FAM57A family with sequence similarity 57, member NM 024792 — 9.46E-05 2.17
220669 at OTUD4 OTU domain containing 4 NM 001102653 — 1.66E-04 2.48
231094 s at MTHFD1L methylenetetrahydrofolate dehydrogenase NM 015440 one-carbon metabolic process 1.81E-04 2.09
222463 s at BACE1 beta-site APP-cleaving enzyme 1 NM 012104 proteolysis 2.67E-04 2.15
244741 s at MGC9913 Hypothetical protein MGC9913 — — 2.67E-04 4.53
211429 s at SERPINA1 serpin peptidase inhibitor, clade A NM 000295 response to hypoxia 3.11E-04 -11.12
Table 5.6 Genes Differentially Regulated in MLL PTD HG-U133 Plus 2 Samples
The top 20 dysregulated probe sets representing 19 genes are listed according to their significance (p value). Fold change is given with respect 
to AML MLL WT mean expression level. Acc: accession; no: number; GO:BP: Gene ontology biological process; pos: MLL PTD; wt: AML 
MLL WT.
5.3.7 Analysis of Significant Gene Interactions
A pathway algorithm was utilised to evaluate direct interactions between the 
fifty-four genes from the combined cohort. The genes were inspected for interactions 
within the list of 54 genes, between functionally related gene groups, as well as for 
co-operation within established canonical biological pathways to gain insight into the 
molecular mechanisms contributing to MLL PTD pathogenesis. To give a biological 
context to the gene list, the pathway function of GenesSpring GX version 10 (Agilent 
Technologies Inc., Santa Clara, CA, USA) was used to search for direct gene/gene 
product interactions from within the 54 genes identified. Ten genes from the list had 
direct interactions as defined by links identified through connections in either 
literature or pathway databases. (Figure 5.10). The two up-regulated caveolin genes, 
CA VI and CA V2, encode for scaffold membrane proteins that provide a compartment 
for signalling molecules (Scherer et al. 1996). Further analysis of CAVI and CAV2 
function can be found in the Discussion Section. The most interesting interaction 
haematologically is between the brain acid soluble protein 1 (BASP1) and AML 
linked gene Wilms Tumour 1 (WT-1). BASP1 protein acts as a co-suppressor of WT-1 
through interaction with the suppression domain on the N-terminus of the WT-1 gene, 
therefore the down regulation of BASP1 observed in MLL PTD may be associated 
with the WT-1 over expression (Carpenter et al. 2004). The six contiguous proteins 
did not have strong connections with oncology, although CD59 antigen and tissue 
factor pathway inhibitor (TFPI) were associated with haematology. The down- 
regulated gene C5a anaphlylatoxin chemotactic receptor (C5Arl), is a neutrophil 
chemoattractant that transduces signals through intracellular GTP-binding proteins. 
Deficiency of C5Arl has been linked to airway hyper-responsiveness in mouse
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asthma models which suggests the promotion of an anti-inflammatory phenotype 
(Karp et al. 2000). The significance of the dysregulation of this gene to AML is 
uncertain.
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BASP1
C5AR1
MAN1A1
SERPINA
Figure 5.10 Directly Interacting Proteins from Combined Cohort
The genes/gene products are displayed as nodes and the relationships between them as 
edges. The 10 genes have direct interaction with another gene from the combined 
cohort gene list.
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5.3.8 Analysis of Significant Gene Gene Ontology
To investigate the biological purpose of the differentially regulated genes, the 
functional groups to which they are associated were identified using the web based 
gene ontology (GO) programme database for annotation, visualisation and integrated 
discovery (DAVID) (http://david.abcc.ncifcrf.gov/) (Dennis, Jr. et al. 2003; Huang, 
Sherman, & Lempicki 2009). The biological processes were ranked using the false 
discovery rate (FDR), after functional groups containing a significant number of 
genes (FDR<10%) from the gene list were identified (Table 5.7). The most common 
biological process identified by the analysis was the regulation of biological quality. 
Regulation of biological quality is defined as a process that modulates the frequency 
or rate of a measurable attribute of an organism and includes regulation of 
homeostatic processes, translational fidelity and protein stability. 5/6 of the 
contiguous genes shown in the direct interaction figure were associated with 
regulation of biological quality as well as CA VI, CA V2 and CDKN2C. There was 
considerable overlap between the groups therefore, the four other functional groups 
contained many of the same genes. The effects of these biological processes, and the 
genes implicated, requires further examination to clarify their impact on the aetiology 
of MLL PTD leukaemia.
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Gene Ontology ID Biological Process Genes Identified (%) P-Value Fold Enrichment FDR
(30:0065008 regulation o f biological quality 15 (24.6) 8.60E-08 5.81 <0.01
G0:0009605 response to external stimulus 12 (19.7) 1.40E-06 6.36 <0.01
(30:0007626 locomotory behaviour 7(11.5) 2.00E-05 12.07 0.04
(30:0009611 response to wounding 9 (14.8) 2.63E-05 7.13 0.05
(30:0007610 behaviour 8(13.1) 3.69E-05 8.33 0.07
Table 5.7 Gene Ontology Analysis of Biological Processes from Combined 
Cohort List
The top five biological processes according to FDR. GO, Gene Ontology; FDR, false 
discovery rate.
To enhance the ability to identify biologically important functional gene 
groups through interactions, the output (gene lists) from the three GeneChip cohorts 
were combined. In summary the GO:biological processes included processes 
identified previously, and indicated a link with regulation of cell proliferation; 
negative regulation of cellular processes, negative regulation biological processes and 
cell proliferation. Some of the processes identified were previously linked to 
leukaemia (Zangrando et al. 2009), however there were no common functional 
processes between the GO terms identified by the MLL PTD signature and the 
paediatric MLL translocation specific signature (Ross et al. 2004). The KEGG 
pathway database (http://www.genome.jp/kegg/pathway.html) (Kanehisa et al. 2010a) 
identified pathways related to the regulation of cell proliferation and cell cycle, but 
the findings were not statistically significant. These results and further discussion can 
be found in the appendix.
5.3.9 Expression of Genes Related to MLL Rearrangements
Members of the HOX  family, specifically members of the HOX A cluster, 
along with ME1S1 and PBX3 are consistently up-regulated in AML and ALL 
leukaemic blasts with MLL translocations ((Armstrong et al. 2002; Kohlmann et al.
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2005). Therefore expression levels of (HOX) genes and genes that complex with the 
HOX family to regulate gene expression were evaluated in this study. The MLL PTD 
significant gene list derived from the combined cohort did not align with HOX genes 
normally identified with MLL translocations, and contained only one member of the 
HOX A  cluster. The three genes identified, HOXA10, HOXB6 and HOXB7 were up- 
regulated. Furthermore, the genes MEIS1 and PBX3, which interact with the HOX 
pathways, were not differentially expressed. HOXA9 is at least partially necessary for 
the leukaemic potential of some MLL translocations, specifically MLL-ENL and MLL- 
AF10 (Ayton & Cleary 2003). Whether the difference in the HOX  expression 
suggests an alternative pathway in the leukaemogenesis of MLL PTD or is the result 
of redundancy within the HOX  gene family remains to be determined. The lack of 
MEIS1 and PBX3 expression may be evidence that a different pathway is used.
5.3.10 Class Prediction
Class prediction was used to determine if gene expression profiling could 
accurately predict the MLL PTD status of a sample. Accurate prediction of MLL PTD 
by microarray analysis could lead to its inclusion in the armoury of AML diagnostic 
tests. The model selection application from Partek Genomic Suite tested the 
effectiveness of four models of class prediction with the differentially regulated sets 
of identified genes from the three cohorts. None of the tests revealed a gene signature 
that could be used to accurately predict MLL PTD samples in any of the prediction 
models tested (results from the support vector machine method (SVM) are shown in 
Table 5.8). This was most likely due to the small number of positives samples and the 
corresponding heterogeneity of expression. A similar failure of class prediction was
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reported previously in a paediatric AML study where the gene signature was 
established from a combined group of MLL PTD and MLL translocation samples 
(Ross et al. 2004).
# Per Class Proportion # Correct
#
Errors % Correct
%
Error
Std.
Error
pos 7 0.04 0 7 0 100 0.00%
wt 163 0.96 163 0 100 0 01)0%
The Average 50 50
Total 170 1 163 j 95.88 4.12 1.52%
Kappa=0.UUOO
Table 5.8 Classification Summary for Support Vector Machine Model
An example of class prediction results made using the SVM model with the combined 
cohort samples.
5.3.11 Connectivity Map Analysis
The differentially expressed genes from the combined cohort were used as a
template to identify compounds that may be potentially beneficial to MLL PTD AML
patients. The dysregulated genes associated with a mutation can identify potential
target areas for therapeutic intervention by revealing unique pathways necessary for
leukaemogenesis. Therapeutic drugs that may reverse or repress MLL PTD were
identified using the web based tool, Connectivity Map (CMAP)
(http://www.broadinstitute.org/CMAP/) (Lamb et al. 2006). CMAP connects up- and
down-regulated genes of interest with a database of gene expression profiles derived
from human cell lines treated with over 1,300 compounds; this enables the
identification of agents that produce the same or the inverse of the expression
signature (Lamb et al. 2006). When administered to human cell lines, three drugs,
tanespimycin, trichostatin A and vorinostat, effectively produced an inverse of the
MLL PTD gene signature (Table 5.9). The composite analysis of all instances
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examined for these three drugs showed negative enrichment scores, meaning they 
produced the inverse of the gene signature template and may be useful for the reversal 
of AML. The one instance of significant positive enrichment, (i.e. a treated cell line 
with a similar gene signature) for tanespimycin involved the cell line HL60, an MLL 
PTD negative promyelocytic cell line. However, the CMAP specificity table, which 
determines how many of 312 published gene signatures scored higher (if positively 
enriched) than the gene signature of interest, demonstrated that the majority of AML 
derived GEPs were associated with the negatively-enriched cell lines, therefore the 
results bear further investigation.
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Rank___________ Drug Name___________  Cell Line Mean n Enrichment P-valuc Specificity
1 tanespimycin HL60 0.405 12 0.726 <1.00E-05 0.0756
2 trichostatin A MCF7 -0.433 92 -0.421 <1.00E-05 0.4654
3 wortmannin MCF7 0.549 10 0.708 2.00E-05 0.0915
4 dapsone MCF7 0.82 2 0.99 1.40E-04 0
5 tanespimycin MCF7 -0.349 36 -0.355 1.60E-04 0.4098
6 phenoxybenzamine MCF7 -0.797 3 -0.955 2.20E-04 0.0092
7 vorinostat MCF7 -0.562 7 -0.733 2.20E-04 0.2136
8 trichostatin A PC3 -0.309 55 -0.276 3.40E-04 0.7356
9 decamethonium bromide MCF7 0.771 2 0.985 4.00E-04 0
10 khellin MCF7 0.8 2 0.98 7.00E-04 0
Table 5.9 Connectivity Map Analysis of Combined Cohort Significant Gene List
The top ten identified drugs are listed according to their p-value. n: number.
Tanespimycin, also known as 17-AAG, is an antineoplastic antibiotic that 
inhibits the protective chaperone activity of the heat shock protein 90 (.HSP90), which 
binds to many known oncogenic signalling proteins (Al et al. 2008). Therefore, 
tanespimycin promotes degradation of the oncogenic proteins over expressed in 
tumour cells. Trichostatin A and vorinostat inhibit HDACs resulting in 
hypereacetylated histones which alter chromatin configuration and ultimately gene 
transcription. HDAC inhibitors (HDACi) cause differentiation, growth arrest and 
apoptosis of cells in vitro and inhibit tumour proliferation in animals (Marks et al 
2001). Tanespimycin and the HDAC inhibitors are compounds with potential to be 
effective in a leukaemic setting (Section 5.4).
5.3.12 Identification and Validation of GOI
5.3.12. a Genes o f Interest Chosen by Venn Diagram Intersection
Due to the scatter of the MLL PTD samples seen in the PCA and dendrogram analysis, 
the genes demonstrating reproducible differential expression in the significant probe 
lists of all three cohorts were chosen for further analysis. To accomplish this, a Venn 
diagram was created using the three significant probe set lists generated from the
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three groups of samples. Nine probe sets were found in the overlap between the three 
cohorts (Figure 5.11). These nine probe sets were reproducibly detected through two 
independent batches of samples and on separate Affymetrix GeneChip types. The 
nine probe sets identified by all three groups were marked as potential validation 
genes and candidates for further study as markers for MRD (Figure 5.12).
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Combined Cohort
HG- U133A HG-U133 Plus 2
Figure 5.11 Identification of M LL  PTD Dysregulated Probe Sets
Probe sets identified from HG-U133A, HG-U133 Plus 2 and the combined cohort. 
Numbers indicate how many probe sets were identified in the intersection. Nine 
discriminating probe sets were common to all three cohorts. The intersections are not 
to scale.
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HCPCA
7 genes identified
6 genes used for validation
9 probe sets
Figure 5.12 Flow Chart Depicting Gene of Interest Analysis Process
The nine probe sets were complementary to seven genes, six of which were used for 
validation of gene expression data. PCA: principle component analysis; HC: 
hierarchical component analysis.
PCA mapping using these nine transcripts was performed to determine if MLL 
PTD samples could be discriminated from the AML MLL PTD negative samples. 
Although not as compact as in previous PCA maps, the MLL PTD samples were 
separated from the majority of the other samples and all occurred in one quadrant
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(Figure 5.13). Hierarchical clustering showed a similar scenario (Figure 5.14) with 
the MLL PTD positives on one half of the dendrogram. Three of the samples were 
grouped into the first two divisions in the dendrogram, showing that they are unique 
to the others and have similar expression levels within the group of nine.
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PCA Mapping <67.1%)
MLL PTD
•C #£13.7%
Figure 5.13 Principal Component Analysis of the Combined Cohort Using the 
Significant Probe Sets Identified
The samples are projected in a three-dimensional space, plotted on the basis of the 
three principal components that best capture the variance of the data. Each case is 
represented by a coloured sphere. The MLL PTD group (n=7) showed accurate 
separation from AML MLL WT (n=162) using the 9 discriminating probe sets 
identified as common between HG-U133A, HG-U133 Plus 2 and the combined 
cohort. Samples were colour coded as indicated in legend.
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Figure 5.14 Hierarchical Cluster Analysis of Combined Cohort Using 9 
Significant Probe Sets.
Hierarchical cluster analysis of AML (n=162) samples versus 9 MLL PTD 
discriminating probe sets. Probe sets are shown by rows and samples by columns. 
The normalised expression value of the probe sets are shown, with colour coding 
representing deviation from the mean, with the higher expression in red and lower 
expression in blue. Indicated below the samples is the MLL PTD and FLT3 ITD 
classification. The green colourings for FLT3 indicate that no data were available.
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5.3.12.b Analysis o f  Validation Gene Probe Sets
The nine probe sets identified as the most reliably associated with MLL PTD 
samples are complementary to 7 different genes (Table 5.10A). The design of the 
Affymetrix human genome chips resulted in multiple probe sets being created for 
different splice variants of the same gene. This reduced the risk of missing 
differential expression due to gene variation, but also created the potential for 
different probe sets of the same gene to record different expression levels. To gauge 
the confidence of the result, the number of potential probe sets for each gene was 
determined, along with whether it was detected in a gene list. A greater number of 
potential probe sets identified in combination with high differential expression 
increased the confidence of the result (Table 5.1 OB). The groups from high to low 
stringency are the Venn intersection list, the combined cohort list of 65 significant 
genes with >2 fold expression and lastly either the HG-U133A or HG-U133 Plus 2 
gene list with <2 fold expression. The multiple probe sets of all genes were detected, 
to a minimum level of p<0.05 and >1.2 fold expression. Identification of multiple 
probe sets supported the use of these genes for validation studies. Several of the 
genes are reported to have an association with the promotion of an oncogenic 
phenotype including CAV1, CAV2, CDKN2C, ENPP2, TPD52 and TWIST 1. 
Expanded examination of the genes identified can be found in the Discussion.
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Affymetrix ID Common Name Venn Intersection Expression >2 Fold
Expression >2 
Fold
212097 at CAV1 Y Y n/a
203065 s at N N Y (1.77)
203324 s at CAV2 Y Y n/a
203323 at Y Y n/a
204159 at CDKN2C Y Y n/a
211792 s at N N Y (1.3)
208923 at CYFIP1 Y Y n/a
210839 s at ENPP2 Y Y n/a
209392 at Y Y n/a
201690 s at TPD52 Y Y n/a
201689 s at Y Y n/a
201688 s at N Y n/a
201691 s at N N Y (1.2)
213943 at TWIST 1 Y Y n/a
Table 5.10 Differential Expression of Genes and Assessment of Value as Discriminator for MLL PTD
A) The nine dysregulated probe sets representing seven genes are listed according to (p value). Fold change and p-value are given with respect 
to the combined cohort values calculated. Fold change is given with respect to AML MLL WT mean expression level. B) The probe sets for 
each gene are indicated as present or absent for three categories of decreasing stringency; the Venn intersection of probe sets for all three 
cohorts, the combined cohort list of probe sets > 2 fold expression and the combined cohort list of probe sets < 2 fold expression.
5.3.12.C Selection o f Positive Controls Cell Lines for Validation Genes
Six of the seven genes common to all cohorts were selected to validate the 
Affymetrix expression data by correlation with expression levels determined by RQ- 
PCR analysis. CAVI was not used for validation due to its similarity in expression 
and function to CAV2. Affymetrix HG-U133A data were used to locate cell lines as 
positive controls for the RQ-PCR validation. The probe sets for the GOIs were 
screened for increased expression levels in seven leukaemic cell lines previously 
analysed on the microarray GeneChip. After normalisation the expression levels 
given for each cell line were rated as either absent, marginal or present for the probe 
set in question. The present or absent call was based on the comparison of sample 
hybridisation levels to the matched and mismatched probes that make up the probe 
set. This rating prevents non-specific hybridisation from being misinterpreted as a 
high expression level. An example of the results is shown for the gene TWIST1 
(Figure 5.15). In this example, six of the cell lines were rated as absent for the gene 
and one as present. The transcript for TWIST 1 was evident in the cell line NB4-R2. 
Interestingly its expression was significantly higher (p=0.028) than the expression 
levels in the other cell lines which included NB4, the cell line from which NB4-R2 is 
derived. NB4 is a commonly used cell line in the study of APL, and has been used to 
derive a number of drug resistant cell lines (e.g. NB4-R2) (Roussel & Lanotte 2001). 
ATRA (all-trans retinoic acid) causes NB4 to undergo granulocytic maturation 
whereas NB4-R2 cells are unresponsive due to a point mutation in the retinoid- 
binding domain of PML-RARa (Duprez et a l 2000). TWIST1 is a transcription factor 
associated with drug resistance in breast cancer, so could potentially be connected 
with the drug resistance acquired by the NB4-R2 cell line. Three other cell lines also
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showed up-regulation of one or more of the genes of interest (Table 5.11). These four 
cell lines were chosen as the controls for the RQ-PCR validation.
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Figure 5.15 Differential TWIST1 Expression in a Selection of Leukaemic Cell 
Lines.
Expression of TWIST 1 is significantly up-regulated in NB4-R2 (p=0.028) relative to 
other cell lines.
Cell Line Gene(s)
KG1 ENPP2
NB4-R2 TWIST1
K562 CAV2, CYFIP1, CDKN2C
HL60 TDP52
Table 5.11 Positive Control Cell Lines for RQ-PCR Validation
Gene expression analysis results identified four leukaemic cell lines with up 
regulation of the six genes of interest.
5.3.12.d RQ-PCR Optimisation o f  Validation Genes
The cell lines identified as positive controls were used to confirm the efficacy 
of the PCRs and optimisation of PCR conditions. All six of the genes expressed in 
these cells successfully amplified PCR products using the initial reaction conditions, 
with sufficient levels of quality as determined by slope, Cp value and fluorescent 
intensity to make further optimisation unnecessary. The Cps of all of the genes are 
shown in Table 5.12. The range of the Cps in the cell lines varies between 18.9 for 
CAV2 and 24.9 for TWIST 1 and is a result of the expression level of the genes and the
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efficiency of the RQ-PCR assays. All of the assays, apart from TWIST7, showed low 
levels of non-specific amplification in H2O with a minimum Cp of 35. The non­
specific amplifications were 12.7-21.2 Cp away from the specific GOI Cp values, 
equivalent to 3.8-6.4 log difference (assuming an efficiency of 2 and 3.3 cycles is 
equivalent to one log change in template concentration) and the Tm values were 
different from the cDNA samples. Due to their different Tm values and appearance at 
cycle numbers >35, the non-specific amplifications should not adversely affect the 
performance or analysis of the RQ-PCR assays. The difference in the level of 
expression for TWIST 1 between the cell lines NB4 and NB4-R2 observed in the 
Affymetrix data was supported by the RQ-PCR results. TWIST 1 expression is 
calculated to be 3.2 fold higher in NB4-R2 than NB4 using ACp values. The identity 
of the amplicons was confirmed by size comparison. Gel electrophoresis sizing of all 
of the amplicons, including ABL, matched the predicted sizes from primer 3 (Figure
5.16).
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Gene Cell Line Avg Cp Avg Tm
CAV2 K562 18.9 90.5
CDKN2C K562 20.5 85.4
CYFIP1 K562 21.1 87.9
ABL K562 17.4 88.9
ENPP2 KG1 24.3 88.0
ABL KG1 20.0 89.3
TPD52 HL60 21.1 86.8
ABL HL60 19.8 88.9
TWIST 1 NB4-R2 24.9 92.3
ABL NB4-R2 20.6 88.8
TWIST 1 NB4 33.8 92.3
ABL NB4 19.6 88.8
Table 5.12 Gene Expression Levels in Positive Controls (RQ-PCR)
Average crossing points and Tm of validation genes (in duplicate) as well as control 
gene ABL for each positive control cell line. Avg: average; Cp: crossing point; Tm: 
temperature of melting.
CDKN2C ENPP2 TWIST1
M CAV2 CYFIP1 TPD52 ABL
400 —  
300 —
200 —  
100 —
Figure 5.16 Analysis of RQ-PCR Amplicon Size.
The amplified RQ-PCR products were run on an agarose gel to confirm base pair 
length. All products were the size predicted by the primer design and Blast analysis. 
M: marker.
5.3.12.e Test for Non-Specific Amplification ofDNA
To prevent the possibility of DNA contamination being misinterpreted as 
RNA expression, all primer pairs were tested for the ability to amplify DNA. The 
standard conditions of amplification were used to amplify 5ng of DNA. All samples 
amplified the DNA sample with different levels of efficiency; the lowest, most 
efficient value was CAV2 at Cp=20 and the highest was ABL at Cp=33.9 (Figure
5.17). Two of the six genes, CAV2 and CDKN2C, produced DNA Tm values that 
were different than the values produced from the RNA samples, which would make 
any DNA amplification recognisable. The remaining four genes could potentially 
have DNA contamination misinterpreted as expression of RNA. To prevent mistakes 
of this sort, all samples were pre-screened for the presence of DNA contamination 
before RQ-PCR analysis. CAV2 was chosen as the primer to test for DNA 
contamination in all RNA samples due to its higher comparable efficiency at 
amplifying DNA. A “mock” RT reaction was performed with all conditions and 
reagents as normal except that the reverse transcription enzyme was excluded, thus 
preventing the production of cDNA. The standard conditions of the RQ-PCR assay 
were followed and the results were analysed for the presence of DNA. Although 
some amplification was observed, it was non-specific, irreproducible and had Cp 
values of 35 and higher. All samples used in the RQ-PCR assays were tested prior to 
analysis and found to be free from DNA contamination.
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Figure 5.17 Quantification ofDNA Amplification
The Cp ofDNA amplification are indicated by green bars, DNA Tm by blue bars and 
cDNA Tm by purple bars. The value of the Cp is inversely related to the amount of 
RQ-PCR product amplified, therefore CAV2 and CYFIP1 amplify DNA most readily. 
; Cp: crossing point; Tm: melting temperature.
5.3.12.f  Establishing RQ-PCR Efficiency
An accurate assessment of gene expression level by RQ-PCR requires
comparable efficiencies between the target gene and the control gene, as discussed
previously in Chapter 3. In order to compare the efficiencies, the cDNAs of all of the
control cell lines were analysed neat and with 4 serial dilutions of 1:10 to establish the
slope of amplification over a range of template concentrations (Figure 5.18).
Differences in amplification due to the concentration of the PCR reagents were
prevented by diluting the cDNAs into a solution of RT master mix ensuring that the
concentration was the same for the neat sample as it was for the dilutions. Each cell
line was amplified using the primers for the control gene ABL and the appropriate
GOI and then the resulting slopes were compared (Figure 5.19 a-f). The Tm values of
all amplifications were checked to verify the specificity of the amplification; samples
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with Tm values that corresponded to non-specific amplification were excluded from 
the slope calculation. All QPCRs amplified successfully down to the 1:1000 dilution. 
Non-specific Tms caused the final 1:10,000 dilution points to be excluded for ENPP2, 
TWIST1, CYFIP1, and TPD52. These four genes that only amplified to the 1:1,000 
point had neat Cp values >21 while the neat Cp values of the two genes that amplified 
to 1:10,000 were <21. This suggested the neat Cps with the lowest initial value had 
greater sensitivity, most likely due to a combination of primary expression level of the 
gene in the cell line and the amplification efficiency of the RQ-PCR.
The slope of a PCR used for the purpose of quantification should fall within 
the range of -3.9 and -3.0 and have a coefficient of determination (i.e. a measure of 
the association between the dilution points and the calculated trend line) of >0.95 
(Van, V et al. 2003b). The R2 values for the GOIs and ABLs were 0.98 or higher and 
the slopes of the GOIs ranged from a low of —4.0 for CAV2, CYFIP1 and TPD52 to a 
high of -3.5 for CDKN2C. The lack of variation in the slope of ABL, 3.6-3.7, in the 
four different cell lines demonstrated reproducibility, as the efficiency would not be 
expected to change due to the origin of the cDNA. The difference in values of slope 
between the target genes and the control gene were acceptable for the purposes of 
quantifying RNA expression levels for validation.
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Figure 5.18 Light Cycler Amplification of CDKN2C Serial Dilution
A) Real time Syber Green fluorescent history was plotted against the cycle number of 
serially diluted CDKN2 cDNA (10°, 101, 10'2, 10'3, KT4). The duplicate dilutions 
amplified reproducibly across the range of dilutions. B) Fluorescent history versus 
temperature. The negative derivative of fluorescence over time was plotted against 
temperature to calculate the melting temperature of the PCR products. All products 
recorded a consistent Tm and the negative control did not amplify.
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Figure 5.19 Validation Gene Efficiency
The Cp of the RQ-PCR is plotted against the log of the dilution for the GOI and the 
control gene ABL. The R squared value represents the level of correlation between 
the plotted values and the slope indicates the level of RQ-PCR efficiency. Cp, 
crossing point.
5.3.12.g Strategy fo r  RQ-PCR Validation
The validation of the genes selected by gene expression analysis was
performed by comparing the relative expression levels of the microarray results with
results from RQ-PCR analysis. All microarray samples with available material were
selected for analysis: 3 MLL PTD, 9 AML MLL PTD WT (CN), and 4 healthy control
samples. Twelve more samples were analysed at the same time as the validation
studies to screen for potential MRD markers and to increase the numbers in the MLL
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PTD and donor groups, making a total of 28 samples. The details of the samples 
chosen for MRD studies are given in Section 5.3.13.a. Considerations were made to 
ensure the RQ-PCR measurements recorded for each of the GOIs were consistent over 
time. All samples were tested from the same batch of cDNA and each GOI was 
assayed using the same master mix. The samples with specific amplification of both 
the control gene and the target gene were analysed with the following formula to 
calculate the ACp.
ACp=CpGorCp^s£ [5.1]
Where Cp=crossing point, Cpooi= crossing point of the GOI RQ-PCR and 
Cp^5Z=crossing point of the ABL RQ-PCR. The ACp is the crossing point of the GOI 
normalised by subtracting the crossing point of the control gene, ABL. This 
normalisation corrects for different efficiencies of cDNA synthesis and amount of 
starting template and produces a normalised description of expression level that can 
be used to compare different samples.
The ABL RQ-PCR was the first assay to be performed from the cDNA and 
then used for all subsequent calculations. To ensure that the first ABL assay was valid 
for use over the time period that the tests took place, it was repeated after all the 
assays were completed. The mean difference between the Cp of the samples of the 
first ABL run and the last ABL run was 0.29+0.23, (n=28). The small difference 
supported the hypothesis that the expression levels calculated by RQ-PCR were stable 
over time.
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5.3.12.h Correlation o f  RQ-PCR and Microarray Expression Levels
The expression levels determined from the microarray analysis were compared 
with the ACp values determined by RQ-PCR, to validate the expression levels of the 
genes of interest. The six genes chosen for validation were all up-regulated; with ACp 
value inversely related to the amount of expression, the correlation between the RQ- 
PCR and microarray data should also be inversely correlated, giving a negative slope. 
Five of the six genes had an r value of less than -0.637 and showed significant 
correlation (p<0.05) between RQ-PCR and microarray expression levels (Table 5.13). 
The correlation plots for all of the GOIs are shown in Figure 5.20. Only CDKN2C 
showed a lack of correlation, with an r value of -0.416 and non-significant p value. 
The r and p values of the correlation studies indicated overall agreement between the 
RQ-PCR and microarray expression levels thus validating the microarray analysis.
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Figure 5.20 Correlation of Validation Gene Expression Levels Determined by 
RQ-PCR and Affymetrix M icroarray
Correlation between the level of gene expression calculated by RQ-PCR and 
microarray. RQ-PCR delta Cp values are plotted against the Affymetrix microarray 
results. The R squared represents the level of correlation between the values. The 
Delta Cp value is inversely related to the microarray data therefore correlation should 
be represented by a negative slope. Cp, crossing point.
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Gene Nam e r  Value P value
CAV2 -0.637 0.008
CDKN2C -0.416 0.109
CYFIP1 -0.814 0.0001
ENPP2 -0.685 0.0034
TPD52 -0.727 0.0014
TWIST 1 -0.675 0.0041
Table 5.13 Correlation of Validation Gene Expression Levels Determined by 
RQ-PCR and Affymetrix
The R value and p values for the correlation of expression levels. All genes except 
CDKN2C show a significant correlation.
5.3.13 Analysis of GOIs as MRD Markers
5.3.13.a Identification o f  Potential MRD Markers
The RQ-PCR analysis of the three sample groups, MLL PTD, CN AML MLL
PTD WT and healthy controls were used to identify potential MRD markers. The
samples selected were nine diagnostic bone marrow AML samples positive for MLL
PTD, plus one duplicate peripheral blood, ten diagnostic bone marrow samples from
normal karyotype AML (MLL WT) and eight bone marrow samples from healthy
donors. Where possible, the normal karyotype AML (.MLL PTD WT) samples which
had follow up samples available were selected preferentially to enable MRD studies.
The representation of GOI expression level as ACp meant that the lower points
on the y-axis indicated higher expression of the gene. Only two genes CYFIP1 and
TPD52, showed a significant difference in expression (p=0.0001 and 0.0007
respectively). CYFIP1 was significantly up-regulated in the MLL PTD group when
compared to the AML MLL WT (p<0.05) and the healthy control group (p<0.001)
(Figure 5.21 and 5.22). The difference between the MLL PTD and the healthy donor
group indicated CYFIP1 was a candidate MRD marker gene. TPD52 was down-
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regulated in the AML MLL WT compared to the healthy controls (p<0.05) and MLL 
PTD (p <0.01). Interestingly, there was no significant difference between the MLL 
PTD and the donor groups (p>0.05). Based on the significant transcript levels 
determined from the RQ-PCR results, CYFIP1 was the only gene that showed 
potential as a marker for MRD for the MLL PTD positive samples.
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Figure 5.21 Gene Expression of Validation Genes in MLL PTD, CN AML MLL 
WT and Healthy Controls
The gene expression results from the RQ-PCR assay are plotted as a column scatter 
plot and with a box and whiskers graph indicating the mean and 95% confidence 
interval. The delta Cp is inversely related to the level of gene expression detected, 
therefore the lower the point the higher the expression. A) CAV2, B) CDKN2C, C) 
CYFIP1. See following page., D) ENPP2, E) TPD52, F) TWIST 1.
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Figure 5.22 Gene Expression of Validation Genes in MLL PTD, CN AML MLL 
WT and Healthy Controls
The gene expression results from the RQ-PCR assay are plotted as a column scatter 
plot and with a box and whiskers graph indicating the mean and 95% confidence 
interval. The ACp is inversely related to the level of gene expression detected, 
therefore the lower the point the higher the expression. A) ENPP2, B) TPD52, C 
TWIST 1.
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The selection of candidate MRD markers was based on the difference in 
expression levels between diagnostic AML samples and healthy donor samples. The 
heterogeneity of AML in both MLL PTD and AML NK disease was apparent in the 
RQ-PCR results as a large variance in the expression levels. To investigate the 
possibility that this variance represented different subsets of MLL PTD positive 
samples with different expression profiles, additional samples were selected for MRD 
analysis. From the cohort of CA V2 samples, there were 5/8 that exhibited expression 
levels below the 95% confidence interval of the healthy controls and had follow up 
material available; one AML MLL WT and four MLL PTD. Similarly, 3/7 samples 
outside the 95% confidence interval of ENPP2 had follow up material and were 
chosen; two AML MLL WT and one MLL PTD. The samples in the TWIST1 assay 
with low ACp values (high expression) did not have follow up samples available so no 
further analysis was possible. These selected samples along with the CYFIP1 cohort 
with follow ups were assayed for use as MRD markers.
The expression levels of the validation genes from the microarray data were 
examined to explore the reason for the lack of significance between groups in the RQ- 
PCR results, after significant correlation between the results of the common RQ-PCR 
and microarray samples. Dot plots of patient samples were made for the GOIs to 
show the relative levels of expression for the AML MLL PTD WT versus the MLL 
PTD; expression of CYFIP1 and CAV2 are shown as examples (Figure 5.23). There 
was less overlap between the two groups for CYFIP1 than the other GOIs, which is 
comparable to the result seen in the RQ-PCR assay. The plots for selected probe sets 
showed that the RQ-PCR accurately represented the varied expression levels of the 
MLL PTDs, with the overlap between the two groups clearly seen in all examples.
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Figure 5.23 Dot Plot Comparison of MLL PTD and AML MLL WT Microarray Gene Expression Levels
The log 2 of the gene expression level for MLL PTD and AML MLL WT samples are plotted with each point representative of a patient sample. 
The scales of the two plots are different. The mean and 95% confidence interval are indicated on the box and whisker plot. Pos: MLL PTD; wt: 
AML MLL WT
5.3.13.b Correlation o f MRD Methods
The MRD status of 10 AML patients, 7 with MLL PTD and 3 normal karyotype was 
monitored longitudinally to assess the value of RQ-PCR for detecting low levels of disease 
and predicting relapse. The results of the GOI RQ-PCR assays were compared against the 
standard measures of MRD that were available to each patient (BM morphology, 
immunophenotyping and cytogenetic analysis) to prove correlation with existing methods, to 
compare sensitivity and to determine if early detection of relapse was possible. The clinical 
characteristics of these patients have been discussed previously (Chapter 4, Section 4.2.20). 
The results of the BM morphology report were used to determine remission with the WHO 
criteria of <5% blasts defining morphological remission. Relapse (>5% blasts) was also 
determined from analysis of the BM morphology. Comparison of CYFIP1 data from RQ- 
PCR and the standard MRD methods gave broadly concordant results; 11/12 MLL PTD 
follow ups and 2/3 CN AML follow ups moved in parallel to the alternative MRD 
measurement given. Figure 5.24 shows an example of ACp values for CYFIP1 in comparison 
to the MLL PTD ACp values calculated for the same samples. The CYFIP1 values mirror the 
results given by MLL PTD but have a much lower expression level than MLL PTD. So, 
despite the success in following the trend, the limited dynamic range of the assay in the 
samples tested makes interpretation difficult and would limit the usefulness of CYFIP1 as a 
marker for MRD. The results of the RQ-PCR for CA V2 were equivocal; 4/7 MLL PTD and 
0/1 CN AML samples successfully tracked the standard MRD results. As with the CYFIP1 
data, the limited dynamic range made interpretation difficult; the proximity of the positive 
ACp values to those of the healthy donor samples could easily cause a negative sample to be 
designated positive, and vice versa. ENPP2 showed more promise as an MRD marker as the 
RQ-PCR data matched the standard MRD results in all samples (2/2 MLL PTD and 2/2 CN 
AML) yet the sample number was limited. The diagnostic range of ENPP2 was wider than
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either CYFIP1 or CAV2, but narrower than MLL PTD, reaching a >llog difference between 
the MLL PTD and healthy control samples. Unfortunately, this larger difference between the 
ACp values was only observed for a subset of the samples tested making it unhelpful as a 
universal marker. Despite the potential promise of new MRD markers, none of the genes 
tested were deemed acceptable due to limitations in sensitivity or numbers of target patients.
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Figure 5.24 Timecourse MRD Analysis of Patients Using CYFIP1 and MLL PTD
The expression levels of three patients are for MLL PTD (blue) and CYFIP1 (purple) plotted 
over the time course of treatment. ACp is inversely related to gene expression so lower values 
indicate higher levels of transcript. For a better comparison between the expression levels 
between the genes, all CYFIP1 values have been multiplied by 2.
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5.4 Discussion
Gene expression profiling using DNA microarrays has been employed to gain a 
greater understanding of the biological mechanisms underlying the different types of AML. 
Unique gene signatures have been identified for established prognostic subgroups, and 
furthermore, signatures for novel subgroups that were undistinguishable prior to microarray 
analysis have also been identified (Bullinger et al. 2004; Bullinger et al. 2007; Metzeler et al. 
2008). Cases of AML with MLL rearrangements were found to have distinct gene signatures 
that could be used to discriminate this population, however the MLL PTD was seldom 
included in these studies (Kohlmann et al. 2005; Zangrando et al. 2009). The MLL PTD is 
exceptional among rearranged MLLs because there is no fusion with an external partner gene; 
instead an internal duplication retains all of the regulatory domains. In this study, a 
comparison between the gene expression profiles of MLL PTD and AML MLL WT cases 
defined a unique gene signature that was then used in conjunction with downstream 
applications to further our understanding of this disease.
For the first time, a gene signature was defined that separated the MLL PTD samples
from AML MLL PTD WT (Table 5.4., Appendix C). Previous studies were unable to
establish a characteristic gene signature, possibly due to smaller cohort sizes analysed, n=20
(Rozovskaia et al. 2003) and n=116 (Bullinger et al. 2004), compared to 162 in this study.
However, one study using a similar number of samples in paediatric AML (n=150) also failed
to find discriminating MLL PTD genes (Ross et al. 2004). Two possible explanations are
inherent differences between paediatric and adult AML and differences resulting from PCR
sensitivity. The PCR conditions used in the paediatric study produced a 2 fold higher
incidence in MLL PTD positives than observed in this study, therefore the characteristics of
the positive population identified was likely to be different. Nevertheless, molecular
heterogeneity in my study was noticeable by the broad PCA clustering of the MLL PTD group
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in the combined cohort. This loss of unity may be due to the limitations of the Batch Remove 
programme or to the heterogeneity of the seven samples analysed. In the PCA, samples from 
each of the GeneChips did not cluster together, appearing inside and outside of the AML MLL 
WT ellipsoid. This indicated the scattered grouping was most likely due to sample 
heterogeneity and not heterogeneity resulting from differences between the two GeneChips. 
Larger sample size may help to determine whether this reflected the stages of differentiation 
and cell types represented by FAB or specific subsets within the MLL PTD population.
Analysis of the gene signature demonstrated a difference in the genes regulated in 
MLL PTD AMLs and AMLs with MLL translocations. Noticeably absent from the MLL PTD 
significant gene list were genes reported to be up-regulated in MLL translocated samples 
including MEIS1, PBX3, and members of the HOX  A cluster (HOXAA, HOXA5, HOXA1, 
HOXA9 and HOXA10) (Kohlmann et al. 2005), with the only exception being the expression 
of HOXA 10. This supported previous results observed in a small-scale study done using the 
GeneChip that was the predecessor to HG-U133A and another in paediatric AML where little 
to no similarity existed between the gene MLL PTD and MLL translocations (Rozovskaia et 
al. 2003)(Ross et al. 2004). Alternatively, redundancy of function within the HOX  genes may 
enable HOXA10 expression to replace the functions of the other HOX  genes making this 
difference inconsequential. The expression of HOX.A10 restored HOX function in early 
haematopoietic progenitors with reduced HOXA, B and C gene expression due to the absence 
of MLL (Ernst et al. 2004b). Absence of the HOX  co-factors MEIS1 and PBX3 make this 
unlikely. The lack of HOX  family expression is in contrast to reported upregulation of 
HOXA1, HOXA9 and H O XA\0  in the BM of MLLPTD/WT mice (Dorrance et al. 2006). 
However, the MLL?TDIWT mice did not develop leukaemia, so this may represent a pre- 
leukaemic stage that would require a second mutation for progression and may not be 
representative of the final gene signature of the disease. The retention of the carboxy terminal 
end of the protein is the sole consistent difference between MLL PTD and the other rearranged
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MLLs, and this may be a factor causing the difference in expression patterns. The partner 
genes in translocated MLLs replace two important regions in the MLL gene, the region 
containing the transactivating potential of the PHD and the SET domain, which directs 
histone methylation. The differential regulation of genes supports the hypothesis that the 
leukaemogeneis of MLL PTD operates via a different set of pathways to the other rearranged 
MLLs.
The seven genes identified for validation were reproducibly selected in the significant 
gene lists of the three sample cohorts illustrated by Venn diagram. Some of the possible 
reasons for the small number of probe sets (10) identified between the HG-U133A and HG- 
U133 Plus 2 groups were the different number of samples and the differences between the 
expression levels of the positives in each cohort. As expected, a higher number of probe sets 
were found in the intersection between the combined cohort group and the HG-U133A and 
HG-U133 Plus 2 GeneChips with 32 common probe sets found for each.
Comparison of MLL PTD gene signatures in this study identified 7 genes that showed 
reproducible statistical significance in multiple cohorts. The majority of these genes 
including CAVI, CAV2, CDKN2C, ENPP2, TPD52 and TWIST 1, demonstrate an association 
with cancer and drug resistance. CA VI has been implicated in a number of different types of 
cancer and may interact with the drug resistance protein MDR1 in diagnostic AML samples 
(Hatanaka et al. 1998; Mercier et a l 2009). Expression levels of CA VI have been positively 
correlated with the expression level of the multidrug resistance-1 (MDR-1) gene in diagnostic 
AML samples. The products for the genes are localised to the plasma membrane and the 
correlation of gene expression suggests the proteins may interact (Pang, Au, & Kwong 2004). 
In contrast, this study did not observe significant overexpression of the MDR-1 gene in any of 
the cohorts studied, so the possibility of this potential interaction in the context of MLL PTD 
is unlikely. TWIST1 and ENPP2 are associated with drug resistance in breast cancer, and 
TWIST 1 is also linked to prometastatic behaviour (Li et al. 2009; Vidot et al. 2010; Watson et
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al 2007). Over expression of TPD52 has been identified in breast, prostate and ovarian 
cancers and its use as a potential tumour antigen target in a breast cancer vaccine for mice 
resulted in enhanced survival (Balleine et al. 2000; Byme et al 2005; Mirshahidi et a l 2009; 
Ummanni et al 2008). The up-regulation of CDKN2C, a regulator of cell cycle progression, 
was not validated by RQ-PCR correlation, so may not be a downstream target of MLL PTD. 
Nevertheless, CDKN2C is a downstream target for the MLL gene (Milne et al 2005). Gene 
ontology analysis revealed regulatory functions in cellular processes, biological regulation 
and the response to stimuli, when the genes from all significant lists were combined. Further 
exploration of the roles of these genes in a leukaemic setting, ideally primary patient cells, 
may determine if they are functionally important to the pathogenesis of MLL PTD.
Over expression of WT-1, a purported marker for AML, was observed in the pathway 
of interacting proteins (Section 5.3.7). Over-expression of WT-1 occurs in a high percentage 
of AML cases (Garg et a l 2003b; Menssen et a l 1995; Sugiyama 1998) and was also noted 
in Chapter 3 of this study. Significant over expression of WT-1 in MLL PTD in comparison to 
the already high level observed in AML has not been seen previously. To determine whether 
this association is instrumental in the leukaemogenesis of MLL PTD would require a greater 
number of samples and functional studies of the two genes in an in vitro or in vivo leukaemia 
model.
An objective of this study was to evaluate the potential of significant genes for use as 
markers of MRD. RQ-PCR assays compared the ACp of MLL PTDs, CN AMLs and healthy 
donors for all GOIs. CYFIP1 demonstrated a significant up-regulation in all MLL PTD 
samples compared to either CN AML or healthy donors. Expression of the CYFIP1 gene was 
assessed for use as an MRD marker along with 8 MLL PTD positive samples that exhibited 
clear separation from the healthy donors in other genes (CAV2 and ENPP2). CYFIP1 
exhibited a low dynamic range that offered no improvement on existing methods, CA V2 also 
had a low dynamic range as well as equivocal results and ENPP2 usefulness appeared to be
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limited to a small number of patients. Despite correlation with clinical data, none of the genes 
were identified as candidate genes for use as MRD markers.
The lack of significant changes in the other genes was due to the similar level of gene 
expression between the three groups, including MLL PTD and the healthy donors. In a 
similar finding, half of the 21 genes from the paediatric ALL and AML MLL translocation 
GEP were expressed at the same level as normal CD34+ haemopoietic progenitor cells (Ross 
et al 2004). Examination o f the microarray gene expression levels showed the variance 
between the MLL PTD and the AML MLL PTD WT patients appeared similar to that 
observed using RQ-PCR analysis (Section 5.3.13.a). However, there are differences between 
the two experiments that may account for the disparity; i.e. the use of different samples 
overall as well as comparison with only the cytogenetically normal subset of AML in the RQ- 
PCR study.
A variety of methods were used to test the effectiveness of class prediction with the 
samples from the HG-U133A cohort, HG-U133 Plus2 and combined cohort. All data sets 
failed to accurately predict MLL PTD samples using a programme designed to find the most 
appropriate prediction model. This was not entirely unexpected, as class prediction also failed 
in a paediatric AML study where the gene signature was established from a combined group 
of MLL PTD and MLL translocation samples (Ross et al 2004). The most likely cause of 
failure was the small number of positive samples in the population and their heterogeneity of 
expression.
Potential target areas for therapeutic intervention can be identified by CMAP analysis. A 
recent publication used CMAP to predict the effectiveness of heat shock protein 90 inhibitors 
against NOTCH 1 mediated T cell leukaemogenesis (Sanda et al 2010). CMAP analysis of 
the combined cohort identified three potential therapeutic agents that may be beneficial to 
MLL PTD AML patients: tanespimycin, vorinostat and trichostatin A. Tanespimycin is 
cytotoxic to primary AML cells positive for FLT3 ITD and has been tested in phase I clinical
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trials. If the co-occurrence of FLT3 ITD with MLL PTD influenced the GEP of MLL PTD it 
could explain why tanespimycin is identified in these samples. However, in a study 
investigating the cytotoxicity of tanespimycin to primary AML cells expressing mutant FLT3, 
a sub-population of FLT3 WT primary AML samples sensitive to tanespimycin were 
identified (Al et al. 2008). This subset may represent MLL PTD AMLs that responded to 
tanespimycin. Vorinostat and trichostatin A are HD AC inhibitors that have been identified as 
antineoplastic agents for potential use with AML (Hauswald et a l 2009). Phase II clinical 
trials have been undertaken in older patients with relapsed or refractory AML to determine the 
efficacy of vorinostat in combination with gemtuzumab ozogamicin, and azacitidine. Activity 
of HD AC inhibitors against MLL PTD leukaemogenesis is supported by functional studies as 
described below. The amino terminal of the MLL gene is essential to the leukaemogenesis of 
chimeric MLLs in mouse models (Lavau et al. 1997; Milne et al. 2002) and the repression 
domain necessary for the transformation of bone marrow in vitro (Slany, Lavau, & Cleary 
1998). HDAC1 mediated repression via the MLL repression domain was reduced by the 
addition of trichostatin A (Xia et al. 2003). A more recent report demonstrated 
hypermethylation of the tumour suppressor gene, SLC5A8 (solute carrier family 5 (iodide 
transporter) member 5), in MLL PTD AML cell lines and subsequent RNA and protein 
suppression (Whitman et al. 2008a). The suppressed protein is a membrane transporter of 
HD AC inhibitors. Restoration of the SLC5A8 activity via the demethylating agent decitabine 
followed by treatment with the HDACi valproic acid resulted in increased apoptosis in the 
MLL PTD cell lines (Whitman et al. 2008a). Additionally, the HDACi compound increased 
the susceptibility o f MLL PTD cells to apoptosis in combination with hypomethylating agents 
(Whitman et al. 2005). In summary, there is clinical and functional evidence to support for 
the use of the compounds identified by CMAP analysis in the treatment of MLL PTD 
leukaemia. This evidence suggests that HD AC inhibitors (vorinostat and trichostatin A) offer 
a particularly likely therapeutic avenue.
5-304
5.5 Conclusion
The hypothesis that MLL PTD has a gene signature unique from other AMLs and can 
be used to add understanding to the aetiology of the disease was supported by the results of 
this study. The genes identified on the significant gene list were distinct from those 
significant genes previously associated with all MLL translocations, suggesting that MLL PTD 
leukaemogenesis occurs via different pathways than other forms of MLL. While the small 
sample size and lack of homogeneity within the gene expression profile of the MLL PTD 
samples most likely prevented the class prediction algorithm from accurate classification, the 
significant gene list derived from the same set of samples identified three potential therapeutic 
agents that may be beneficial to AML MLL PTD patients.
The most promising genes investigated for potential as markers of minimal residual 
disease showed positive correlation with patient disease level, but ultimately fail for use as 
suitable therapeutic markers because of the lack of sensitivity or a limited number of target 
patients.
It would be useful to explore further the potential therapeutic agents identified by 
means of the MLL PTD specific gene signature as a possible improvement on the current 
treatments for the patients with poor prognosis. The best avenue for further study would be to 
identify MLL PTD patients through association with a large-scale AML trial. This would 
provide primary patient material from a large number of MLL PTD patients which could be 
used to scale up this study and provide further validation of its findings.
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6 General Discussion and Future Directions
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6.1 Summary and Relevance of Data
Abnormalities of the MLL gene such as recurrent translocations, gene amplification, 
and PTD aberrations have been reported in AML patients (Poppe et al. 2004). The MLL PTD 
is preferentially co-associated in AML patients with trisomy 11 or normal cytogenetics 
(Caligiuri et al. 1994; Caligiuri et al. 1998). Use of the duplication as a prognostic marker 
has been reported either as an indicator of poor outcome or equivocal, although the general 
consensus is one of poor prognosis (Dohner et al. 2002b; Schnittger et al. 2000; Steudel et al. 
2003). On this background, the data presented in Chapter 3 have clearly demonstrated that 
the duplication is a significant independent prognostic marker capable of identifying a subset 
of de novo AML patients with an increased risk of relapse; the prognostic significance of MLL 
PTD is maintained even after adjustments were made for standard prognostic markers and 
molecular genetic markers. The MLL PTD provided a diagnostic and prognostic indicator for 
around 5% of patients in the CN-AML subset. Co-occurrence with complementary mutations 
such as FLT3 ITD and TKD but not with NPM1, provided support for the theory of 
complementing class I and class II mutations (Introduction, Section 1.2.5) (Gilliland 2002). 
In addition, the importance of the MLL PTD assay was demonstrated since co-operation with 
complementary mutations such as FLT3 TKD may have a negative impact on the prognosis. 
A recent publication confirmed that the occurrence of the MLL PTD with FLT3 TKD 
negatively influences patient prognosis (Bacher et al. 2008).
The increased risk of relapse in MLL PTD patients highlighted the need for a strategy
to identify mutation positive patients; therefore the potential of RQ-PCR MRD monitoring
was investigated (Chapter 4). MRD monitoring of fusion transcripts in CBF leukaemias and
APL are prognostically useful and have been adopted in clinical practice (Section 1.3). With
the high risk of relapse observed in MLL PTD patients, a sensitive, accurate and reproducible
method of monitoring the patients’ therapeutic response would allow for a change in
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treatment strategy if  a sub-optimal response was detected. This study demonstrated that the 
duplication was stable upon disease relapse and therefore was an appropriate target for MRD 
detection. MLL PTD positive AML patients who subsequently relapsed had low levels of 
MLL PTD transcript detected while in haematological remission. This persistent residual 
disease may explain the high level of patient relapse found in this study (Chapter 3). In 
addition, the proportion of MLL PTD patients exhibiting clonal evolution at relapse was 
greater than published accounts. One explanation is that the MLL PTD positive cells may 
represent a mutator phenotype that have increased genomic instability and are consequently 
associated with an increased risk o f relapse (Alcalay et a l 2003). An alternative theory would 
be that clonal evolution is due to intra-clonal genetic diversity already present in the 
leukaemic stem cell population at undetectable levels, and the selective pressure of 
chemotherapy determines the subclone that repopulates the patient BM after treatment 
(Greaves 2010). The results of the RQ-PCR assay may therefore be beneficial to MLL PTD 
patients who are at an increased risk of relapse, the majority of whom lack a useful marker.
The effect of MLL PTD expression on transcription was investigated to gain an insight 
into potential dysregulated target genes and their downstream signalling pathways through 
identification of a gene signature. A gene signature unique to the duplication was identified 
and confirmed using RQ-PCR analysis to validate six genes. CMAP identified three potential 
chemotherapy compounds that could antagonise the effects of MLL PTD expression. 
Tanespimycin (17AAG) is a FLT3 ITD inhibitor that functions by inhibiting the protective 
chaperone activity o f  the HSP90 leading to degradation of oncogenic proteins in tumour cells 
(Al et al 2008). 17AAG treatment of a cell line expressing an MLL-AF4 fusion protein and 
FLT3 ITD caused cell cycle inhibition and apoptosis, which may indicate a potential 
effectiveness in MLL mutated AMLs (Yao et a l 2003). The other two compounds, 
trichostatin A and vorinostat, are both HD AC inhibitors which alter transcription through the 
alteration of chromatin structure by histone acetylation. The MLL PTD is associated with
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increased histone acetylation in the promoter regions of Hoxa7 and HoxA9 genes and an 
increase in HSC proliferation in murine models (Dorrance et al. 2006). Furthermore, 
enhanced cell death has been reported to result from the treatment of MLL PTD cell lines with 
a demethylating agent in combination with the HDAC inhibitor, valproate (Appendix) 
(Whitman et al. 2008a). Trichostatin A reduces the activity of the MLL repression domain 
mediated by HDAC interaction (Xia et al. 2003). These results support the further 
investigation of the candidate chemotherapy agents identified. However, my related study on 
class prediction using gene expression profiling was unsuccessful. Potential reasons for this 
were the low frequency of MLL PTD positive samples in AML patients and the molecular 
heterogeneity of these samples. This heterogeneity may be due to co-operation between MLL 
PTD and other molecular genetic mutations that were not screened in this study or are not yet 
discovered.
6.2 Future Work
The above conclusions suggest a number of avenues for further study.
• Investigation of the candidate therapeutic compounds using functional studies
in MLL PTD cell lines would be the next obvious step forward in this study.
Similar studies using other HDAC inhibitors have shown a beneficial impact.
• Investigation into the effects of 17-AAG in primary AML cells found that
FLT3 ITD positive patients were sensitive to the drug but also identified a 
group of responsive patients that were FLT3 ITD negative (Al et al. 2008). 
These could be MLL PTD positive patients who would potentially benefit from 
administration of 17-AAG. Functional studies could show that 17AAG has a 
cytotoxic effect on MLL PTD cells in addition to FLT3 ITD cells. Primary 
AML samples with MLL PTD status ascertained samples could be tested as 
well as MLL PTD positive cell lines.
• Another direction for future work is investigation of the function of the
validated genes from the GEP analysis. Confirmation of regulation by MLL
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PTD could be assessed in a model system in which the effect of MLL PTD 
transfection on candidate target gene expression could be assessed by RQ- 
PCR. Functional analysis of MLL PTD-regulated genes could also be 
attempted by modulating their expression in an in vitro haematopoietic model 
system through ectopic expression or RNAi technology. If the gene plays a 
direct role in the leukaemogenesis of MLL PTD, the change in its level of 
expression would be expected to change the characteristics of the cell (e.g. 
proliferation, survival, and differentiation).
6.3 Broader significance of the results of the thesis
The cumulative results of this study provide a “proof of principle” that the MLL PTD is 
an adverse risk prognostic marker; this finding provides the rationale for larger scale studies. 
The inclusion of a standardised MLL PTD RQ-PCR assay in a large clinical trial would be 
constructive in furthering understanding of the duplication’s prognostic significance. 
Standardisation of the RQ-PCR would eliminate inconsistencies in the reported frequency of 
MLL PTD, which may be the result of false positives. Prospective identification of a cohort 
of MLL PTD positive patients would provide follow up samples for longitudinal study of the 
patients’ levels of MRD. In addition, the diagnostic characterisation of the patients’ MLL 
PTD status could be used to stratify this subset of patients into an adverse risk group to 
receive specialised treatment. In a similar small-scale study, autologous PBSCT in CR1 
enabled 50% (12/24) MLL PTD patients to achieve long-term survival, however, 59% still 
relapsed within 18 months. The outcome of the patients appeared to be influenced by the 
presence of other molecular markers (Whitman et al. 2007). An increase in the number of 
MLL PTD positive samples analysed would increase the confidence of the clinical outcome 
studies. These would need to be coupled with the identification of other known molecular 
genetic mutations so that the cumulative prognostic impact could be observed. Furthermore, a 
greater number of positives might allow GEP analysis on subgroups within the MLL PTD
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cohort to be analysed, thereby reducing the overall heterogeneity. The ability to analyse a 
group of MLL PTD positive samples that is homogeneous in terms of FAB or WHO 
classification might improve the likelihood of identifying further gene pathways involved in 
MLL PTD AML by removing the confounding differential expression resulting from analysis 
of different cell types. However, the difficulties associated with the low incidence of the 
mutation would remain and any results would have to be assessed to determine if they applied 
to the MLL PTD cohort as a whole. Greater understanding of MLL PTD mediated epigenetic 
and post-transcriptional dysregulation might also provide insight into the pathobiology of this 
subgroup. Heterogeneity may be due in part to the effects of global dysregulation within a 
particular cellular context (Appendix). Likewise, a greater knowledge of patient molecular 
markers (e.g. CEBPA, c-KIT) that could co-occur with MLL PTD may prove helpful in 
stratifying the observed heterogeneity.
The findings presented in this thesis confirm and expand upon the knowledge of the 
MLL PTD in AML. The complexity of the pathogenesis of MLL PTD leukaemia dictates the 
need for more research, and the results of this study provide further important steps towards 
improving the outcome of this adverse risk group of patients.
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